%PDF-1.3% 46 0 obj<>endobj xref 46 40 0000000016 00000 n 0000001529 00000 n 0000001610 00000 n 0000001803 00000 n 0000001957 00000 n 0000002450 00000 n 0000002756 00000 n 0000003450 00000 n 0000003953 00000 n 0000004346 00000 n 0000004854 00000 n 0000005247 00000 n 0000005418 00000 n 0000005520 00000 n 0000006597 00000 n 0000007602 00000 n 0000007747 00000 n 0000008119 00000 n 0000008399 00000 n 0000009428 00000 n 0000009614 00000 n 0000009830 00000 n 0000010897 00000 n 0000011938 00000 n 0000012981 00000 n 0000013134 00000 n 0000014179 00000 n 0000015166 00000 n 0000019395 00000 n 0000025654 00000 n 0000030912 00000 n 0000031620 00000 n 0000034257 00000 n 0000036807 00000 n 0000037066 00000 n 0000037337 00000 n 0000037550 00000 n 0000037604 00000 n 0000038500 00000 n 0000001096 00000 n trailer <]>> startxref 0 %%EOF 85 0 obj<>stream xb```f```~AX,  :mMť f@G&z2\d_6Ez7C%pٚ. s}s힙]PKa7ۓZGݳܓ\\]MW&{6d$qFGJiiiwe9fiip)0ɭ@ Vbs/KTs3rr5h4[`CSтvׅ^.t1ed`r)2qB Δì;L_`ʜ"fo 01p)FLL5Mfpׁuu6@5]0k endstreamendobj47 0 obj<>endobj48 0 obj<>endobj49 0 obj<>/ProcSet[/PDF/Text]/ExtGState<>>>endobj50 0 obj<>endobj51 0 obj<>endobj52 0 obj<>endobj53 0 obj<>endobj54 0 obj<>endobj55 0 obj<>endobj56 0 obj<>endobj57 0 obj<>endobj58 0 obj<>endobj59 0 obj<>stream HdUn8}WlV$uclM }eVINޝᐍLgϜXd7Lnɻ[N:+$_,:-(2<`T7>ybiuӹRFR=w'׻WlimӯG`"gҰK@@w3ME.E2\dR҇n߮P\Fۻ΢b@0C97vhƶiY]N?Кh/ cR#gKgr( -XH Yɔ@Ƕyx݌& &l Lw3"tsr[ՌەT A"Qm.ߓWp3)R\QA@[a9SJ3gTؙwԵ϶aC;^޲Y5rQm}>"vYlg1 gx@2sKoVƝRbXBO`P_]d`b]!Lce7 @už`/p&bro0ZGÙs6䍊3EL!Lk >(D1Sɶk= [n PFcdцPdo0@Dd=y_4} ĩ#0B} £h}i5ƦLpIS!4>LOl:|x2K7dxk ݶ/9Xh}飼I|4/ JickÝ_jw=̠W(3SL*>stream HlUMo0Wі ş@QUUTE{@]v- Mϼ7fzTe])wQLqi.jjl2b&բ'R'znh.jd7i8cn.Qޯ-G>"2BP[o2a czeNQ 7RusՒ/IbOx 46Å2ڿf0gm5W%jIK c̥L NǣL O]uJ9PYfņPSl6 d3pzN+3SfV~!ǰ(} @5 J6<4q $#"[?"Qނ tϖ@O͏3ƩjyΡ|;E>ņԐзL7䇸pbB9znlɲ<`բWo&٥sՉpfj&|0TW`wv& qCS)#ù+9w KxAkȩZ{us(\IBCއGݦ^i׆Ugkŗ4O#/sa6qb :@ ̈,'dV\7[?p[`պe_SZ0< wd߹#KΤjAL<:)]A 8^A\%r8JUX>J,9@ؽ4cqi]BSh?HaÕmÉ'x0r"l%8O+obb3˅FH`+ sVdW>endobj62 0 obj<>endobj63 0 obj<>endobj64 0 obj<>stream HUɎFr@%9a''%2E)UZb>zN̖F'y,\:iVwbvtLb.2-&۹_Wy}*%Cy&E}NVɭyTQA>}J1-Y΅Dbx@ufNnW/!1Z㎔h+Td!3rHd-Ŕ.*i#!@:D|H#fR-D cL^T*%#%j]j Ϟp $*m:^2dM s4rS;\'w8H͕@n6DqKn<(fwCZs"%Uڧ7$@@ljO$U z(;͵Ds][q湨h]JQ?ag0w~\WA܇ *.C9nC;mE|H1Ia:.KLtHEr4]uS;LAI30lL+|b'FSqHآv\ڙ[ilCӷ VşǗ2jn*3t1x,7+_w?]<,{lB1⇴*ŪҦ`ͣxrcGZ\4,@3Bɏm/q0uQ}fj1> If Vǯ&Fw~h?qXur&-pW-SC'-U։Su݉o_o)#Ltƭ.tVY^0`*ONۣ|K[md4KV""@w ފÝצ`;jE%F?U3aXEZ?$ͱ3Cɢ$cl endstreamendobj65 0 obj<>endobj66 0 obj<>endobj67 0 obj<>stream HtUM6 WHw,uL&ɤ9&D[H+mDÃ_75F4S<1lk[*]riI킶[31#?$:Rc#&PbIa}ueC>noZZn*m2+mU!#9am٭hFl[~Z*M#Z-m蠏~\9ḺJ v!t7Ï<::Φ@-Wp>:֢&pepp}*١)l'02Xh$9ݒ!kbXgLj&@J;}Gg{ůL^rH[''rfHtg<2\[p_oH>̧3,$spUl2-9xSIP%4/48N s5q6T5L=K IWyF0kT:[_3tpOerSîsÌEՄջx  xtlØB<+R N t pt؅0|ScPYdRKzv üCGF->o@{!n[q8l߻S%"iAP4^5ڢ4o-Ot8$p,-0]Y)VpHCvWsȧp)Hw7D/5l]/"FAR`[ǁZ-\ Z#e@2丆'V)1!糼7"~eb#$k-C&o;s೤u.8.\UPiw}-VB*(GgY(nٕw,% 5lVh?HX( Nw?'] ="2#mQ:)[6γ!)4)߶yW endstreamendobj68 0 obj<>stream HUn6+d #Dr;(iWE]cӶf,Q[z.tAᅩ\>}+䚅 'kc8i%t&eCQ3P[O$l9c66@ ?rmk:zk^qӹq+l3ۯwlQ~9͍7XMڏl[p vSL)9s\͉=ٝ/XQ>_P`{V}CY,|v%ELE]琇%Ms k&mSXѲ1X(|絫 R%/-fm%)F^qedUK!\S>$q=څ{HU@t3|HC¿*9_7teْHWca˦HyVk`lws(yTڻVaZRia+C8QҬ4 l2 qaZt[tNӀЯM#zumA_\n3/}%@%F瘯lyۃ9͗s@fT*{>hJO+DƹK`^HHdCܭwe!)opF(PK=ĢpaA-t9#Mi%-EE_!W3 0u- H;fތ9R5fTPDHO 7u,? a -HAZ*rԿFJ m\wD]mR[[Urٝ*?]R@;^RP݆#ʤ4߇ $%()%$~/8'&fT})ΉlMti`a+WT04\oScK{m}96#b)gZXaRD&Hu!/x:]DmaQ5|cG endstreamendobj69 0 obj<>stream HtU6,h3H<)` $w[Wr/ j=֨@9^n5f)5_WHÔiZx^N!S jȮxT)vp3rr30ԓԟǒ}^S})!݇'H8y/LۈB5]N0| ؆e6$~s6O >kqf KW(Hۥ! 0݀-s`etT$LZs+f𹘀߸f$EH% 5Z yR/O~7xC£b1b`t "Q-LBj͐c-|5L9c]`b ym0 VҚ 4vWaS26GU HD (**Gni< ʘN@4dZpoU sڦa΁w(x1mjyNqS]-* t7Y7`F4B{ʜ..b0?КrV)c"P&@i>/HQ\fGݑuz0:Nkr-6zdzgpQȷ =pWvya/n8M=]\ssW${4ˌ[I9w4*.֋ |4nn2bBa=7BGۇtc%a؁8!5VJvb)b4/Si\tǒůXTԪɋ 4nS{_#` endstreamendobj70 0 obj<>endobj71 0 obj<>stream HtUM4W&B_# lQ[Kr:J"-2Yʾ 0KKVw~{J[#j+茭v?l>Oq<~n: YoYɲyw[-̻ŏP37 .!=}nrJ[ Y[)R4W[um+ٵ6`o|.G>q,*f9Kb.>Ln%ſapR,CET6xR o^Oat.[/})FrzfR%'elt_c˹;n8/!%F27ɤM'7?>+MBil`'ycz$Т[5c{ѲO?xFHb^.G:X䧘Jku8 ?Fh8(\CXKbˆbny:K.R>K"[5;8kw/3͵OWW4w ߗ,]D>؂ZQG 0YkB&mP(" j BPG_?ѱ)~!pöH+p▴Oskt*QԚULWۮڢ`TWL VpZ6apKL4𺡁~tJA}K0ttct]PEk dנXѬך3riPʖ76G|յ̚M4żjb}gM|!S&B Q{IF׈N aޣqc&vYsJ}lf~i3$DZҺ) )cZ(R]ɨIU mJ+ao~Ln3`VUs)ɧ?6=-!=IAK0Y%z8>Qh\\[&MUWJBȅL?67 ȸjU5l S endstreamendobj72 0 obj<>stream HlTn8+lV$ERiNƱ㢇Yfb2镥~ΐJ ߼!/%)j6 H LǟSd)Xzt2O,KoYK|Lǐ=&jOI-(a1F/D9&_r4))'ukOh"rNZSjv M W ̩3h8eĴ1 L՞"A$yhQiEhNKl۾j/HA8@r:'f9h8BNo5"nzp=Y9%f 碌Q3%yDŽ7ELJNuT4PG8FTU2`3po@Ge|/sQ k"w!(«5(ȽoM>stream hޔWiT׶nQ)e[8QEE@@Yfhf#3 80H4h4q&1h5yo}ߺ&+뽵VU?N=}DDvvv<\\|g K:ռ)Ԏ2j"~ae!n ԍ+2ih]I?*y8wd8/m{/~^b{/q S %jٺP*V +2pu*AX+2Z"S+BTQ2.x8S|EyPg :|P9BuPylVyh\hם-9 D0/aS ϲ}_=`ClGXۇw] ^18﮸z4gp !\\*(`-TE:u݂%WM'*rJۡwq۔+pzb!w^b 4Bvi7ٸ>%l) _Z0`Cx$Rn? ne+ETT3-c=G?w*A OA;xvpcy72x_ʇ:јfJ d,=V`S*rK[cccYT`"S_w6N?i c2$#ٛ ɾHP(sYR&7lrTp:?A.Xu bx/͋""hGXE̫NXdCzr\l&և bHy~@$+'BZUPs᧙.nP=u TkMi7W1BEU֜1d2;&(?yh:ch0W d c 2=ną7]p;0vA .FN(0hO2}̀IƳƁ6lJ+xGEk-f^/-=#oq|.]k,+k~&n.2~u2x:Nosަ3RiBU3a`.YPYfDA,`xU !D'J R)F@BX%}ZƤ @"&PsWRQny3nJejVwUUA\D!Pla: ^(tb!!ClEjK^ ^ z#l~mx$?/fp~wG8w噦S`uTW "WZ;m.TdP12-M-㊊dŷΚ# G¿c6ۮB|Uv[Oj`5–jͭf2;;cbs3m T8ri,-.>R:spQ6xI88kl%oś3Ii*y%tZir~^CqE!`延.qBTfeEFVY\XF7{b҈Զ8jHFh3W^xGwOF|-HD'pPltcbd|p-g`0ѱ=1^_k[Qhz\砣6ZFLo5tTq`$0lYxm,) #[S4fXkc щ^<+-%R'| L63XJ{nEnɶ]D+f~>"h9!o]O1HMCu1JJ>sgbr՗>0,nZVO?81G활E @7)}#>'4N T^Fbk|^F?L s%'tD٤3DoIn&ٵG^?uTasU/|&m&C/&Ohr^PVB2Tϟ_8!gњ_A⌉8q큃)do! B&@$L?u[T-% ]s!=Fտ5hX%:[KLyFt8czK;$ $X־cSC%I0:HC8!3%:Fj>stream htxyTg>UE\0&BUREw%FEEQQ}inhvhzoYf_e܍&n11|$[s~:|;_un=s{o }J/wR>]>刋07$c@?v{6v%UqĈp'u[ s6=8n_Vy$$&+v\b|\b$$x{t+B˖Dv[DLHKDK$1(8$&(1%.;"6N"qq_<;.%B.)y_RDpDPbDHҬLVِmFqam;tV1o6MZd&ۻvvv&ͳKؽdXG;l#8JԇTuC{w>{g;U#F6BxdH{ԉQ4C1nc<}wڻ>ˏ;Vx/~&7H>81qpNSSxgsssvpq_O(&ฏִF?i0+(p[[=_o`2&j_WnHMi,N|'aϵo./e϶+y_nK ;tr#q͒v/RG,%)/4عpt./ #4FKU2ٸ-6N+m+ɾWTDmB 9k&08/as]/6=e= 6F(#bR$GڞMǝZN a2ǏrO^Xmy|!n+m IbbB-.Vv{0z!giAc k/DW:2B+zt"t=h%L pwp!nmnLsehŸI M_9ȅջ~q(&fg`t p :.Ftv;L).MݭIѱI萃"p^)LAlx\0ŝ INJXHq4f_p:ENU(&֐!DCFf\-:Bez2CӰ #`)Nq1Nhd`ztxB1EEp)Lٞ蕒Dg,ULqx37(JLcB#5 J њ1Qz^*0e3C>Gfxp^510WqA?:Otc9^N07M5\IWY#?u?Cc]K@2!%#s#ubUWԃ w:^^MD1,#e+ 5'YsgǍU:B 8?[^F>/~̴l5Zw>~ wsCâ Ev}@fq'#'cY`Ɯ^ع#+;I= rm-, Ú\|# Pl_b]|$g}'zDD!7'mF>?!VSn"tX(CJ}(i.[lN'%rFTZ="rGp9ɪf̅0"ˏTFvLf1E-m>g6nðؿ`Οxn7nqv 0r}p} -uAgvu/$n{CR#GV'wbI?9_Z]8I3=*˨tfh?HOB^Ʀҋ*|VYcF? `U*\Q'u<RAh=2ꆲ.oJԚY1_?&:#~$jvX E~hLl۷j_:[,w) WvAXI$8~.B XnOHLc'_F+MFXdZi?aDBpm'2f! gQrࡵ.ZuL(\| \.#W*wCh!FO CG*w/[ ZdpH, S1&#x]qؤ2+e?[)ݼLJLj:J`4\;WU{8"aQk; 8g 7nFWz~KۮTӎ9U`S~x#Eܬm#pL<~sgrk.ݦX}fENJf[+2V9_ʗ.VB-6f[3:ȡ@>Bg1ij [QJf흛عs"ɕ=/w0ʈ-[#2NBaQGKjXp?k`sT_uIYLF(9K]j2C_h v!鮒̱ eAeAC ԢȌdnW얨ݩ wN2Ҕ%:UjVtPMO80QTٸV yHݥHSN;BrJgfZ~aQ̾9:d&!Q4hpvЊ$NUWA0#͍ɕr8_@(z3몘vFFј;v9`NFʊ*TStL/FeJS=p,a C&:ɋ DބJӉ{k2V 9"M&Hb9$ Hx(atu"9uAY~lKeel+pA և2&F'? Q).g;U⎜P)sc&bFl?NEIH$r*r-eLK5uۜp%\%juj.#Z;|қvmW&xKIC0S)h"W_ ,$C^C KAA.ETvLBF}c҄Xgy.w7"/^A3:_v8ɞ縁lM}Ek[y:,5K)Lkd:8Pu۪k{:*{̎{D&sgUo*KV]1ӽ˨4Dʛ'˧͝x%ڌT&)9 ߵOշ<-w] 9]9W犺Kv8@ k*:8f 0XMP2;o{d/>d 5=yɔJ1"rX.6frQY%6`@|e~2TgЛJƇG45$NLQmuu-1(&\{h7햝\XAL` +MFMSVf2EGDK;9yLF*) L냋LL{hϰfܛNff)>¢z'aUߑ#R*ޢڞӨu,3ِZr~W7@mgXOgzFe EO0E?{tU1:jUr3Omx@!Y)Ǐ0j}zggĞb][ Sd$)ןݿݾ/jRpN%ok;:{ ^J.Ԫ2CEudfQ˿r]'z.(u?P=vR_CE[Yp(\9Wm T8v*!~孾*7;%+T",TndcXhM6Wf'OU+X_w4նlfyfOa@2u4m0Y;Rj#B"RH,MˏE:a*aT8&;h*vZ@ \-#LymxF;jMߡ4d0XEmR= Jo0`u}\ȏ[\Rs];PfZ5p`RYUszc:tY9?QkMFΗiv5 cl9^>6DDX.Lm6Wg LJOHifp #5 ?8Z.d0\  J2#BT3FMKTzV"px=B T5 X/$ endstreamendobj75 0 obj<>stream htXwtg 3D 30c1$1qŽ[%Klbu[nr16SCqHB l&!$9w{3Lɏ3u ]ܴq$/u/?z%S(,(9g_y< =5MkV໮]׼1)719hT(J9+$m E% bdaP0(!H$HHJNdNI6nJIZ+Jg$ ӓec̩~yv6g5pֳ9S98g!'cpp<{Oww)]SݏM}qj6ۊh5λ:miL1]5[fhf5sߜś>'#zjSOyzo^8[L?/;K\tk thi:r ERL/Dhezisnbwz-֐蹿h;`L5<хz@ r=t,9I"pD(W }"j۲ޢF-#&f{c|x ^$~e`"34C3:yȎ)T IRP(GH߉2on0g`Oݍvy{`-js-R6hQ@yBg3ļcz'3YۍiT/ICDԏvظmrYC;je9` AJ1gmpG}ukg\" (#wmт`?Ow[jAQꦯBny)pQV%nbS]ܽN% <}m=DwDO:aĉL*d%Uy~Y/&?U`h'KA&&,z/$8- =iMr eG\ZN`u=N?D"B${#q48oWkl:[Dʴx Fy] 1poE56D[h}ECX= 0Qs&'=޵CSvTrX/ 2s!@ =хw!/"t!3of'AN4dR:erkv',ufs "a`NSYNxz#}5kLl/BM=B0X*D}btM!5 Oc 7͛F AKK%)q2NK-[7JB'm kf}UnqXi5 V:zϥKA{?};.>kKZN3mφYXvfO@̺| Z0*o5]C)]h(4Ԯ_} O2eUY1F.@$cg0O+o?i_7 C#;$TF?❧{|j9j^G߳G\ݕv9'Rν1kH́<8\~Vr4~EǠ=noIXJz|B0#ZcІ-JD){%17 qA9˺omU5Uq 0fSl)ڃVx|'?c&L/2`xUzbx`ZgGa(k^^FyĪP*{Vn`,uW2T\͙0anx部[W^A,ЦO!mđÉ{{߿ [ޣ/bdE|RV6wt ήB?VVOP󥺇AL=e'8N$JSew&F8<=q/[+hɄ5=M]hIDX SnI3D\xwFh uoj(k+$&0 \D$F&S ͷ<cJ|Dj92x CwwˏV} rbvDmy9S2בՊR:dN61].m?ٍ!~u~JUW4Re. μz#݌Dk^ɧ|ow1k.qIDjCSL(>',tTUaiPM;G‰("2*vEؿi6v'UCiPbv.bu䒝wNް;'X2L#YJ)b?Wy3`shYdmt.V7%YHLQx<0z3`gj)^ɼjioľI ֖UUkphMҮ'b&w&SO]9FwzD'C(*LKkvypWL녂Zi`͍d-I1Fz_ +?{⯐'Z^C+#m%CfrXܜjZ޻փʃpw2w{Ƈ?(6nCϳ:~CޙSU.M#yu sųӎ2}RʤyĬ^7 hWBY$ށf9sGN˻TS!elDF!c997Y f)-\=ͅ0kJgjty)9ĻnOLaNfbe2巳&lSC7X`5Rhy[ 9JaM7#>g9γLqQ#C"|)]̞ӟMwf3C`m*x9[qd\x[Eѳm6]H)kW*UW6rs]8a䀰-C"WÕIdZ4#l/O! Q_ZQ &?lHeUmtpvW(̙2leg;ѻXŬ*O1'`9D|IvSrR1O%#^~%3aRCKaXի`ohQP&a-#$)bJm50tSOoNLBT4ԷTF](/`E*sP؋j+\Eߋ$zfE~L*m(%RVUUP ?8X.;̀p{2Tb;S>6' QHzZ.-Ȧ$28aX3X3%m)JL$CTVZ{a{qi5&w|׈MA qtm[*κnr:720%pE% #Q*bDUhɧ#e;k`~D,ew^AU^2pJbU0..iS dձ7}AORcbr2kaZ ^ku;e,m:$gLS.oQ^(X(]=c›bЪChŒ\e\ڍq6<"Ge endstreamendobj76 0 obj<>stream KBDIEC+AdvPSMP10 q AdvPSMP10BKMdHL ] ^5ObLQYuyhgbz =3K u}G][1,9ĿGAߵ}Ebo=g{}`hkVX/Y+3migEv]yhD].n=K:Ufypo]]l1i_V!QBg5fqu!@`w|wsbm\a[18$;t~ri{w~~yy`U8zYFֆsIG[xwcpzpnzz~9T~ymcgcccff]\7|JQ17pjjfjzu:aӕzkzbntDTN~?$MisL endstreamendobj77 0 obj<>stream htV{TT?s0H>Tt\.C`^2hU ekN^ ]R2wYrи|ik-BJYK(lz◸KL>oOuwTpr0GoTg@xSbwږxc['dm#f]54R/zǸ{rS%Y39io8F65soIP%^d)UXt.F)Qkx# A|^$g6&Sr%"I9LgjyKL۴C@  Q5\c,1Y3/+;uGI[MشXF#3*d Ϥ00WC;;dߑ-2\"_?xx3^U[ٺHY&G5)H_lPpƱfZ沴C)‘Oˋ=3L'q8Gk@?0}Ҽl"Ѐ-mR]aH"oZU6djeLkiw8.pp7xOEg[]WvB]J9\$ v^$Lf5C`BU׉s?Dc^4^umkj9wpKLҲ̥|lp-܁:Doc,%%-+Tץ TyV$iohAܱAaz+b[:Bl=/KYrnkrf`(ÔP͜i뺡:+_խUb&\H$#*rnyKdNU$1s&*2޻ʃWw_n( _u[6n[O=쑁Ɂ*Oyk0a>C/}|ƈ$lnaTM]Vg(ɕIx 7'v9F C+D:vD0>Pj)."qr$Dŭ.q;10j^o$׆<rr}RKMGz endstreamendobj78 0 obj<>stream hTTyTSWONOi}myϾXBU, B $d!dg $,a ! ;PEYlqAmZA\Fgt\0gs?~˽t2N}D䞸8pAv\|pPpPJ S+_~&AU Vh_5]h] N-uB~T,Ր9Eh^9_V*

9Ōc1X:DPE5%0 Ư`o^h<8,vS%vs/K"7/F[!(S7*]c/v]J\Gӡ.,БrMX^ ,JKd,F"p{47dl@!د[`qN6_cSY+ԩjYn(f*R*Ԍ sY,"/!QX\]3Lͨ\њ6G7GWjfJΏSMn[v]?V>NA-fkܞop8u;u2e |y[0ZWLPa1e>C,]~ ,`qZ2Bn*^G%j(79Oi^Tt>l~J4pYy.KT~}x!~<(})%$h"€93!3h}.R0۞%%~C7*+-=kh9G =OHgSiW`n]砻°h8 7@L_ Tx5d憚q>zq"Oyj/fm%]1`TWȣ'f/w-/UxNXndBo3֣eh7_YZ6XE\.iv[Su :M a \ }'c=DD,jcr|SLip?6//Cx[VR0[6Ǘ(S2l1Vh7aq/3NgX=cRE1Kyᅙ; ȼ̑$i2cMcu  enUλzQ72=pF#Li`kv^u` '|g"^L /燿5jh?叶XlrLx($ ( sҠFz`™iVWsxk}Q! lى"Qe$eEUM_ذtBHܖmGJp?:h)ߴoCD862-pҊr"SCo`6M0w]#u,\촨G`H_xӨon*.$":7rJNj72$<{-Q0hdc 7p'?WAX0;d+VgPGAK`!ՖA±[@e[ˊy1DgY$X;L[^R\j.ۑc DH؏zV'04YE㥎[ ]xt^ɵc3r jO̼ƫbj0 c5xyx#r&rM 5mUA[pPJoU:´s#lHqf0niyŷ@yl\Y}#NoN}+yʪbp2؛iR2V;i&H^^gmĖ#`/{\.MN{[}3 .wF𛓏;Hs5Z`@?Y/:$c( jKZ^ uJϾ?-֗%[S0QZhf(Z(K/T G{ endstreamendobj79 0 obj<>endobj80 0 obj<>stream KBDIDB+AdvP4C4E74 wR`C15AdvP4C4E74 s3!%0; 5|#p3Lp|~zx~M~c~kqqt endstreamendobj81 0 obj<>endobj82 0 obj<>endobj83 0 obj<>stream h,Rˎ4n5g3K ҈ 6M'Ny?} ??ᓧ=]W7G~Lg;."'r"Ͻ^vXk\{wFRGBL霂Yl,F1ڡd}՗x6`dN}HП؉C1Xs5*wƴx`J&Y`)P:oAɇ|(UneHQԢP IJdԇ"UBjϣE^)N4'F8,A~x3LqON~xݝ닸N=g3'6ґn-%\g]-IX%`n6w2`9 ԩl$v& 4 Q`ga#d!dt{!4#`0)jH3L %`ЌVL.-NaWgKKV[k5׳ڹEay\uXYн3Cm"!: 48%̣sanPcy[ hB=nٟ1Xv|De-XƷkq.^Wg5nQP }^UjfgPϢ-rÓ}2ŻLr JR]KrNh8Xƒ`7ExNa53>D_4 endstreamendobj84 0 obj<>endobj1 0 obj<>endobj2 0 obj<>/ProcSet[/PDF/Text]/ExtGState<>>>endobj3 0 obj<>stream /GS1 gs BT /F1 1 Tf 10.4607 0 0 10.4607 94.337 724.8187 Tm 0 0 0 1 k 0 Tc 0 Tw [(MATERIALS)-332(AND)-333.6(METHODS)]TJ /F4 1 Tf -5.0186 -1.7126 TD [(Chemicals)-332.8(and)-331.8(reagents)]TJ /F3 1 Tf 1.0026 -1.6421 TD [(Finasteride)-261(tablets)-261.2(\(5)-169.6(mg)-263.6(per)-259.2(tablet\))-264.4(were)-266.2(purchased)-260.4(from)]TJ -1.0026 -1.0948 TD [(Merck)-417.5(Sharp)-415.7(&)-416.7(Dohme)-414.1(Ltd.,)-413.7(and)-417.3(testosterone)-415.8(propionate)]TJ T* [(\(25)-168.2(mg/mL\))-324.8(was)-330.6(provided)-330.2(by)-327.8(Shanghai)-326.8(Tongyong)-330(Medical)]TJ 0 -1.1002 TD [(Co.,)-317.6(Ltd.)-316.9(Enzyme-linked)-312.9(immunosorbent)-312(assay)-318.2(kits)-319.8(for)-313.5(de-)]TJ 0 -1.0948 TD [(termination)-218.5(of)-218.4(testosterone)-220.7(and)-216.8(DHT)-220.8(were)-217.4(supplied)-215.4(by)-219.4(R&D)]TJ T* (Systems.)Tj /F4 1 Tf 0 -2.1137 TD [(Plant)-333.3(material)]TJ 1.0026 -1.6421 TD [(S.)-382.7(china)]TJ /F3 1 Tf 3.745 0 TD [(L.)-387.9(rhizomes)-385.3(were)-390.8(purchased)-385(from)-383.4(Wuhan)-384.8(Hu-)]TJ -4.7476 -1.0948 TD [(manwell)-457.9(Healthcare)-453.7(\(Group\))-457.5(Co.,)-453.1(Ltd.,)-451.7(and)-455.3(identied)-454.5(by)]TJ T* [(Prof.)-606.3(Changgong)-606(Zhang)-604(\(College)-609.7(of)-608.6(Pharmacy,)-604.3(Tongji)]TJ T* [(Medical)-429.8(College)-433.2(of)-429.8(Huazhong)-429.6(University)-434.8(of)-429.8(Science)-434.2(and)]TJ T* [(Technology\).)-443.2(A)-452.6(voucher)-447.5(specimen)-444.7(\(BQ201006\))-445.4(was)-449.8(pre-)]TJ T* [(served)-298.3(and)-303.5(deposited)-294.1(for)-302.7(reference)-298.2(in)-302.9(our)-298.3(laboratory.)]TJ /F4 1 Tf 0 -2.1949 TD [(Preparation)-331.5(of)-330(FMR)-334.5(and)-331.8(quality)-331.7(analysis)]TJ /F3 1 Tf 1.0026 -1.6421 TD [(According)-402.3(to)-411.3(the)-403.3(procedures)-409.7(described)-408.9(by)-403.7(Shu)]TJ /F4 1 Tf 19.8683 0 TD [(et)-404.7(al.)]TJ /F3 1 Tf 2.1624 0 TD (,)Tj 7.4718 0 0 6.641 285.4487 499.6912 Tm (24)Tj 10.4607 0 0 10.4607 41.8394 484.2708 Tm [(FMR)-330.4(was)-336(prepared)-330(as)-333.2(follows:)-330.4(the)-332.8(air-dried)-333.3(and)-330.6(powdered)]TJ 0 -1.0948 TD [(rhizomes)-455.7(of)]TJ /F4 1 Tf 5.4142 0 TD [(S.)-453.1(china)]TJ /F3 1 Tf 3.8804 0 TD [(L.)-458.4(\(2)-164.2(kg\))-450(were)-455.9(extracted)-452.1(with)-458.3(50%)]TJ -9.2946 -1.0948 TD [(ethanol)-377(\(2)]TJ /F9 1 Tf 4.3303 0 TD ()Tj /F3 1 Tf .7208 0 TD [(10)-165.2(L\))-375.4(under)-375.6(reux)-372.4(for)-378.6(2)-166.6(h)0(,)-371.9(and)-379.4(extraction)-372.8(was)]TJ -5.0511 -1.0948 TD [(repeated)-342.9(three)-344.1(times.)-344.4(The)-346.7(resulting)-339.9(solvent)-346.9(was)-341.4(eliminated)]TJ T* [(under)-218.4(reduced)-218.6(pressure)-219.8(to)-221.6(obtain)-217(a)-219.6(dried)-220.6(extract,)-222.4(with)-219.8(a)-219.6(yield)]TJ T* [(of)-478.5(13.3)-168.5(g/100)-163.2(g)-480.9(o)0(f)-478.5(the)-479.2(starting)-482.2(crude)-477.4(material.)-484.2(The)-476.8(dried)]TJ T* [(extract)-423.6(\(100)-166.8(g\))-424.3(was)-422.7(dissolved)-426.6(in)-422.1(20%)-421.5(ethanol)-425.8(\(1.5)-162.1(L\))-429.6(and)]TJ T* [(ltered,)-204.1(the)-202.8(pH)-201.9(was)-200.5(adjusted)-203.4(to)-205.4(about)-200(4.5,)-201.7(and)-200.6(then)-201.4(NaCl)-202.2(was)]TJ 0 -1.1002 TD [(used)-568.9(to)-568.5(bring)-568.7(the)-571.3(solution)-565.7(to)-568.5(its)-570.5(nal)-566.7(concentration)-568(at)]TJ 0 -1.0948 TD [(1.5)-164.5(mol/L.)-485.1(T)17.8(h)17.7(e)-474.3(e)18.9(x)17.7(t)20.9(r)18.7(a)13.4(c)18.9(t)-466.9(s)16.5(o)17.7(l)20.9(u)17.7(t)15.4(i)20.9(o)17.7(n)-470.1(w)18.9(a)13.4(s)-465.9(s)16.5(u)17.7(b)17.7(j)20.9(e)18.9(c)13.4(t)20.9(e)18.9(d)-470.1(t)15.4(o)-470.1(H)18.9(P)20.9(D)13.5(1)23.1(0)17.7(0)]TJ T* -.0181 Tc [(macroporous)-245.5(resin)-244.3(\()-4.9(Cangzhou)-249.7(Bon)-249.7(A).8(dsorber)-248.7(T)-.3(echno)5(logy)-244.3(Co.,)]TJ T* -.0167 Tc [(Ltd)6.4(.).3(,)-514.6(C)4.4(an)6.4(gzhou,)-514.6(Chin)6.4(a\))-512.9(column)-508.5(ch)6.4(ro)6.4(matography)-508.5(\(water)]TJ /F10 1 Tf 22.8057 0 TD 0 Tc (/)Tj /F3 1 Tf -22.8057 -1.0948 TD -.0177 Tc [(70%)-257.8(ethanol)]TJ /F10 1 Tf 4.8668 0 TD 0 Tc (/)Tj /F3 1 Tf 1.1815 0 TD -.018 Tc [(95%)-258.1(ethanol\))-264.9(t)2.9(o)-260.5(g)-.3(ive)-259.3(t)-2.6(hree)-264.7(fractions.)-261.2(T)-.2(he)-259.3(70%)]TJ -6.0483 -1.0948 TD -.0174 Tc [(ethanol)-294.6(fraction)-297.8(was)-299(u).3(sed)-297.8(a)1.5(s)-299(F)3.5(MR.)]TJ 1.0026 -1.0948 TD 0 Tc [(According)-218(to)-221.6(previous)-217.6(studies,)-222.7(total)-220.7(saponins)-219.8(are)-220(the)-224.4(main)]TJ -1.0026 -1.0948 TD [(constituents)-263(of)-261.8(FMR,)-264.6(and)-260.2(their)-260.8(contents)-263(were)-266.2(determined)-263.1(as)]TJ T* [(described)-452.3(by)-457.9(Baccou)]TJ /F4 1 Tf 9.2133 0 TD [(et)-453.5(al)]TJ /F3 1 Tf 1.9619 0 TD (.)Tj 7.4718 0 0 6.641 161.348 304.8944 Tm (25)Tj 10.4607 0 0 10.4607 173.5936 300.9826 Tm [(with)-452.9(some)-455.9(modication.)-451.8(In)]TJ -12.5952 -1.0948 TD [(brief,)-208.1(30)-165.2(mg)-204(of)-207.6(FMR)-205.7(was)-205.9(dissolved)-204.4(in)-205.4(5)-166.6(m)0(L)-209.2(o)0(f)-202.1(hot)-209.4(water,)-206.7(and)]TJ T* [(the)-457.5(solution)-457.3(was)-460.7(extracted)-457.5(by)-457.9(20)-165.2(mL)-458.5(of)-456.9(butanol;)-454.9(the)-457.5(ex-)]TJ 0 -1.1002 TD [(traction)-306.4(was)-314.3(repeated)-305(three)-311.6(times.)-306.5(The)-308.8(extract)-309.8(solution)-305.6(was)]TJ 0 -1.0948 TD [(concentrated)-506.3(to)-503.4(dryness)]TJ /F4 1 Tf 10.4761 0 TD [(in)-503.4(vacuo)]TJ /F3 1 Tf 3.6799 0 TD [(.)-503.3(Then)-502.5(the)-506.3(extract)-504.9(was)]TJ -14.156 -1.0948 TD [(dissolved)-274.8(with)-274(25)-165.2(mL)-268.8(of)-278(methanol)-268.1(and)-276.4(diluted)-272.1(to)-275.8(40)]TJ /F7 1 Tf 21.0606 0 TD (l)Tj /F3 1 Tf .5474 0 TD .2753 Tc [(Lt)275.3(oa)]TJ -21.608 -1.0948 TD 0 Tc [(new)-356.5(test)-351.1(tube.)-352.4(The)-357.5(methanol)-354.8(was)-352.3(eliminated)-355.2(by)-349.5(heating)-355.4(at)]TJ T* (70)Tj /F9 1 Tf .9972 0 TD ()Tj /F3 1 Tf .3956 0 TD [(C,)-433.5(and)-428.2(then)-434.4(5%)-428.4(vanillin)-430(\(0.2)-162.1(mL\))-434.4(and)-428.2(perchloric)-429.2(acid)]TJ -1.3928 -1.0948 TD [(\(0.8)-167.5(mL\))-358.5(were)-363.7(added)-364.6(to)-362.5(the)-359.9(test)-361.9(tube.)-363.3(The)-362.9(tube)-358.5(was)-363.1(main-)]TJ T* [(tained)-438.1(in)-438.4(a)-441.8(7)0(0)]TJ /F9 1 Tf 5.9995 0 TD ()Tj /F3 1 Tf .3956 0 TD [(C)-439.6(water)-440.4(bath)-439.8(for)-438.2(15)-165.2(min)-437.8(to)-443.8(develop)-434.4(color)]TJ -6.3951 -1.0948 TD [(completely)-282.5(and)-281.8(then)-282.7(put)-279.8(in)-281.2(an)-283.2(ice)-282.9(bath)-282.7(for)-281(3)-166.6(min)-280.7(to)-281.2(stop)-279.6(the)]TJ T* [(reaction,)-258.9(and)-254.7(lastly)-253(5)-166.6(m)0(L)-258(o)0(f)-256.3(glacial)-253.4(acetic)-262.2(acid)-254.4(was)-260.1(added)-250.7(to)]TJ T* [(the)-549.6(tube.)-547.5(The)-547.2(absorbance)-545(of)-549(the)-549.6(resulting)-545.8(solution)-544(was)]TJ T* [(measured)-343.9(at)-345.1(415)-169.2(nm)-344.9(with)-344.5(a)-344.3(model)-341.7(756MC)-347.1(spectrophotom-)]TJ 0 -1.1002 TD [(eter)-323.8(\(Shanghai)-313.6(Precision)-322.4(&)-319.2(Scientic)-320(Instrument)-319.8(Co.,)-317.6(Ltd.,)]TJ 0 -1.0948 TD [(Shanghai,)-526.7(China\).)-529.5(A)-528.5(standard)-530.8(curve)-531.6(was)-531.1(prepared)-525.2(from)]TJ T* [(diosgenin)-506.7(using)-505.8(the)-506.3(above)-505.5(method.)-502.2(On)-505.4(the)-511.7(basis)-505.8(of)-505.6(the)]TJ T* [(standard)-243.5(curve,)-243.6(the)-240.7(content)-247(of)-240.1(total)-247.8(saponins)-241.5(was)-243.9(calculated.)]TJ 1.0026 -1.0948 TD [(Fifty)-275(milligrams)-271.9(of)-278(FMR)-276.2(was)-276.4(dispensed)-276.8(in)-275.8(30)-165.2(mL)-279.7(of)-278(2)]TJ /F4 1 Tf 22.1662 0 TD (M)Tj /F3 1 Tf -23.1688 -1.0948 TD [(HCl)-258.9(solution)-251.4(to)-254.1(hydrolyze)-257.2(for)-253.9(3)-166.6(h)0(,)-258(and)-254.7(then)-255.6(the)-257(solution)-251.4(was)]TJ T* [(extracted)-224.5(three)-224.9(times)-220.4(each)-229.3(by)-219.4(50)-165.2(mL)-225.5(of)-223.8(petroleum)-222.3(ether.)-224.2(The)]TJ 26.2851 62.4231 TD [(extract)-331.5(solution)-332.7(was)-330.6(concentrated)-332.9(to)-335.4(dryness)]TJ /F4 1 Tf 18.4646 0 TD [(in)-335.4(vacuo)]TJ /F3 1 Tf 3.5065 0 TD [(,)-335.3(and)]TJ -21.9711 -1.0948 TD [(the)-359.9(residue)-364.2(was)-363.1(dissolved)-356.1(with)-360.7(20)-165.2(mL)-360.9(of)-359.3(methanol)-360.2(for)-362.3(the)]TJ T* [(following)-306.2(determination)-306.6(of)-310.5(diosgenin)-306.2(in)-308.3(FMR.)-302.6(The)-308.8(content)]TJ T* [(of)-305.1(diosgenin)-306.2(in)-308.3(FMR)-303.3(was)-308.9(determined)-306.4(by)-306.1(high-performance)]TJ T* [(liquid)-404.7(chromatography)-400.6(with)-398.7(ultraviolet)-404.2(detection.)-401.6(A)-403.9(high-)]TJ 0 -1.1002 TD [(performance)-476.2(liquid)-475.2(chromatography)-471(system)-472.7(\(Hitachi,)-477.9(Hi-)]TJ 0 -1.0948 TD [(tachi)-493.6(High-Technological)-491.3(Corp.,)-492.6(Japan\))-493.4(equipped)-492.6(with)-490.8(a)]TJ T* [(model)-292.9(L-2130)-293.9(pump,)-292.6(an)-294.1(online)-292.9(solvent)-292.7(vacuum)-293.5(degasser,)-294.8(a)]TJ T* [(model)-477.2(L2400)-475.2(ultraviolet)-480(detector,)-475.7(and)-476.9(a)-479.8(manual)-474.6(injector)]TJ T* [(with)-474.5(a)-479.8(20-)]TJ /F7 1 Tf 4.5145 0 TD (l)Tj /F3 1 Tf .5474 0 TD [(L)-480.8(injection)-470.8(loop)-479(was)-476.9(used.)-476(Chromatographic)]TJ -5.0619 -1.0948 TD [(separations)-387.9(were)-390.8(carried)-387.9(out)-382.8(on)-387.4(an)-386.2(Amethyst)-388.5(C)]TJ 7.4718 0 0 6.641 523.2755 609.0518 Tm (18)Tj 10.4607 0 0 10.4607 530.7023 610.2424 Tm [(P)-389.6(chro-)]TJ -20.4482 -1.0948 TD [(matography)-224.1(column)-221.1(\(Sepax)-223.4(Technologies)-223.5(Inc.\).)-222.8(The)-227.5(column)]TJ T* [(temperature)-248.6(was)-243.9(maintained)-250(at)-242.1(25)]TJ /F9 1 Tf 13.5274 0 TD ()Tj /F3 1 Tf .3956 0 TD [(C.)-243.8(The)-249.1(mobile)-245(phase)-246.5(was)]TJ -13.923 -1.0948 TD [(a)-382.2(mixture)-383.5(of)-381(H)]TJ 7.4718 0 0 6.641 382.3369 574.6959 Tm (2)Tj 10.4607 0 0 10.4607 386.0786 575.8865 Tm (OCH)Tj 7.4718 0 0 6.641 413.2912 574.6959 Tm (3)Tj 10.4607 0 0 10.4607 417.033 575.8865 Tm [(CN)-382.8(\(10:90,)-382.3(vol/vol\).)-378.5(The)-379.2(ow)-381.6(rate)]TJ -9.5819 -1.0948 TD [(was)-601.6(1.0)-164.5(mL/min.)-592.9(The)-596(ultraviolet)-599.3(detector)-595.6(was)-601.6(set)-594.2(at)-599.8(a)]TJ T* [(wavelength)-300(of)-299.7(205)-163.8(nm.)]TJ 1.0026 -1.1002 TD [(The)-232.9(methanol)-230.1(stock)-228.3(solution)-229.7(of)-234.7(diosgenin)-224.9(was)-233(prepared)-232.5(at)]TJ -1.0026 -1.0948 TD [(the)-224.4(concentration)-226.5(of)-223.8(1.00)-168.5(mg/mL.)-223.6(A)-225(series)-225.8(of)-223.8(standards)-227.1(were)]TJ T* [(prepared)-400.5(by)-398.3(diluting)-393.3(proper)-400.3(aliquots)-396.5(of)-397.2(the)-397.9(stock)-396.3(solution)]TJ T* [(with)-507.1(methanol.)-505.8(The)-503.9(calibration)-503.7(curve)-509.9(for)-503.2(diosgenin)-506.7(was)]TJ T* [(drawn)-206.4(by)-203.1(simple)-202.8(linear)-204(regression)-208.4(of)-202.1(its)-202(concentration)-204.9(versus)]TJ T* [(its)-229(peak)-230.5(area,)-233(and)-227.6(the)-229.9(calibration)-227.3(curve)-228.1(was)-233(used)-227.4(to)-227(calculate)]TJ T* [(the)-300.3(content)-301.2(of)-299.7(diosgenin)-295.3(in)-297.5(FMR.)]TJ /F4 1 Tf 0 -2.7369 TD [(Animals)-335.8(and)-326.4(treatments)]TJ /F3 1 Tf 1.0026 -1.6421 TD [(All)-568.1(experiments)-566.3(were)-564.3(conducted)-571.3(under)-565.3(the)-565.9(European)]TJ -1.0026 -1.1002 TD [(Community)-309.8(guidelines)-305.8(for)-308.1(the)-311.2(use)-310.1(of)-310.5(experimental)-310(animals)]TJ 0 -1.0948 TD [(and)-379.4(approved)-375.6(by)-376.6(the)-381.6(Animal)-373.8(Care)-383.2(and)-379.4(Use)-374(Committee)-380.1(of)]TJ T* [(Huazhong)-337.5(University)-331.9(of)-337.6(Science)-336.7(and)-336(Technology.)-337.2(In)-332.2(total,)]TJ T* [(50)-430.8(male)-434(SpragueDawley)-431.8(rats,)-433.9(weighing)-429.8(200)]TJ /F9 1 Tf 19.0933 0 TD ()Tj /F3 1 Tf .7208 0 TD [(20)-165.2(g)-432.2(each,)]TJ -19.8141 -1.0948 TD [(were)-455.9(purchased)-455.5(from)-453.9(the)-457.5(Research)-457.7(Center)-453.1(of)-456.9(Laboratory)]TJ T* [(Animals,)-383.7(Tongji)-380.6(Medical)-386.5(Center,)-381.9(Huazhong)-386.2(University)-380.6(of)]TJ T* [(Science)-282.5(and)-287.3(Technology,)-277.6(Wuhan,)-281.2(China.)-282.6(The)-281.7(animals)-286.9(were)]TJ T* [(housed)-539(under)-532.8(controlled)-536.6(conditions)-540(\(12-h/day)-533.8(controlled)]TJ T* [(lighting,)-267.9(maintained)-266.3(at)-263.8(25)]TJ /F9 1 Tf 10.3677 0 TD ()Tj /F3 1 Tf .3956 0 TD [(C)-266.2(and)-265.6(5575%)-265.6(air)-266.8(humidity\))-264.8(and)]TJ -10.7634 -1.0948 TD [(fed)-270(with)-274(normal)-268.8(rat)-272.2(chow)-268.4(and)-271(water)]TJ /F4 1 Tf 14.698 0 TD [(ad)-268.2(libitum)]TJ /F3 1 Tf 4.1081 0 TD [(.)-270.3(All)-275.4(animals)]TJ -18.8061 -1.0948 TD [(were)-526.3(allowed)-522.1(to)-525.1(acclimate)-525.4(for)-524.9(7)-518.9(days)-525.5(prior)-524.3(to)-519.7(the)-522.5(rst)]TJ 0 -1.1002 TD (treatment.)Tj 1.0026 -1.0948 TD [(Forty)-413.7(male)-417.8(SpragueDawley)-415.6(rats)-418.3(were)-412.5(castrated)-420.8(as)-414.5(de-)]TJ -1.0026 -1.0948 TD [(scribed)-223.2(by)-219.4(Van)-221(Coppenolle)]TJ /F4 1 Tf 11.0668 0 TD [(et)-220.4(al)]TJ /F3 1 Tf 1.7289 0 TD (.)Tj 7.4718 0 0 6.641 453.2597 270.4818 Tm (26)Tj 10.4607 0 0 10.4607 463.0676 266.5133 Tm [(Chloral)-222.1(hydrate)-222.1(\(350)-166.8(mg/)]TJ -13.9826 -1.0948 TD [(kg)-279(of)-283.4(body)-276.2(weight\))-278.5(was)-281.8(used)-281.6(for)-275.6(anesthesia.)-280(Castration)-285.1(was)]TJ T* [(performed)-232.1(through)-235.3(the)-235.3(scrotum)-230.7(sack,)-236.4(cutting)-234.1(open)-231.7(the)-235.3(scrota)]TJ T* [(and)-357.7(then)-353.1(taking)-352.5(out)-355.7(the)-354.5(testicles.)-357.5(Another)-352.1(10)-354.9(rats)-358.7(received)]TJ T* [(sham)-352.9(operation,)-345.4(compared)-353.5(with)-349.9(the)-349.1(castrated)-350.3(rats:)-348.7(an)-353.7(inci-)]TJ T* [(sion)-295.9(was)-298.1(made)-296.3(in)-297.5(the)-294.9(same)-297.5(area,)-298(but)-296.1(without)-293.7(taking)-292.9(out)-296.1(the)]TJ T* [(testicles,)-335.8(and)-336(they)-336.9(served)-336.2(as)-333.2(the)-338.3(control)-333.9(group.)-332.7(After)-337.6(oper-)]TJ T* [(ation,)-472.5(all)-476(rats)-478(were)-477.6(treated)-472.4(with)-474.5(penicillin)-477(for)-470.7(3)-475.5(days)-476.7(to)]TJ T* [(prevent)-357.5(infection.)-353.1(After)-353.9(7)-356.3(days)-357.5(for)-351.5(recovery,)-356.4(the)-354.5(rst)-356.7(drug)]TJ 0 -1.1002 TD [(treatment)-299.2(was)-303.5(begun.)]TJ 1.0026 -1.0948 TD [(The)-357.5(10)-360.3(sham-operated)-358.6(rats,)-363.4(which)-361.3(served)-357.9(as)-360.3(the)-359.9(control)]TJ -1.0026 -1.0948 TD [(group,)-229.7(had)-227.6(olive)-229.3(oil)-227.9(injected)-230.3(subcutaneously)-227.5(once)-230.5(a)-225(day,)-232.4(and)]TJ T* [(all)-416.3(the)-419.6(castrated)-415.4(rats)-418.3(had)-417.3(testosterone)-415.8(propionate)-415.2(\(0.5)-167.5(mg/)]TJ T* [(0.1)-164.5(mL)-420.6(per)-421.7(rat\))-421.6(dissolved)-421.2(in)-416.7(olive)-419(oil)-423(injected)-420(subcutane-)]TJ T* [(ously)-467.9(each)-473.2(day)-471.5(to)-470.9(create)-470.4(prostatic)-468.8(hyperplasia.)]TJ 7.4718 0 0 6.641 523.7857 110.0409 Tm (27)Tj 10.4607 0 0 10.4607 536.1447 106.1291 Tm [(The)-471.3(40)]TJ -20.9685 -1.0948 TD [(castrated)-279.9(rats)-277.4(were)-277(divided)-275.3(randomly)-276.9(into)-275.2(four)-279.6(groups,)-272.9(with)]TJ T* [(10)-463.3(rats)-467.1(each:)-463.1(one)-466.1(model)-466.3(group,)-462.8(which)-464.3(was)-460.7(administered)]TJ T* [(0.5%)-507.6(sodium)-505.3(carboxymethylcellulose;)-506(two)-511.7(FMR)-503.8(groups,)]TJ /F11 1 Tf 9.9626 0 0 9.9626 200.0692 748.6864 Tm [(S.)-338.7(CHINA)]TJ /F12 1 Tf 4.3817 0 TD [(L.)-337.9(FMR)-336.1(INHIBIT)-12.9(S)-333(BPH)-336.5(IN)-335.7(RAT)-340(MODEL)]TJ /F13 1 Tf 30.8428 0 TD .0071 Tc [(64)7.1(7)]TJ ET endstreamendobj4 0 obj<>stream hlOKBAߘ"]eC D0F7䛑QyA-E]}@ZzZZtw!V8dB6KBT:?<4AɕE2|?{opa h}RA`4Eחjk{m: % y!WIASC'] %VQ=d6K"v/-(}q)o*E1=L)BA+(aX *%ڟ)N戵f-ƃ:xںY.28Fo+wz쇞hU{>?&XW6ヒ endstreamendobj5 0 obj<>endobj6 0 obj<>endobj7 0 obj<>/ProcSet[/PDF/Text]/ExtGState<>>>endobj8 0 obj<>stream /GS1 gs BT /F3 1 Tf 10.4607 0 0 10.4607 44.1071 724.8187 Tm 0 0 0 1 k 0 Tc 0 Tw [(which)-225.8(were)-217.4(administered)-220.3(FMR)-222(at)-220.4(doses)-221.8(of)-223.8(300)-218(or)-218.4(600)-169.2(mg/kg)]TJ 0 -1.0948 TD [(of)-299.7(body)-297.9(weight;)-292.5(and)-298.1(one)-298.1(positive)-298.9(control)-295.9(group,)-294.8(which)-296.3(was)]TJ T* [(treated)-515.7(with)-517.9(nasteride)-514.9(at)-513.1(the)-517.1(dose)-514.7(of)-511.1(3)-166.6(mg/kg)-516.3(of)-511.1(body)]TJ T* [(weight.)-307.3(The)-303.3(drugs)-302.1(were)-309.5(administered)-301.6(using)-305.3(a)-306.3(stomach)-300.9(tube)]TJ T* [(once)-279.2(daily)-278.1(for)-281(3)-275(weeks.)-282.5(All)-275.4(rats)-277.4(were)-282.4(weighed)-276(every)-276.8(5)-280.4(days)]TJ 0 -1.1002 TD [(during)-301.7(the)-300.3(experiment.)]TJ /F4 1 Tf 0 -2.1895 TD [(Blood)-336.5(and)-331.8(tissue)-333.2(samples)]TJ /F3 1 Tf 1.0026 -1.6421 TD [(After)-245.5(3)-242.5(weeks)-245.3(of)-240.1(treatment,)-244.3(all)-242.9(rats)-244.9(were)-244.5(deprived)-242.3(of)-245.5(food)]TJ -1.0026 -1.0948 TD [(for)-335.2(18)-165.2(h,)-333.9(weighed,)-329.5(and)-336(sacriced.)-333.4(Blood)-333.2(was)-330.6(collected)-336.1(and)]TJ T* [(allowed)-500.5(to)-503.4(clot,)-495.5(and)-498.6(serum)-502.3(was)-498.6(separated)-499.9(at)-502.2(2000)]TJ /F4 1 Tf 21.8356 0 TD (g)Tj /F3 1 Tf 1.0026 0 TD (for)Tj -22.8382 -1.0948 TD [(15)-170.6(min)-264.4(and)-265.6(used)-265.4(for)-270.2(determination)-263.3(of)-267.2(testosterone)-264(and)-271(DHT)]TJ T* [(by)-360.3(enzyme-linked)-360.6(immunosorbent)-355.4(assay)-361.5(kits.)-357(The)-357.5(prostate)]TJ T* [(was)-460.7(removed)-453.7(from)-459.3(each)-456.9(rat)-456.5(and)-455.3(weighed)-460.3(to)-454.7(get)-457.5(the)-457.5(wet)]TJ T* [(prostatic)-392.9(weight)-389.2(index.)-388.9(Then,)-393.4(all)-389.3(specimens)-390.3(were)-390.8(xed)-391(in)]TJ 0 -1.1002 TD [(10%)-302.3(formalin)-299.8(for)-297.3(pathological)-297.4(examination.)]TJ /F4 1 Tf 0 -2.1895 TD [(Statistical)-333.9(analysis)]TJ /F3 1 Tf 1.0026 -1.6421 TD [(Data)-339.9(were)-336.6(expressed)-332(as)-338.6(mean)]TJ /F9 1 Tf 12.3025 0 TD ()Tj /F3 1 Tf .7208 0 TD [(SD)-334.2(values.)-333.3(Results)-339.3(were)]TJ -14.026 -1.0948 TD [(analyzed)-360.2(statistically)-359.2(by)-354.9(one-way)-354.1(analysis)-361.8(of)-353.9(variance)-359.2(fol-)]TJ T* [(lowed)-431.8(by)-436.2(Dunnetts)]TJ /F4 1 Tf 8.6876 0 TD [(post)-431.4(hoc)]TJ /F3 1 Tf 3.978 0 TD [(test.)-431.7(Differences)-434.2(were)-434.2(con-)]TJ -12.6656 -1.0948 TD [(sidered)-304.5(statistically)-299.6(signicant)-297.1(at)]TJ /F4 1 Tf 13.5761 0 TD (P)Tj /F9 1 Tf .7804 0 TD (<)Tj /F3 1 Tf .7154 0 TD (.05.)Tj /F1 1 Tf -5.3383 -2.1895 TD (RESULTS)Tj /F4 1 Tf -9.7336 -1.718 TD [(Quality)-335.9(analysis)-330.4(of)-335.4(FMR)]TJ /F3 1 Tf 1.0026 -1.6421 TD [(The)-352.1(content)-349.9(of)-348.5(total)-350.7(saponins)-349.9(in)-351.7(FMR)-346.6(was)-352.3(expressed)-348.3(as)]TJ -1.0026 -1.0948 TD [(diosgenin)-252(equivalent)-243.8(in)-248.7(milligrams)-250.2(per)-248.3(gram.)-247(The)-249.1(FMR)-249.1(was)]TJ T* [(found)-414.7(to)-411.3(contain)-415(187.2)]TJ /F9 1 Tf 9.7228 0 TD ()Tj /F3 1 Tf .7208 0 TD [(8.67)-163.1(mg/g)-414.7(of)-413.5(total)-410.3(saponins.)-414.2(The)]TJ -10.4436 -1.0948 TD [(percentage)-279.3(content)-268.6(of)-272.6(diosgenin)-273.6(in)-275.8(FMR)-270.8(was)-271(determined)-273.9(as)]TJ T* (1.07%.)Tj /F4 1 Tf 0 -2.1895 TD [(Effect)-337.1(of)-330(FMR)-334.5(on)-333.2(prostate)-330.4(weight)]TJ /F3 1 Tf 1.0026 -1.6421 TD [(FMR)-308.7(was)-303.5(well)-310.8(tolerated)-303.8(by)-306.1(all)-308(rats)-309.9(and)-308.9(during)-301.7(the)-305.7(entire)]TJ -1.0026 -1.0948 TD [(experiment,)-256.9(with)-252.3(no)-257.3(side)-256.8(effects.)-252.9(As)-257.3(shown)-253.1(in)-254.1(Table)-258.2(1,)-252.6(after)]TJ 0 -1.1002 TD [(injection)-210.7(of)-207.6(testosterone)-209.8(propionate)-203.8(for)-210.6(3)-204.6(weeks,)-212.1(the)-208.2(ratios)-206.4(of)]TJ 0 -1.0948 TD [(prostate)-527.6(weight-to-body)-524.6(weight)-530.2(were)-526.3(consistently)-528.6(higher)]TJ T* [(than)-271.8(in)-270.4(control)-268.8(rats)-266.6(\()]TJ /F4 1 Tf 8.2107 0 TD (P)Tj /F9 1 Tf .7804 0 TD (<)Tj /F3 1 Tf .7154 0 TD [(.01\),)-269.8(especially)-270.9(in)-270.4(the)-267.8(model)-271.2(group,)]TJ -9.7065 -1.0948 TD [(where)-378.6(the)-376.2(ratio)-380(was)-379.4(nearly)-375.2(twice)-378.6(that)-377(of)-375.6(sham)-374.6(group)-376.8(rats.)]TJ 26.2905 43.3352 TD [(This)-517.9(result)-515.3(indicates)-517.4(that)-517.9(prostatic)-517.5(hyperplasia)-516.8(was)-520.3(suc-)]TJ 0 -1.0948 TD [(cessfully)-288.9(induced)-288.1(by)-289.9(subcutaneous)-287.7(injection)-292(of)-288.9(testosterone)]TJ T* [(propionate)-507.3(after)-516.5(castration.)-514.2(As)-512(also)-516.9(can)-513.7(be)-510.9(seen,)-518.2(in)-508.9(the)]TJ T* [(groups)-208.6(treated)-212.2(with)-214.4(nasteride)-211.4(\(3)-164.2(mg/kg)-212.8(of)-213(body)-205.8(weight\))-213.4(and)]TJ T* [(FMR)-438.8(\(600)-437.8(or)-440.6(300)-163.8(mg/kg)-440.4(of)-440.6(body)-438.8(weight\),)-440.3(the)-441.2(indices)-437.8(of)]TJ 0 -1.1002 TD [(prostate)-251.2(weight)-259.2(were)-255.3(reduced)-256.6(by)-251.9(32.2%,)-250.7(27.4%,)-256.1(and)-254.7(18.6%,)]TJ 0 -1.0948 TD [(respectively,)-298.9(compared)-299.4(with)-295.7(the)-300.3(model)-298.3(group.)]TJ /F4 1 Tf 0 -2.1895 TD [(Effect)-331.7(of)-335.4(FMR)-329(on)-333.2(concentrations)-332.7(of)-330(testosterone)]TJ 0 -1.0948 TD [(and)-331.8(DHT)-331.6(in)-330(serum)]TJ /F3 1 Tf .9972 -1.6421 TD [(The)-314.2(effects)-318.6(of)-315.9(FMR)-314.1(on)-311.5(the)-316.6(concentration)-313.3(of)-316(testosterone)]TJ -.9972 -1.0948 TD [(and)-314.4(DHT)-318.4(in)-313.8(serum)-318(are)-317.6(presented)-316.8(in)-313.8(Table)-317.8(2.)-317.7(DHT)-312.9(concen-)]TJ T* [(trations)-482.2(in)-487.2(all)-486.8(drug-treated)-485(groups)-485(were)-488.4(signicantly)-486.2(de-)]TJ T* [(creased)-635.9(compared)-635.4(with)-637.1(the)-636.3(model)-639.8(group.)-630.8(Testosterone)]TJ T* [(concentrations)-323.9(were)-325.8(not)-323.2(signicantly)-323.7(different)-322.4(between)-323.6(the)]TJ 0 -1.1002 TD [(BPH)-296.9(model)-298.3(group)-300.9(and)-298.1(the)-300.3(drug-treated)-295.4(groups.)]TJ /F4 1 Tf 0 -2.1895 TD [(Histopathologi)8.6(cal)-338.3(examination)]TJ /F3 1 Tf .9972 -1.6421 TD [(The)-363(rat)-364.3(prostate)-365(gland)-362.6(morphology)-356.5(in)-362.5(the)-365.4(control)-361(group)]TJ -.9972 -1.0948 TD [(had)-547.4(no)-544.6(obvious)-546.4(changes,)-545.3(but)-545.4(for)-546.6(the)-549.6(model)-542.2(group,)-544.1(the)]TJ T* [(prostatic)-447.1(epithelial)-448.7(cells)-451.5(presented)-446.9(the)-452.1(typical)-449.7(features)-447.3(of)]TJ T* [(glandular)-367.8(hypertrophy:)-374.6(papillary)-370(fronds)-370.2(protruded)-376.6(into)-367.4(the)]TJ T* [(gland)-308.4(cavities,)-312.1(the)-311.2(prostatic)-311.6(epithelial)-307.8(height)-314.6(was)-308.9(increased)]TJ T* [(notably,)-469.7(and)-471.5(the)-473.7(gland)-471(lumen)-471.8(diameter)-477.2(was)-471.5(signicantly)]TJ T* [(smaller)-383.4(\(Fig.)-387.3(1\).)-391.1(Compared)-383.9(with)-387.8(the)-387(model)-385.1(group,)-386.9(the)-387(rat)]TJ T* [(prostate)-630.5(gland)-639(morphology)-627.5(in)-638.9(the)-630.9(FMR-treated)-637.8(groups)]TJ 0 -1.1002 TD [(showed)-218(some)-222.8(improvement,)-219.6(especially)-222.1(in)-221.6(the)-224.4(FMR)-216.6(\(600)-166.8(mg/)]TJ 0 -1.0948 TD [(kg\)-t)-25.7(r)-24.7(e)-29.9(a)-29.9(t)-27.9(e)-29.9(d)-567.7(g)-25.7(r)-30.1(o)-25.7(u)-25.7(p)-567.7(\()-30.1(t)-27.9(h)-25.7(e)-571.9(p)-25.7(r)-30.1(o)-25.7(s)-26.9(t)-27.9(a)-29.9(t)-27.9(i)-27.9(c)-571.9(e)-24.5(p)-31.1(i)-27.9(t)-27.9(h)-25.7(e)-29.9(l)-27.9(i)-27.9(a)-24.5(l)-569.9(h)-25.7(e)-29.9(i)-27.9(g)-31.1(h)-25.7(t)-569.9(w)-24.5(a)-29.9(s)]TJ T* .03 Tc [(r)5.3(e).1(d)4.3(u)-1.1(c)5.5(e).1(d)-250.4(m)3.5(ar)5.3(ke)5.5(dly)4.3(,)-251.1(w)5.5(h)-1.1(e)5.5(r)-.1(ea)5.5(s)-251.6(t)2.1(h)4.3(e)-249.2(gla)5.5(n)-1.1(d)-245(l)2.1(umen)-245(vo)4.3(lu)4.3(me)-249.2(w)5.5(a).1(s)]TJ T* .0285 Tc [(incr)3.8(eased)-295.3(signicantly\).)]TJ /F1 1 Tf 3.8967 -2.1895 TD 0 Tc [(DISCUSSION)-332.3(AND)-333.6(CONCLUSIONS)]TJ /F3 1 Tf -2.8995 -1.6421 TD [(BPH)-394.4(is)-390.8(one)-395.7(of)-391.8(the)-392.5(most)-394.3(common)-393.1(diseases)-392(among)-393.7(aged)]TJ -.9972 -1.0948 TD [(men,)-206.1(and)-206(its)-207.4(lower)-208.6(urinary)-206(tract)-205.4(symptoms)-206.4(reduce)-209.2(the)-202.8(quality)]TJ T* [(of)-451.4(daily)-456.9(life.)]TJ 7.4718 0 0 6.641 375.0235 322.0157 Tm (28,29)Tj 10.4607 0 0 10.4607 396.6235 318.1038 Tm [(Safe)-453.9(and)-455.3(effective)-462(natural)-451.9(interventions)]TJ -7.4086 -1.0948 TD [(that)-209(reduce)-214.6(the)-208.2(symptoms)-211.8(and)-211.4(reverse)-213.4(or)-213(halt)-209(the)-213.6(progression)]TJ T* [(of)-516.5(BPH)-513.7(have)-517.7(been)-517.7(the)-517.1(subject)-513.7(of)-516.5(considerable)-519.6(research)]TJ 0 -1.1002 TD [(interest.)-301.5(In)-299.7(this)-303.5(study,)-299.2(we)-303.7(demonstrated)-299.4(that)-301.1(FMR,)-302.6(a)-300.9(bioac-)]TJ 0 -1.0948 TD [(tive)-366.2(fraction)-362.8(from)-367.2(the)-370.8(rhizomes)-363.6(of)]TJ /F4 1 Tf 14.5083 0 TD [(S.)-366.4(china)]TJ /F3 1 Tf 3.7124 0 TD [(L.,)-365.5(effectively)]TJ -18.2207 -1.0948 TD [(mitigated)-856.4(testosterone)-854.8(propionateinduced)-859(BPH)-855.1(in)-855.7(a)]TJ ET 44.107 219.572 251.093 .28348 re f 44.107 124.441 251.093 .28348 re f 44.107 190.998 251.093 .51022 re f BT /F6 1 Tf 8.9663 0 0 8.9663 82.0913 236.4661 Tm (Table)Tj /F3 1 Tf 2.9971 0 TD (1.)Tj /F6 1 Tf 1.2519 0 TD [(Effect)-330.5(of)-335.1(Fraction)-337.1(of)]TJ /F14 1 Tf 10.3949 0 TD [(S.)-329.8(china)]TJ /F6 1 Tf 4.0277 0 TD (L.)Tj -20.3661 -1.2203 TD [(Macroporous)-334.5(Resin)-336.1(on)-332.5(Index)-332.3(of)-335.1(Prostatic)-331.7(Weight)]TJ /F4 1 Tf -2.5418 -2.0739 TD [(Group,)-340.1(dose)]TJ 0 -1.1065 TD (\(mg/kg\))Tj 8.106 1.1065 TD (Prostatic)Tj -.2466 -1.1065 TD [(weight)-334.7(\(g\))]TJ 7.9858 1.1065 TD (Body)Tj -1.0622 -1.1065 TD [(weight)-334.7(\(g\))]TJ 8.264 1.1065 TD [(Index)-333.8(of)]TJ -1.6123 -1.1065 TD [(prostatic)-334.9(weight)]TJ /F3 1 Tf -21.4347 -1.8336 TD [(Control)-334.4(\(\))-2513.5(0.47)]TJ /F9 1 Tf 9.4907 0 TD ()Tj /F3 1 Tf .7208 0 TD [(0.10)-1967.9(292.00)]TJ /F9 1 Tf 6.6327 0 TD ()Tj /F3 1 Tf .7208 0 TD [(23.73)-2530.1(1.58)]TJ /F9 1 Tf 6.7023 0 TD ()Tj /F3 1 Tf .7145 0 TD (0.29)Tj -24.9818 -1.1065 TD [(Model)-339.8(\(\))-2956.1(0.86)]TJ /F9 1 Tf 9.4907 0 TD ()Tj /F3 1 Tf .7208 0 TD (0.14)Tj 6.351 0 0 5.6449 151.37 173.8771 Tm (a)Tj 8.9663 0 0 8.9663 169.0015 170.6456 Tm (280.89)Tj /F9 1 Tf 2.9149 0 TD ()Tj /F3 1 Tf .7208 0 TD [(17.72)-2530.1(3.07)]TJ /F9 1 Tf 6.7023 0 TD ()Tj /F3 1 Tf .7145 0 TD (0.41)Tj 6.351 0 0 5.6449 283.8046 173.8771 Tm (a)Tj 8.9663 0 0 8.9663 44.1071 160.6676 Tm (FMR)Tj 1.0053 -1.1128 TD [(300)-5069.5(0.71)]TJ /F9 1 Tf 8.4853 0 TD ()Tj /F3 1 Tf .7208 0 TD (0.11)Tj 6.351 0 0 5.6449 151.37 153.9779 Tm (b)Tj 8.9663 0 0 8.9663 169.0015 150.6897 Tm (283.78)Tj /F9 1 Tf 2.9149 0 TD ()Tj /F3 1 Tf .7208 0 TD [(14.81)-2530.1(2.50)]TJ /F9 1 Tf 6.7023 0 TD ()Tj /F3 1 Tf .7145 0 TD (0.31)Tj 6.351 0 0 5.6449 283.8046 153.9779 Tm (b)Tj 8.9663 0 0 8.9663 53.1212 140.7684 Tm [(600)-5069.5(0.63)]TJ /F9 1 Tf 8.4853 0 TD ()Tj /F3 1 Tf .7208 0 TD (0.13)Tj 6.351 0 0 5.6449 151.37 143.9999 Tm (c)Tj 8.9663 0 0 8.9663 169.0015 140.7684 Tm (280.67)Tj /F9 1 Tf 2.9149 0 TD ()Tj /F3 1 Tf .7208 0 TD [(16.56)-2530.1(2.23)]TJ /F9 1 Tf 6.7023 0 TD ()Tj /F3 1 Tf .7145 0 TD (0.43)Tj 6.351 0 0 5.6449 283.8046 143.9999 Tm (c)Tj 8.9663 0 0 8.9663 44.1071 130.7905 Tm [(Finasteride)-338.8(\(3\))-1616.1(0.61)]TJ /F9 1 Tf 9.4907 0 TD ()Tj /F3 1 Tf .7208 0 TD (0.10)Tj 6.351 0 0 5.6449 151.37 134.022 Tm (c)Tj 8.9663 0 0 8.9663 169.0015 130.7905 Tm (291.80)Tj /F9 1 Tf 2.9149 0 TD ()Tj /F3 1 Tf .7208 0 TD [(17.53)-2530.1(2.08)]TJ /F9 1 Tf 6.7023 0 TD ()Tj /F3 1 Tf .7145 0 TD (0.34)Tj 6.351 0 0 5.6449 283.8046 134.022 Tm (c)Tj 7.9702 0 0 7.9702 52.1008 111.9118 Tm [(Data)-489.9(are)-487.3(mean)]TJ /F9 1 Tf 6.4303 0 TD ()Tj /F3 1 Tf .7184 0 TD [(SD)-486.9(values)-484.4(\()]TJ /F4 1 Tf 5.1286 0 TD (n)Tj /F9 1 Tf .6686 0 TD (=)Tj /F3 1 Tf .7113 0 TD [(10\).)-486.9(The)-487.6(index)-482.1(of)-490(prostatic)-478.6(weight)-481(was)]TJ -14.6602 -1.2519 TD [(dened)-333.2(as)-327.4(\(prostatic)-330.5(weight/bod)12.5(y)-332.2(weight\))]TJ /F9 1 Tf 17.1071 0 TD ()Tj /F3 1 Tf .7113 0 TD (10)Tj /F9 1 Tf 5.6041 0 0 4.9808 195.0236 104.7685 Tm (-)Tj /F3 1 Tf .7183 0 TD (3)Tj 7.9702 0 0 7.9702 201.8267 101.9338 Tm (\).)Tj 5.6041 0 0 4.9808 52.1008 94.7905 Tm (a)Tj /F4 1 Tf 7.9702 0 0 7.9702 54.5952 91.9559 Tm (P)Tj /F9 1 Tf .7824 0 TD (<)Tj /F3 1 Tf .7113 0 TD [(.01)-521.2(compared)-512.1(with)-510.4(control)-515.4(group;)]TJ 5.6041 0 0 4.9808 186.1795 94.7905 Tm (b)Tj /F4 1 Tf 7.9702 0 0 7.9702 188.9574 91.9559 Tm (P)Tj /F9 1 Tf .7753 0 TD (<)Tj /F3 1 Tf .7184 0 TD (.05,)Tj 5.6041 0 0 4.9808 216.9637 94.7905 Tm (c)Tj /F4 1 Tf 7.9702 0 0 7.9702 219.4582 91.9559 Tm (P)Tj /F9 1 Tf .7753 0 TD (<)Tj /F3 1 Tf .7184 0 TD [(.01)-514.1(compared)-512.1(with)]TJ -23.4947 -1.2448 TD [(model)-329.2(group.)]TJ 1.0029 -1.2519 TD [(FMR,)-328.7(fraction)-327.9(of)-333.6(macropr)12(ous)-329.3(resin.)]TJ ET 319.124 189.694 251.036 .28342 re f 319.124 104.542 251.036 .22681 re f 319.124 171.099 251.036 .45357 re f BT /F6 1 Tf 8.9663 0 0 8.9663 357.0518 217.5307 Tm (Table)Tj /F3 1 Tf 2.9971 0 TD (2.)Tj /F6 1 Tf 1.2519 0 TD [(Effect)-336.8(of)-328.8(Fraction)-337.1(of)]TJ /F14 1 Tf 10.3949 0 TD [(S.)-329.8(china)]TJ /F6 1 Tf 4.0277 0 TD (L.)Tj -21.7824 -1.2203 TD [(Macroporous)-334.5(Resin)-336.1(on)-332.5(Concentrations)-333.4(of)-335.1(Testosterone)]TJ 4.7738 -1.2203 TD [(and)-336.9(Dihydrotestosterone)-334.4(in)-331.6(Serum)]TJ /F4 1 Tf -5.893 -2.0739 TD [(Group,)-333.8(dose)-330.4(\(mg/kg\))-2888.5(Testosterone)-334.1(\(ng/L\))-2881.8(DHT)-338.8(\(nmol/L\))]TJ /F3 1 Tf 0 -1.8273 TD [(Control)-334.4(\(\))-7742.5(0.40)]TJ /F9 1 Tf 14.7197 0 TD ()Tj /F3 1 Tf .7208 0 TD [(0.10)-5774.3(3.00)]TJ /F9 1 Tf 9.4464 0 TD ()Tj /F3 1 Tf .7145 0 TD (0.68)Tj -25.6015 -1.1128 TD [(Model)-333.5(\(\))-8191.4(2.61)]TJ /F9 1 Tf 14.7197 0 TD ()Tj /F3 1 Tf .7208 0 TD (0.78)Tj 6.351 0 0 5.6449 476.2203 153.9779 Tm (a)Tj 8.9663 0 0 8.9663 520.5542 150.6897 Tm (17.65)Tj /F9 1 Tf 2.4217 0 TD ()Tj /F3 1 Tf .7145 0 TD (4.80)Tj 6.351 0 0 5.6449 564.3778 153.9779 Tm (a)Tj 8.9663 0 0 8.9663 319.1243 140.7684 Tm (FMR)Tj .999 -1.1128 TD [(300)-10304.9(2.51)]TJ /F9 1 Tf 13.7207 0 TD ()Tj /F3 1 Tf .7208 0 TD [(0.40)-5274.8(10.46)]TJ /F9 1 Tf 9.4464 0 TD ()Tj /F3 1 Tf .7145 0 TD (2.40)Tj 6.351 0 0 5.6449 564.3778 134.022 Tm (b)Tj 8.9663 0 0 8.9663 328.0818 120.8126 Tm [(600)-10304.9(2.46)]TJ /F9 1 Tf 13.7207 0 TD ()Tj /F3 1 Tf .7208 0 TD [(0.35)-5774.3(8.57)]TJ /F9 1 Tf 9.4464 0 TD ()Tj /F3 1 Tf .7145 0 TD (2.81)Tj 6.351 0 0 5.6449 564.3778 124.1007 Tm (b)Tj 8.9663 0 0 8.9663 319.1243 110.8346 Tm [(Finasteride)-332.5(\(3\))-6851.5(2.56)]TJ /F9 1 Tf 14.7197 0 TD ()Tj /F3 1 Tf .7208 0 TD [(0.30)-5774.3(5.71)]TJ /F9 1 Tf 9.4464 0 TD ()Tj /F3 1 Tf .7145 0 TD (1.60)Tj 6.351 0 0 5.6449 564.3778 114.1228 Tm (b)Tj 7.9702 0 0 7.9702 327.0613 91.9559 Tm [(Data)-333.4(are)-330.8(mean)]TJ /F9 1 Tf 6.1244 0 TD ()Tj /F3 1 Tf .7113 0 TD [(SD)-330.5(values)-327.9(\()]TJ /F4 1 Tf 4.8227 0 TD (n)Tj /F9 1 Tf .6686 0 TD (=)Tj /F3 1 Tf .7113 0 TD (10\).)Tj 5.6041 0 0 4.9808 327.0613 84.8126 Tm (a)Tj /F4 1 Tf 7.9702 0 0 7.9702 329.5558 82.0346 Tm (P)Tj /F9 1 Tf .7824 0 TD (<)Tj /F3 1 Tf .7184 0 TD [(.01,)-228.5(compared)-227.5(with)-233(control)-230.9(group;)]TJ 5.6041 0 0 4.9808 451.8424 84.8126 Tm (b)Tj /F4 1 Tf 7.9702 0 0 7.9702 454.6771 82.0346 Tm (P)Tj /F9 1 Tf .7753 0 TD (<)Tj /F3 1 Tf .7184 0 TD [(.01)-229.5(compared)-234.7(with)-233(model)-229.6(group.)]TJ -17.5054 -1.2519 TD [(DHT,)-331.9(dihydrotest)12.5(osterone.)]TJ /F13 1 Tf 9.9626 0 0 9.9626 44.1071 748.6864 Tm .0071 Tc [(64)7.1(8)]TJ /F12 1 Tf 23.519 0 TD 0 Tc [(CHEN)-340(ET)-332.8(AL.)]TJ ET endstreamendobj9 0 obj<>stream hlOMLQ%ZY$ @1R) , KABI@Z J 1hzR&*O(h zm}܂ḟcq K%rvDQeWR'{`D,LJƋ&:@20w14dXŁ26DIΞ@AC0d`dNr82dsUb57W k(^'TɼJ<'gwp, b;X:";ebIʬPGT^']<NꎩglMI*$*gO{l eY (+vmmmͮ3 GRQE:ۻtc`ǷoX/{6Yxx~m3kNAT$x!6hc~J?4WF&C˽ZurψWA >endobj11 0 obj<>endobj12 0 obj<>/Font<>/ProcSet[/PDF/Text/ImageB]/ExtGState<>>>endobj13 0 obj<>stream /GS1 gs BT /F3 1 Tf 10.4607 0 0 10.4607 41.8394 507.2314 Tm 0 0 0 1 k 0 Tc 0 Tw [(prostatic)-560.9(hyperplasia)-560.1(rat)-559.5(model,)-563.2(as)-560.8(evidenced)-559.3(by)-560.8(lower)]TJ 0 -1.0948 TD [(prostate)-299.9(weights)-296.9(and)-303.5(histopathological)-296(indices.)]TJ 1.0026 -1.0948 TD [(Tissue)-482.6(androgens)-483.8(stimulate)-483.6(prostate)-489.6(enlargement.)-482(Tes-)]TJ -1.0026 -1.0948 TD [(tosterone)-266(and)-265.6(DHT)-269.6(are)-268.8(involved)-263(in)-270.4(the)-267.8(progression)-262.4(of)-267.2(BPH.)]TJ T* [(By)-286.4(contrast,)-293.8(DHT,)-285.1(which)-290.9(is)-287.8(converted)-288.5(from)-291.3(testosterone)-285.7(by)]TJ T* [(steroid)-476(5)]TJ /F7 1 Tf 3.7016 0 TD (a)Tj /F3 1 Tf .4986 0 TD [(-reductase,)-480.5(plays)-472.1(a)-479.8(more)-475.4(important)-475(role)-476.8(in)-476.3(the)]TJ -4.2002 -1.1002 TD [(progress)-351.1(of)-359.3(BPH.)-350.4(5)]TJ /F7 1 Tf 7.9614 0 TD (a)Tj /F3 1 Tf .4986 0 TD [(-Reductase)-359.6(inhibitors,)-352(like)-349.9(nasteride,)]TJ -8.46 -1.0948 TD [(which)-252.9(can)-253.6(block)-248.7(the)-251.5(formation)-255(of)-250.9(DHT,)-252.6(are)-252.5(commonly)-251.6(used)]TJ T* [(for)-324.4(the)-327.4(treatment)-331.7(of)-321.4(BPH.)-328.7(Administration)-326.1(of)-326.8(FMR)-325(reduced)]TJ T* [(the)-208.2(concentration)-204.9(of)-207.6(DHT)-210(in)-205.4(serum,)-203.5(whereas)-207.8(the)-208.2(testosterone)]TJ T* [(level)-266(in)-265(serum)-258.4(was)-265.6(not)-263.6(changed,)-262.3(indicating)-263.4(FMR)-265.4(exerted)-264.2(its)]TJ T* [(effect)-302.6(by)-295.3(inhibiting)-300.6(5)]TJ /F7 1 Tf 8.5901 0 TD (a)Tj /F3 1 Tf .4986 0 TD (-reductase.)Tj -8.0861 -1.0948 TD [(Prostatic)-237.9(inammation)-242(frequently)-240.7(accompanies)-243(BPH,)-242(and)]TJ -1.0026 -1.0948 TD [(the)-560.5(inammation)-561.7(can)-562.5(contribute)-563.7(to)-563.1(the)-560.5(development)-560.7(of)]TJ T* (BPH.)Tj 7.4718 0 0 6.641 64.6866 350.759 Tm (30)Tj 10.4607 0 0 10.4607 76.1953 346.8472 Tm [(In)-381(BPH)-383.6(development,)-381.2(proliferation)-380.9(was)-379.4(enhanced,)]TJ -3.2843 -1.0948 TD [(whereas)-229.5(apoptosis)-226.1(was)-227.6(suppressed.)]TJ 7.4718 0 0 6.641 187.4267 339.307 Tm (31)Tj 10.4607 0 0 10.4607 197.2913 335.3952 Tm [(Some)-223.8(studies)-228.9(that)-225.3(have)]TJ -14.8606 -1.0948 TD [(evaluated)-209.3(the)-208.2(mechanism)-205.6(of)-213(FMR)-205.7(for)-205.2(treatment)-212.5(of)-207.6(prostatitis)]TJ 0 -1.1002 TD [(indicated)-570.4(that)-577.5(the)-571.3(observed)-571.9(anti-inammatory)-570(and)-574.5(anti-)]TJ 0 -1.0948 TD [(microorganism)-396.5(effects)-394.5(of)-397.2(FMR)-395.4(might)-399.3(be)-397.1(due)-395.7(to)-395.1(the)-397.9(main)]TJ T* [(active)-317.6(constituent)-317.4(of)-310.5(saponins)-317.4(in)-313.8(FMR.)]TJ 7.4718 0 0 6.641 207.6094 293.4991 Tm (22,23)Tj 10.4607 0 0 10.4607 227.7921 289.5306 Tm [(Some)-310.6(literature)]TJ -17.7763 -1.0948 TD [(also)-278.4(indicates)-278.9(that)-279.5(saponins)-279.4(in)]TJ /F4 1 Tf 12.3621 0 TD [(S.)-279.7(china)]TJ /F3 1 Tf 3.5336 0 TD [(L.)-279.5(showed)-277.6(excellent)]TJ -15.8957 -1.0948 TD [(bioactivities)-718.9(with)-723.8(antitumor)-718.9(and)-720.8(anti-inammatory)-716.3(ef-)]TJ T* (fects.)Tj 7.4718 0 0 6.641 64.2897 259.0865 Tm (32,33)Tj 10.4607 0 0 10.4607 84.8693 255.1747 Tm [(Among)-361.1(the)-359.9(saponins,)-360(diosgenin,)-354.2(which)-361.3(was)-363.1(also)]TJ -4.1135 -1.0948 TD [(found)-387.6(in)-389.6(FMR,)-389.3(is)-385.4(a)-393(safe)-387.8(and)-390.2(efcacious)-392.3(chemopreventive)]TJ T* [(agent)-345.1(against)-340.3(a)-344.3(series)-345.1(of)-337.6(human)-344.9(cancers.)-342.6(Its)-339.6(anticancer)-346.6(ac-)]TJ T* [(tivity)-374.4(involves)-378(a)-376.8(variety)-376(of)-375.6(molecular)-372.8(and)-379.4(cellular)-375.6(targets,)]TJ T* [(including)-334.3(cell)-343.3(cycle)-338.5(arrest,)-336.8(suppression)-340.5(of)-337.6(the)-338.3(signal)-337.5(trans-)]TJ T* [(ducer)-325.6(and)-319.8(activator)-325.5(of)-321.4(transcription)-323.5(3)-318.4(pathway,)-324.1(and)-319.8(activa-)]TJ 0 -1.1002 TD [(tion)-557.1(of)-559.8(caspase-3)-563.9(and)-558.2(p53,)-558.7(and)-558.2(it)-559.9(can)-562.5(also)-560.3(reduce)-561.5(the)]TJ 0 -1.0948 TD [(expression)-209.4(of)-207.6(signal)-207.4(transducer)-206(and)-211.4(activator)-206.2(of)-207.6(transcription)]TJ T* [(3regulated)-255.4(gene)-252.1(products,)-254.9(like)-257.8(vascular)-253.2(endothelial)-255.4(growth)]TJ T* [(factor,)-378.9(Bcl-2,)-379.1(Bcl-xL,)-372.1(etc.)]TJ 7.4718 0 0 6.641 153.9779 155.9622 Tm (34,35)Tj 10.4607 0 0 10.4607 174.7275 152.0504 Tm [(Furthermore,)-373.9(diosgenin)-376.6(can)]TJ -12.7036 -1.0948 TD [(exert)-203.2(anti-inammatory)-201.5(activity)-206.6(by)-197.7(suppressing)-205(activation)-202.6(of)]TJ T* [(c-Jun)-561(N-terminal)-556.9(kinase,)-555.5(nuclear)-562.3(factor-)]TJ /F7 1 Tf 17.2398 0 TD (j)Tj /F3 1 Tf .5528 0 TD -.021 Tc [(B)-21(,)-579.1(lip)-3.3(op)-3.3(oly)-3.3(s).9(ac-)]TJ -17.7926 -1.0948 TD -.0203 Tc (charide/interferon-)Tj /F7 1 Tf 7.1431 0 TD 0 Tc (c)Tj /F3 1 Tf .4173 0 TD -.0198 Tc [(tr)4.3(i)-4.4(gge)4.5(r)-1.1(ed)-332.7(CK2,)-328(and)-327.3(activator)-331.7(pr)4.3(otein-1.)]TJ 7.4718 0 0 6.641 285.6188 121.6062 Tm -.0296 Tc (36)Tj 10.4607 0 0 10.4607 41.8394 106.2425 Tm -.0199 Tc [(It)-318.8(is)-323.2(likely)-316.6(t)-4.5(hat)-318.8(a)-1(ll)-324.2(these)-320.8(a)4.4(bove)]TJ 12.2483 0 TD [(activi)-4.6(ties)-317.9(a)-1.1(re)-320.9(conducive)-320.9(t)-4.6(o)-316.7(t).9(he)]TJ -12.2483 -1.0948 TD -.0201 Tc [(pr)4(otective)-304.7(e)-1.2(f)4(f)-1.4(ects)-301.7(on)-300.5(BPH.)]TJ 1.0026 -1.0948 TD 0 Tc [(In)-240.1(conclusion,)-243.2(a)-241.3(3-week)-247.1(oral)-243.7(administration)-239.4(of)-245.5(FMR)-238.3(from)]TJ /F4 1 Tf -1.0026 -1.0948 TD [(S.)-480.2(china)]TJ /F3 1 Tf 3.9346 0 TD [(L.)-480.1(inhibits)-475.8(the)-479.2(prostatic)-479.6(enlargement)-477.2(of)-478.5(experi-)]TJ 22.3505 41.6172 TD [(mentally)-389.5(induced)-385.7(BPH)-389(in)-384.2(rats,)-390.5(probably)-384.4(by)-387.4(inhibiting)-387.3(5)]TJ /F7 1 Tf 23.1688 0 TD (a)Tj /F3 1 Tf .4986 0 TD (-)Tj -23.6674 -1.0948 TD [(reductase.)-255.3(Further)-257(ongoing)-247.1(studies)-256(are)-258(focused)-253.6(on)-251.9(exploring)]TJ T* [(the)-392.5(bioactive)-391.5(components)-388.9(of)-386.4(FMR)-390(that)-393.3(mitigate)-386.3(BPH)-394.4(and)]TJ T* [(elucidating)-298.8(their)-298.7(mechanisms)-303(of)-299.7(action.)]TJ /F1 1 Tf 10.959 0 0 10.959 384.6046 447.0802 Tm -.0003 Tc (ACKNOWLEDGMENT)Tj /F3 1 Tf 10.4607 0 0 10.4607 327.2881 429.5054 Tm 0 Tc [(Financial)-632.2(support)-626.7(from)-632.7(the)-630.9(National)-631.4(Nature)-634.1(Science)]TJ -1.0026 -1.0948 TD [(Foundation)-528(of)-527.3(China)-527.1(\(grant)-527.1(81173065\))-522.9(is)-531.7(gratefully)-524.8(ac-)]TJ T* (knowledged.)Tj /F1 1 Tf 3.1109 -2.2871 TD [(AUTHOR)-333(DISCLOSURE)-327.5(STATEMENT)]TJ /F3 1 Tf -2.1082 -1.6421 TD [(No)-299.5(competing)-299.2(nancial)-295.3(interests)-301.9(exist.)]TJ /F1 1 Tf 7.6471 -2.3521 TD (REFERENCES)Tj /F3 1 Tf 8.9663 0 0 8.9663 321.2787 323.8298 Tm [(1.)-501.9(Beduschi)-706.4(MC,)-702.9(Beduschi)-700.1(R,)-702.7(Oesterling)-708.3(JE:)-705.4(Alpha-blockade)]TJ 1.2519 -1.2203 TD [(therapy)-261(for)-263(benign)-256.4(prostatic)-262.9(hyperplasia:)-263.8(from)-259.7(a)-261.2(nonselective)-263.7(to)-262.3(a)]TJ T* [(more)-360.7(selective)-360(alpha)]TJ 6.351 0 0 5.6449 408.4723 300.9826 Tm (1A)Tj 8.9663 0 0 8.9663 416.2393 301.9464 Tm [(-adrenergic)-357.6(antagonist.)]TJ /F4 1 Tf 9.6614 0 TD (Urology)Tj /F3 1 Tf 3.6863 0 TD (1998;51:)Tj -22.6866 -1.2266 TD (861872.)Tj -1.2519 -1.2203 TD [(2.)-501.9(Vikram)-474.5(A,)-467.3(Jena)-472(G,)-473.6(Ramarao)-476.3(P:)-469.5(Insulin-resistance)-477.3(and)-468.8(benign)]TJ 1.2519 -1.2203 TD [(prostatic)-477.9(hyperplasia:)-478.8(the)-479.2(connection.)]TJ /F4 1 Tf 16.1487 0 TD [(Eur)-473.8(J)-476.1(Pharmacol)]TJ /F3 1 Tf 7.8214 0 TD (2010;)Tj -23.9702 -1.2267 TD (641:7581.)Tj -1.2519 -1.2203 TD [(3.)-501.9(Marker)-444.1(PC,)-435.2(Donjacour)-446.7(AA,)-438.5(Dahiya)-439.2(R,)-443.4(Cunha)-441(GR:)-440.5(Hormonal,)]TJ 1.2519 -1.2203 TD [(cellular,)-476.2(and)-475.2(molecular)-478.6(control)-477.5(of)-475.8(prostatic)-477.9(development.)]TJ /F4 1 Tf 24.6341 0 TD (Dev)Tj -24.6341 -1.2266 TD (Biol)Tj /F3 1 Tf 2.0107 0 TD (2003;253:165174.)Tj -3.2626 -1.2203 TD [(4.)-501.9(Culig)-256.9(Z,)-248.8(Hobisch)-260.4(A,)-252.3(Cronauer)-257.5(MV,)]TJ /F4 1 Tf 15.7504 0 TD [(et)-252.1(al.)]TJ /F3 1 Tf 2.0107 0 TD [(:)-256.5(Regulation)-257(of)-254.5(prostatic)]TJ -16.5091 -1.2203 TD [(growth)-399(and)-399.3(function)-394.9(by)-397.4(peptide)-401.5(growth)-399(factors.)]TJ /F4 1 Tf 20.1764 0 TD (Prostate)Tj /F3 1 Tf 3.7937 0 TD (1996;)Tj -23.9702 -1.2203 TD (28:392405.)Tj -1.2519 -1.2266 TD [(5.)-501.9(Handisurya)-295.6(A,)-296.6(Steiner)-295.2(GE,)-295.9(Stix)-295.5(U,)]TJ /F4 1 Tf 15.6113 0 TD [(et)-296.3(al.)]TJ /F3 1 Tf 2.055 0 TD [(:)-294.4(Differential)-300.5(expression)]TJ -16.4143 -1.2203 TD [(of)-260.9(interleukin-15,)-262.5(a)-261.2(pro-inammatory)-259.3(cytokine)-261.9(and)-260.2(T-cell)-265.3(growth)]TJ T* [(factor,)-513.6(and)-506.8(its)-513.6(receptor)-512.1(in)-508.9(human)-509.3(prostate.)]TJ /F4 1 Tf 18.7854 0 TD (Prostate)Tj /F3 1 Tf 3.9012 0 TD (2001;49:)Tj -22.6866 -1.2266 TD (251262.)Tj -1.2519 -1.2203 TD [(6.)-501.9(Kyprianou)-311.5(N:)-309.8(Doxazosin)-312.5(and)-310.8(terazosin)-318.2(suppress)-308.2(prostate)-316.3(growth)]TJ 1.2519 -1.2203 TD [(by)-466.9(inducing)-468.1(apoptosis:)-473.5(clinical)-468.4(signicance.)]TJ /F4 1 Tf 18.9181 0 TD [(J)-469.8(Urol)]TJ /F3 1 Tf 3.2689 0 TD (2003;169:)Tj -22.1871 -1.2266 TD (15201525.)Tj -1.2519 -1.2203 TD [(7.)-501.9(Foley)-331.4(CL,)-328.9(Kirby)-330(RS:)-328.3(5)-328.3(Alpha-reductase)-332.3(inhibitors:)-334.7(whats)-326.7(new?)]TJ /F4 1 Tf 1.2519 -1.2203 TD [(Curr)-333.9(Opin)-334.2(Urol)]TJ /F3 1 Tf 6.8224 0 TD (2003;13:3137.)Tj -8.0744 -1.2266 TD [(8.)-501.9(Carlin)-267.8(BI,)-268.5(Seftel)-270.4(AD,)-267.8(Resnick)-270.6(MI,)-264.5(Findlay)-264.9(J:)-269.8(Finasteride)-269.2(induced)]TJ 1.2519 -1.2203 TD (gynecomastia.)Tj /F4 1 Tf 6.1016 0 TD [(J)-337(Urol)]TJ /F3 1 Tf 3.0034 0 TD (1997;158:547.)Tj ET q 360.113 0 0 192.983 43.824 539.263 cm /Im1 Do Q BT /F1 1 Tf 8.9663 0 0 8.9663 425.877 666.8219 Tm [(FIG.)-265.2(1.)]TJ /F3 1 Tf 4.0403 0 TD [(Effect)-263.9(of)]TJ /F4 1 Tf 3.8127 0 TD [(S.)-255.3(china)]TJ /F3 1 Tf 3.4966 0 TD [(L.)-261.5(FMR)-255.5(on)]TJ -11.3496 -1.1065 TD [(histopathological)-416.3(changes)-416(in)-407.7(testoster-)]TJ 0 -1.1128 TD [(one)-544.7(propionateinduced)-546.7(prostatic)-547.4(hy-)]TJ T* (perplasia:)Tj /F1 1 Tf 4.1605 0 TD (\(A\))Tj /F3 1 Tf 1.644 0 TD [(control)-256.2(group,)]TJ /F1 1 Tf 5.9372 0 TD (\(B\))Tj /F3 1 Tf 1.587 0 TD (model)Tj -13.3287 -1.1128 TD (group,)Tj /F1 1 Tf 3.1551 0 TD (\(C\))Tj /F3 1 Tf 1.9601 0 TD [(FMR)-571.6(group)-569.2(\(300)-165(mg/kg\),)]TJ /F1 1 Tf -5.1152 -1.1065 TD (\(D\))Tj /F3 1 Tf 1.802 0 TD [(FMR)-419.8(group)-417.5(\(600)-165(mg/kg\),)-421.1(and)]TJ /F1 1 Tf 12.7027 0 TD (\(E\))Tj /F3 1 Tf -14.5048 -1.1128 TD [(nasteride)-803.2(group.)-793.4(Hematoxylin)-802.4(and)]TJ T* [(eosin)-334(stain.)-334.6(Magnication)]TJ /F9 1 Tf 10.7173 0 TD ()Tj /F3 1 Tf .7208 0 TD (100.)Tj /F11 1 Tf 9.9626 0 0 9.9626 200.0692 748.6864 Tm [(S.)-338.7(CHINA)]TJ /F12 1 Tf 4.3817 0 TD [(L.)-337.9(FMR)-336.1(INHIBIT)-12.9(S)-333(BPH)-336.5(IN)-335.7(RAT)-340(MODEL)]TJ /F13 1 Tf 30.8428 0 TD .0071 Tc [(64)7.1(9)]TJ ET endstreamendobj14 0 obj<>stream AdobedC        s!1AQa"q2B#R3b$r%C4Scs5D'6Tdt& EFVU(eufv7GWgw8HXhx)9IYiy*:JZjz?Nlٳf͛6lٳf͜iӡe~E'zFrœTua Pޤ g ͚>_En+Q"f]WRZtVVwP$C .4MGcіo^+H:(OHE]Yᷕ@5.nd,moyOey BK+7YDWV=+=; kBP EPz (O|ޘQEG z>_WUW [E ,X g[yfPd".#=wTz ~Y%BX-a!pBP0[zsfRAvM1{Uo/Ӯt"MUoۯ+0(t>)d!COR)lW_.S"LP+S1soK]1@\j2Xm|bt:U㑇$&DOŶs_(EiWS*–|m@]'ԯ;5Wso:[E żv-@\k&QICoZeq]BWVh2G/k~X7hZ Ƞ[ o7yN夋Ե*X>Fgoۢ=C/!>)m##ŧ)@OTTJ8r7֍冒geGdFT|u+ BY'dLk">`q~8x-o.$mB$|x%BF` mi,Ǖ{$)H$3x5Y5Vb9XlFtM3Mv:ŜwzޱdoUϩ5 C$}jz:gBԴpc*Hop3|w_BƽH=)ae-Zۨ9s SV({gԞRu 6[7jd+-|nE #7}TAXޗ2wQ]0om&_UX紼K]FIu2QH$F"T(GoGa$^C#"+IȨ6=1CaKugXbdB)`65?+i~Vկ]Azuw2/j}5V 裒T5-/%{֋p&Z=6P3 oK6ڤ7(%R!i %-'ma+$:עP&X1 cB޸m/ >4gүg];Xgr_t#:"^N7( fOb:+n{S Y~Z5j/ ދzcQE'|Z–qB5ynI"Tj%5ڕj秴}^_MiCoA5UTO+ceZo($1 TQP.ĥW  Mc@KMٷCA(E; E>dK)Urfig}͛6lٳf͛6lٳf͛6lٳf͛6lٳlX OCSd %yO›)=k@J׾Gшdg<>J Zu{uhPy5w7#fot )lev&9~P?q_'~FRЏԲq$ӏ%#Ө#vag?/贻8Yǧ0us@Iu)P:P[,46r}Z MǟlT§j줊}Sbը m0;zh GǙ죥3lj"2!"8%$V4'`*WL]OW(I dJFUﲭ|s=Aާ/^avJhyLGO v8*dbXI5!5*֨hAA8G N57@VFDZlkֹ=o@;[-'i0ZKqgyVU)M8,U!ޕv߮sM-j":֟!R8)m>j^O<&v;+ F=sf͛6lٳf͛6lٳf͛6lٳf͛6lo~SiIt{h #{rӺ e}HCITR6=j7>I*yEIWIeh8`A'4htMHr-hYK31bN':loeV-~AVQY$"9 OTm76JXɧ[1[zJSH9Ҟ]cS%Cz3G(fG<7QuX|_&H(h)lOKc.mCN }RhĬ%([A;REwN?0=!0ӓ;$?A҂|_֍bK˹d;$@B(ɕ+4^A1Kq=_ iɋ;xh $evHyvbYdKn݀kSڞa5"{Y~F@e9¼sȚr4 )OG;14?2i!HH[ XiRs+T%4.6lWV#c(Pl6忐'Uȸ|b$mTB:s[,ĐC%P4Y-0=jޔ 11Ekҽ1 5bE=9<ߤ?;76֗Ҩ)mvSԓJ?`F_ۊWΩ?ȯ{(n7^^W{;HW.t gFŪ2-.Bf/VI XF鮵 K3,w!mcRiƤ)ĽujA,{ պ7#'-"v 94j>KGy{Pe.{mǠDFcPA*2u1fm5="f79"x;n{dB@z^s38fSJ`;͹72?Zր5mTmt};HR~XcbyYY+R!~+M9?αGM Ԩb-HEPySSJ$2[h\0UW7vӫqk٤B뿪^RS6 \@kˆ r|0UUZGlUeHO:xz]Z;pBם0N6[RhS}ܳf͛6lٳf͛6lٳf͛6lٳf͛6lZu^ x#(}.{:QE&mg>;\$A-?m;X-q塡YjquSr;Ѝ_kcҴKWchR W6PNNF<}~aMo6D$ w't] $ZL]lf-?LRAi(H2Z=0lw /ץ9t:l)%gXۄEI>*`ՖF@ G41F^tuuqKŚB{3)|TιA gH[1?".g`jY+L^mHI2LX Eb 1QM&xƜ{0"_>D!x향R t8ݍg%+qg:&ھ 8Σ8ODH/l[7R w>2}b74\8hSɟMm 9jg%<zL/ON-E(I>,X88k +Uy`A8ܹvAd3ȠRB*N(Z{C(l<>u;^d*:{c qc:mi+R7`aFs=/5?n6\G {'?2<',̋# o'nI SQ@6 [R/ BʭvvF&jr$4h XjG(QЩ={e򾿥iZֳEqiiMnl,+n;'U [ο~]i vf 8oRv(瓼[I-5;QG$f/bU@BPiZc_QDᙗN*iE fĄrW{V aH2z|HKɹbS <-Nt(㷶KNjMif&Kt5yX(MwaN}+M#Xkh71Vea66ϓȠ*&ߓC7l:B$v9-eD\|DQEgop(!=]sP4{X緀:At[߉}\OP_T77%+q>r%Tqwۮ4! k'6g*"cJзU˦u/΋(izXEXN]IJ1eU-QLxlGoq3Xk8-cXtV(Z⤏TQ(7毘5-FY\%os18Cn ?u=s]r=JW4=^}EKW,@k^dW|'ou+ê.Y%G?B*Sl752C//eRn"WIV>(죛AJqRF:\Q-9dHڟ xTڞΛqlG IPkxZ+ Uj)b).ky'e_/M{tjRHRT_WO8>e'y/p# ,* baiZW@K0v`/GL3cv?5䴭Ve?:jXmLxѬ7Qګ TxdC2-$6SO4hg˹jzFI%A9_䛄z<kvCm#rz{l#}5Q-VJq7F *RiU6:`xz`K؝#^G=rW^s hk=6++N&qa<,b*xւXq}ףTꑨcl 0($ 1-!EQ~*ejNHJe-*ʿ9n`a "[#/q1k };РѼexJXT~9/<Q1zȌdGhF^|q!}lc`Ch:m%)0) wL[ E@4I()(}xVsS)נO㜗rkJ{cvjŖ5vW;RSSK5a$v+9c(@o`F8m$$Q_<\UIVw'[&FHYyK!nATǹ6,oS$$v@#A8lf9scXԱӋ[%MԓfD: (#qn.}7D qhwekU{vWP4~9?< 2 V+j|*(h]wO>]V@KS^., ,? G!Ȁy^<5b}kѴx0VE⣀,XrnϲMK0G\\$jЈYި1b7me"ZkiI-h9)ӟq/H.bEȈ zD WG4fDk^]C7oqj%z-TgnNZ^=)]~pa!m{c2>(\-­й*z_Ջ[x/.K4Wʡ76j7_ X"H:^aq$UFH1I#p3KPZvi{xe{z;9ZsEhʫqTE]Cl2\5OY*~܌t1,ĝSi:jA ck(څ֬O6]"q]$WP@L|n\%"bt}JVmw7kj5LަG5j(ڕϣf͛6lٳf͛6lٳf͛6lٳf͛6s]M>ZyڑqEF)U#s]뿾2H1 w~k׮sXy~I,5h/5(eVh\Hyn[_&-{៘׷wx$9YIV^o\ZMm\TE|-\E ĻzEiZp64&j; wkƌ@4|i7ä!ZzmZW9MM55wא6jߺU"A,5[YJ~V̭J"ybMGj!?Gvvtn7Rb [7SZg?3Qܡ9YԈ$m"q!`f*.u7.^Itv |plwly5c{4^V,]V-M]:?N.=>l~FG{s%3<1#.*y.-k-aT%+ɦu'XsԵ w$WLǔG"ً7HntQIg*w uv*6'/NY@hW,?A{ |p@Z(%'9(a{䛻"oE||*h(RR}ȕԨ(NܹzJ+Cl;5GW'aslAkge[4޹'U|fW[] TB i”9ooI⷗/^1)^WJJHçAKccKKHDs iOJQ䢜?6 uʼn^QŇ\@/VVz"o j0GsU%U4m BI=E)jvʚƵ+JQW|eO^i3 &rYmM!OF`}6!In 5͛6lٳf͛6lٳf͛6lٳf͛6lٳpAm=֍ʜ¢@1&-c\Xqu۸J?Z-`U k`f[v%ہv.#ׯHSJ*5'6n98+(s $~mNE!ѩX!}ztZL!NTDQۯlSյO)kց{a"]ZLBz0֎;ՎcߤlZ t *7eJ !X W t\bν~8\b!^.=BCLJߥig9/ߗEq-^AV"oo-;-{0MP0IAFA)NNxgksT4WMXn ;Bk=/>j݊>oqcE;u0yfFH U|p44+[Eon{߯WqznI>)Z5j'OJ䤍'oyk_LJPxOP@5S^L[oj|4޸i6 }ߐ>0EvNyzIg'2JIw2RH$_%V/ϚTRnTiQv($EdOXg"}7C;tYAIE$s;g&򶫦i:>e`S4ͷ֣tRB WkoKNfH烗Z ^@7w:vO^oo|~`&ΞR.yF*b КI1~D~l)4s\j0H]Y|vM;i'cSfR}+[XU87L>z:wvyVDbY/C*5%%ZRǒ0KlZ/Sz`d%C vd'4/g nƓ[MVj?M_^$ o Hc)w^IX6uΫtH<37Tp"LMu ~#ӄQI`[I-+{m%zr@L߲謍Tg@[HAS7T.mm>[#P\pRzLk0v0h^pwI$vR[ڋiFٚ46TW<_ևnv\Y㧁uhHD0}E.b4]OK˟ZOXׅn. cS/Y>niZSлy[k>1%ܟEUȠ%+[}69^f g.xjcOJc~+'$2$aʨUp>4G4 Ӳ˶ލq1*ʕT?̏7ȴ/F |q5H"kc,u >_Ï@Sד!uq'jZx̱}@|s^Xԯl+i甘xncg@" Jd缳f͛6lٳf͛6lٳf͛6lٳf͛6lUu%֥ ;2@;7vd 35mi$E/! Iۊ+uOdg0BO-F W)4%oko2JZHp,))']f:GtmQdU@4 L2@nenW` ݭ#PvdFgue^FBKYLSDZ=kT>u\ZM }|.b͐.y_ NҠy+Pт4/ OsԹX-7rW$Y-ʓ?8e_䧅Ȓ2-D>Ygs{-^*" JZQpFӥM Hi]%K ND׵Lk~oY횺v Pm{QX}a*kSM^j|6XIeH,qxyR;JUu=C%$ Eү|U,Ux܍syyZO+;+bđDL?V#sa?/=Əۥխ .mU!˹.iM$R)K ӛU?kMpVsa6TV3YiiL>,iz7ջX<2+FRFHK?2ھO>6pjK9ygߟ?FkvHUUu4V[r*bum'y˾o?HFXm;$}9o=A"{8_Giy@1^VVn#dٺoXvi;m epc1N2n\GBs.keUKUҡ)L)zЌU4MEu}>سdӖJr $,=> Ww+.rb"ӾqvU 1 ]t9K8 Պ4t+DQ!n2GԀzdZm3QOHieW@@c# +;;[k "UXUAqq ՠ۾J?+,|Lãm }SPC[ Wb5߹+叓F՝NVI.݅'(5;_]|ͤhZMd[t!hQӗxPW_ƹ(w3L'Y9=V5NJOʭg~nŦ[QwjV1B~D_vS4jSgN>Hov>"F&M5e14^S(<"[b6chݼ*|.+UUxv>Zz7g"KUy=5ә滯0K=V.j_+dWƼ!bn07Wg22W榡%RAL>Ki5[ Ŵc$[4P$fn+SJVٳf͛6lٳf͛6lٳf͛6lٳf͛9檓6 =@mx87Fk6DUYF,+ bT Q6aimrIwoQ]]@U^GDӚU0/5;bP~ZkzHy{̏p!{YDrFf.kPZt9i4-.A% [݀D!巙حzۀ ,RfW:!:Fh@rh>VL('UӌL[kl-?k-ӏ":SiFGn9D~yP_ EAM]5]+I劧Ǔ"3&x {xᝯo;xu-9`w(F?+<j1_(||ߗ?0ZC+F*=,4rҢ'h1Ta@$O_0NHgUgMnT)J5{+Zֱ\5WP0Ѓ^{IXd1QRD'qPLJoI4&oӮ9Lb )D`({PUBG ԡ[L#ml>h6׏Oi"$ESy (֙Ubd=UyJ]9<2*0DRp_A^^rPZ&e 'T~B牠^@)֦g?%-3Vhڵp\[ʨe5Y H9^sKMc}#%2*$'5Rj;$?ϗo[E";B KDWUo'zRh:志5V Xn9cuWBSc4W ?&PHv'Ι84+)o%k{mMdo$bxz֯5M?BW~uB]yOpR jıیbUrx9zpt-O[EW_Q \F^,5N}ίtX] ]Bcaa$M q=ZLH-Gx/d)HB~U^'% V8Hvp;{dD2ih&25PH#; z7\ҞSio5U6ūTVBX|/ NUwNzbS+{(Կ2xzFcJmG'yfBӅR Lrw=U %un {׶D|O5NyP :f CTbj:P8!S^}:%$"^1GngB֙[)yf:#AW죀kԬh[*l\}YhaT´c~#8FkZ~+D$'_9Wđ(KނZAƢ'\4&f:-,DŽ:-!7Rx)NE*3:uI/iZ}Z`u-SBZ'sVzuCYgs r0Mls^}rS Q=~rJ lzM嗘[儌L ;!9ޢu&[*5U5~Ӫa1k_K6~fI,"ՠ@*MX צȯ$W8&f9՗=qH#0۔CTRghdL r<6SD$=07liW:VX@[BNB(w AG$Fdj"~eۀ+Əu5D*HVχLO5kZW1D$XHES@)A^_+^UцdN}WU^97l}|x|I,rq'p~5{n+i%@`7?_+JE')'7Aؑ«<=H&D$V#i>9(* 8P5O15L"f>R *6l(4JUHְt2W={Ɉ22LMO"qswDFQcHcx"Uz9id6 YK]}឴҃bW.؉_eIYm^.$(`/*p}sqm͎MĊH_SU&ms2E^FG1K;GzI8!PQҿ#oP[_X,"bS% cEF(H܊64_etf5.[8u4wSܱ^jZ̯oT? PS{A-lɶsveX,4ƈ}5Czd_'GW/3[,il@d/A#2!kVԼr?}woQ;WǦGanrOĩu`VMϻ// EګϠ޾ދcq á\jm5$K9O(f Z QYvSrr}K>a.Z4_/e<)ٗFqwA-bԥ+JTIJ_Mm3Vj!cl JB1:v[QI1M\*nfH f@I^C">d4~mU݃[^n,wBȓySG6pєI- ]NG+`YrXVJ:Je_kCFAXynfm˧bfb$fPڧ >BVX=ǖw=;L0iQ0EV*:P{n<7EEW3sm[S4zJ1 rSƛ?ܧb75)SkZ귥ao-8PVzhmm!,nF.x;}55ۈCLko^hƞWk?^4-=$)'(W|8'֟ud헕͔Q#4oj:pTriE4DH5B5]ZjrHUnGlzj/$4[XhK$6ʑd8/Ezki^ե˻wUhb8>4|뚥^M N^1Hdv „/Rڇcs,Wvcӌ,@A `#=_.`hVkq5;xf+0 57y~Ku꺤WW*G 'z.ڝ=EcRދTޘ`H]ao_jF(Kh2q?WS;V?!mdHcibhI@Gġ輀=, A^>+O0(fOGL SH2yuu%Uc6(KQ8U&:~:\Z+,!%7Ҡ:0<QK'_J퉆 :~ 5:g7S!)ni ͥij U -Nol~jDo8 P(=ZݸO^ѵH(*R&NG|U˜ThX ^&Zb̚c-:[x6%n97 \kG !3\^̠TsΣ?-bV u 19Vm/<{}Nв[F"@EU}=1?Vo4Mh-r[Kkx^hXNmTg`0nEzg@D[\CY#99 Q<)yPJ!ugzk'?l7s<eXjs\Xc$WAZq@ %ze(k S/e٦s[I0E_yު̤ȋ+ɿMuk[j dP"ϒJVv޹"ִSѢ+In$/h^^|H%P|B̯$fZ(]#-75IcGE+@ZvVVwlF5jNKz/Haʬ:RI ֎IO":S "X1w7}fUT?g]0Kwu-*RTHEgӸgU82WB\}ZԀJ@HԩOٮ緉.'!?Tm\G-bȎL XS ;N~oH,g->gpyp-&[j g= /OJ$~C'Rjk3):7JASu€)PR&dZqzNP7zbE{n~xk_^}N]4?$ʿ[pVj??{L¬)EFƹ󏑴3ۺ:oa,N\fi$ZmVywEo++7>y"g ;!ԄMhz $q̨:I@‡t{-闚z30dš V7K{G匬"PQ@UP;`╭{cz(Н]V7nj. SjLJǓ4Ƶo v>qPMj(j6!#Zˢncm@o?!IJp~fGCZS$Ʋ("Hdǃ+mmC˚ּ:5-}˵@Ìn|JUr%-̚vqUBSB-`H5/!D~*TF"/P=M|o-7U]&rMwk,ۤ8 nqWUvkƵ}3zڴz,0!B/XJUѴOVF8k6Fa($[,yr605W3d)o?y0wdQN_S 4{DTY%6EK,?F.Wm E2%f\rqThp mNoBTɩvcqH=oeieZZ¼b=m' |T&W}oO^ (܂j oN48+ivZs}wU8"($8ƪ#GB*=;^T r?7 Xg]dzxHwf]ߞ~_>Qs,cw$RrGv¡GSsa -HWC" >Qt{̞^\#y$aE޸5!<zgSԿ%-t:noy%Vr䐂c\6Ve6(@!MkZwŤx~2kDڶ$$[*S ́Rl=;骋a,^XYxÕ_mӰu/s:h{JɦXUXH'f|+5iq,ZcH522z"JcE*r?sto$A.G,r^TN=sʟ~k󖫬~eA[ĆKz{\A=RPU**%8_/"N[fh^=> $XسDE:~)ₑ%INJ[~7KVơ<,;-$@&p~*xgsf͛6lٳf͛6lٳf͛6lٳf͛6l~fd2mxح}ƕþPo5W'+PCtmz;`F^SlM:WoUԡM ROᎻzwv {=7R9$DX @=77XՕ么 דHA* ǽxҟ<3Ii?u)-- :H$~XOEmVKzݶ?FIQEr fݜXr >CMhW]"Q3 7YGY\Oi[_Gs$o2:0ǕFjezX̖ ޼XP\ٟI(g/AȏVR!Z}>g*} V[\Sk6N4Hm6EnHWo}gS(uԐkN % V$+#;~-Um`j*ǔ*B4툴i~OjFy=l@Z xByTx#7P7l%fӮ'XQ幹nC~, GWpSe2BٔvHHZ)āQ:+yVm:n^ɅGxOD(R3È!$bT[71\}J7zs[4R(x5kQhZNHԏ8MZT:ċTj~H;0ĻmP:t@GӦµ<):y<ͣͥݰ:łn 3ؓfĥU^'F̤xg3g<(T J;=q֗q'ՀF%a$ Sg}:Х,Jt"S $G ަ H9/|Oc P֠n;DŽUV@OlĒū^u2Gs36ars:0&xG%R dƥ$kTygvw^p7aiJMr?hfu+}nm(䷿cImd&8e) _3sXhIQxè8,H rr5Zsyz f' ЈV@|}ߛgm* qP0z*k6~mʷ-eju *4EkHp̌ne:h3޻F +Z0]OXDwxaQd@91{[b>hKP?@5z10E;m]6K[Gf Qn@-n& I>iV+v+K+Y x![i)$#O՛jz/BA.5t[f}fH*sPcAwmV;9ghIʼTVjr@9ln$~}Z&>ꃟA1uĞ&tIZ=BD ^_Ye5o7\iw,_3! >B1xu ufF} 1d VIg$E0dY9AԀ|^Nɱ6ߤ-Cutg-#*82/z6lٳf͛6lٳf͛6lٳf͛6lٳf7^ϧ֓ƙV mpOSGZ]%J vqH-VPx0ޥH>Uq5־A雏/oP#rE+`Iؽp_BIpRȿ鳍0"״D+êJo=9" ~!2c8Mn0W[[ES17Zpi3 ?v:D0$(#U8W~t݀!RSR˸. PlOPkGxcFݽ\D4>JXfVjGz(68hVӧx#%`7ҽ | m-:X4ReUҵHZ:V–2j62%Lxv"?,NѴZr\隭ޭ+EܪCvRWaz"#T~?7koil%ZJS 3Gvfv$ "y=( $_.#VGt^aM'2H\;u*Ʋ:އބ@qeFkxទ]iq\o2-UǍvKANMZcIGjuؤVU,@I ȥI?.F<oԕu=V(.N*:|0 ц,7ڢ{1k?iJgGwc29+_٩ /Ϛ/[ԥ;I`Y"swuZ7sQއd4ocw/ 9 ey W?OEk*[*-Q^'PU*`ŶHzM/MpgI87WnvH)%#uKtht 7K *B,yKȦv7zl^_N,!h:«O6k;~+jw w/@Tҿlh֏C尥^yW~Z ^*KWpҴA¹յ1MV9%-N\P:ӝCQ#[GzFQq]I0APun' cܥb=5ҙZ&@o^}LȦTC ]NqU4n>$ Z/mokgY=T|.+խTkga{lۿG;PH=_1{s!]^I}uCioJ,^X P1Sjp_ӾNzI'd~ rCCF¾׶,Wj +Abv6ZpӨ4?`=RCF8(|IXS$cu5? d3Y)))TWSf oNauJxR^ +8iI{g5D,uU?^V53cYS1KD4)%Ql fι9_j0KbeukFJĎ=Smkoei) E QQ#QAJxo7*Ns΍>%%Z: 5P~.lӝ/6lٳf͛6lٳf͛6lٳf͛6lٳfYBF]ZY[)Ȟ ig欟3Sjȡ} # n=Kw &5]ŹT_9&R}Jp<$4F´?<5ɉ&KudOssƃ拨mPƺ|irEdaQLsyCg̚K^L8YRlERe>Qr7E'UMv4Of C zpiP=cշ"¤vm3: Hz5ALA֟3Lkt:Q^OExӟ‚>;M3r6%TKurqBCP& G<9h?a.lȪLHfլcZ2Uʘx:GopSMv.$#owier}nj^39q}r[i|~K;-yZkkxu)// Ԡ0lwEl|RZv$Egܱ&<DDμiɏS-実]$˨<2%ѼEG1𰎝ɯls^]*},oVތ,E3kw~=6Z<XGepџ-h3((s~8x)Ռ*(cNUiֽ8@oƕ~jSUKHCj>}%f %vj*K50դHeMZ B/# ~f |]-t R.މ!Xs%}x,H0qV֫u Y辱V d59?ƽkP:871;avnxFM_ 98y J}Imlٮ:ӆ1Kt&pz-;S#zR:SVP悟j-.S:$H _FRD>qei}ZkZ]w0q3Z $|[PV4H6&ZPHI@%jvߍw6cy#[P"P؇(T_1XܭpkkIP+~R/St =%z(+q Hzdiko6O<ցlH;% ۓܜ:5riZ[,9 r~fZ/P65pG,/,6{Gg;$)t^-F$$|R=Kp"z*RNԼg0]N}v4 *)e cMKoI=۬hѠ#9NchץpZakv &WJGs)WF X\,,\sGhztΕ{ahn^'NT]ڠkuRΨ(m%O6\JՊ!DžBEҭjZ+G1Et y+^[p5Ģ9O{dפm֒-]*]fn&ڟhi\,$ͽFvTn*]LuF7㌃*(d`z׾i]eeQ򽲑,j> @RFPjKaaXDK/4Oִm%זU>)rjUj{c'G͜;|~oyU5=CHMV*0Is"=}>\y#L=Uafyu &Y3׉#gqv)50vqèki&!@*#;|sYf͛6lٳf͛6lٳf͛6lٳf͛6@3؉4Ud|*:lJ{-F$BGt,c֛,|M5_fkihH~2ʍf'dYFXk"VL~=?y;`V @D%/ࠣ-S_Hb<$$n4g⍁؆iRk@c@jw$Pf4V 4@rVwh~Lįv6)CSJPxV>F14]rN#H6/T6np/懔/v0Gm0UpVYA2G*mJg@! !+V* &a6=<7C־+4'&U_zmbrU+AMe8O7dézK72=NIjW HE]*/1?w|=zW2Ҽysɰq}B܊HMCʿUa,ۈѪIpOI&J9Wc;y[ͺ iH9RgM sWJ?Vq2M){k+qs$\: ίͽkoZY14R5r65M+PE.wr5L:=dUzԉ rsc?"CcԒ[.Rh ;@ v!Ӣ~t@|}*]i/n5drt$AK(߭3͖OqodgmAb8| "ZgMfp@~9xn-mKF3Au$˲(${w#!K=6XTfYPh0H. nC-\oM6'@ԉ~ZU5OLmMyV:$g4|_;̱ZF%di"U¤W!ozb6Wr,gЏ1^[Z/^HO#ذ3~_~YyZtTzfsu;_KkU}%5_w$|K2G%̈́H[&lFPIѸҿNr[}-1i$w_QSp> M)];`:8քhb 4TSN~M;[HY?0>|b`Vە\ȏQ)\iףVЯ9Ip:FUs;̽2{2iwSem'k{&8`FY!/n8?Dnc+)qZ+-M4$,+$Օ2rSƛXԤ@*xOAO=SRK]d=_]z#:2ȌëU .FO/k,45Ir/,Q 4AU#kH'oЊ|~m~hj^v蘥:M$i,~%  UWڣ%>[}|_f26-DoLJ߱-&k9$ zqD*Fڃ&f͛6lٳf͛6lٳf͛6lٳf͛6@3A4O) ~~_ x/OqoNe5Sk#Oɖf[.Vs̓ڊ _PTh|3^Z.W@ס+̊=[*S_ק2kk=<ɢCpuah$ H]{{cn74Thz׉-$Eri֤t=Hyfr 28%v./+c s[EZAŒow0~ryBJKd"i@y(i?e`z'R jHmomo-71\ījnw K )(;ve_\Z.Ff-zN{ZkT#`n v2kz-䒐PlSU<9s"G]ķ8fbX6JնoʐyA٤W:p#G1cafEZGІq]- XH)KOg9?-.ORK^I(Z:65zA-j6RjJܖD^G 8W?$,jVI"%z_&ͱ\)֭u-+' 7&R9ՉORpXr)Z.U*G4qB8J:v Go-|{"4i#fULo٥2A^V5GLo.@fT(kłſ^D|kk4錗~Vztbw%TB#pݱM X3NfG!_(w{y~\jX-`qʯ,I*Zy'OFd5\i"x2Pu$T-z~3hT=On c^rVUgXWdE#Oxb9bV7Wikne-0 G{u_jPG;ѣ(1Qāַ֕>v&{͉)#X5`խiyNu=f#`+أFFk&O/D]@Թ%4`Rr?m4_YEԒZ4Qժ2[ҿ%"nqx#" xw^~`jK͢Yzr/eSJ8:d:R l=:D##fNo?RA2E8ک*MY|['-40jIM|R EOztz+N#h8PpUGEP#w/l=0yI %Z(2 ~T@lzՆG}fܢtb9't~pØWn^lS{ֹhw vjt>ZHmtuN+ES_\y9جQ-#l>ctK)(ҴHXddPRM>yfs0˫yd#NK2ç؞Ui.x0GsL_ }MskYVdJ|!V@rh[ %+O|A00;PoƙA#;}%?/]r(5>q+9 dQZ2QurЮgЯ㿎 eZ󎂄`\^hѼ[}uUEV( Ǡ#%:w%KoK#X\CV**!?pՠɗ6ڷ=m;@(ֈ#iW^5!-ӮD6e(-b}w37sgeA*ܤZ3f; lSQ vhV9^""2/:TTOWfo:H\ZA\N?LVLyΰ Ӽ.2JxӄfMU oDgfH4x!"#j+ }>`GOM*e&ļe%u2UF7}MW Ty;BoA=]:cEPCTq'MMއdEͅGopMЀ~!^oMӢ41D)B:rX˹mӦ{^~<\wn>-xZ /7n$a2]"WKE6>/+ژ+:wqyh ܁ybӒmk"w?T=Gg3AM7ȵ/΁W Y.AyMbe666ʹi-MԂ*P>:;o_ndbV(Z(欼\nEzh,u]nщ,)3eQ4?;>ż.k\$ a*%UU;*9ѫw5yf͛6lٳf͛6lٳf͛6lٳf͛6sJ_N{.._Ը+E@6Qhhۥ>xBXfY )qF*B69aIE6-͝ˢE*/P z6XiȚj333\XG٦/Re!qQ ZGS[*V~+y]~MSmQ_jl-1x,HI$cF?CQjm;I$u4kʫDbh=&*ەI7vQ3\Y*K({lRiA2|Bg|c:_+BWY%ZX0!B*TS˙g,nUQ.VDO_Duwm2h 97:2Pzq5J[Ė$5dv?O+{wX nx!Qy ZIjKt'fKYRӈW~E0AkX~;K ~\$oƎFP|yoyZ7~)`-qZ'k/'Sck}*Ĉ} W evRdNݭԟ%޾d*7tcUM(['~W}/:\MY^2-P3z4`S:F5S{ $Icn~V4Ftk3ޤ l?ny7b7@'_)-OiхlIim#[̡q='h%7oPBK,nmHnlFMMPEi^I˚Yk^n 5H"n1 }1,!'8IEP5?#P/yDyM0!>eAhZND-[΅gsk>xmGvQHfT49Z^Vqs?iwixϥ%ԆKFOtY%2qR: 0/.umB'yV1Cg1}bzB0P'G▟gֿ9&+{TeYd%FNl^~6~IN840ja}FS5  -knZy-F8d|.Uhc@%T)L5M5#ڿsʯ?i*L~qG4喚:^ tƹR~Yiδ7=Iuq#Uҟ_NQ҈@8Wia}v~~aA{p)4i?,4{pAH]Tmr啂SQ=E./d .VG26 e zǨ\?j>0?(~V镩.\>{[ir^|,,5;Mo\V_}:JIne Pʵnt.B&8ci2(Zlƴ>77sqt5JrPG#֘XT:F< x1WqGp$zVSք c/쳘һҹ$?|-֝ypoGe@q~97MK#dfҁ^9Uit#.4Sg@__ʍ( GExg>мj:ŻY@KFή$G%ɋ%]\I7Z]̈́  /4J.}ai$v^e+JӮA_Yi<8qH΅?˗ɯ_j~WР:*S$iJ=HRFYYH P:*b+]Imswme/&ӁHmݻ tUf v*Yy뺔8H-R7%_aǔo+knkڂICoKqs):QJ1ۥ@? f̍-b/BxЍF|hZ4MxbmO {2E`G֦hiC?fۧMӍ•ڿFӼ1Y@l&Z -t:yj}ymH3V9_ O/IKdžBRVBʃ7?^}uk?OKhOYXWcLq_!77WH"D^:Ֆ"kZa{ejRj]^&QlV ΂ۈݽzoV.ԒOI''k^,~U\jF(Ez|>1M?LR᧷%?БOQWn}o;K{6EKLrE ͋+)p?gMw H'i B.0U@U-BLҭ4Kb$wrn0Z%GM:W͛6lٳf͛6lٳap'OMRjyv>?B,rk:C݉T?⫨X7ٹA6uDT/^텒pͯ̌Q{o8=q&n ;}aG_1c{o5ϒ`Mvm-<(">YVkm^eSFh"p^MFGGq+3j%V $" 0>ttĬ:# wNޙ󧓡=mwNnx^-Wc~He,a /-<OoSWvskq 4N=Icu4ۀʀ&yS],O3M0LT($ւ EG4xvޟǜm#EsHp#C8;^ӥqT|_QD_VQW]b_V2?8FF ­$ףe)$AXLexa)oA"SBkV"гGu ^!>Xu{!GY_+aǚ|5{#jk$bĕ_0>obZ H58y,M:5\Vň_次+lH=l+WX[~V=5G0Y'X na~^Be-# ZxԌsJľ|p :ō_+MbőV0G(]"/,yggIXO;J*1Pb~.A'nU4YWPH;qcE^;[u+sq_^ۆf9Sߏ$,+ ~/1ZH7_VR<;wj"Lŀ|W<>]JOk}jxN}FZI,:MbɕV1~G__v,"<W{/Hj(]"/7_v欿?gIYNf"Y$E5e?]Ef70Ǟc21i0x+֕O7JJpx6%/< qlmy-wOt$wwy@mJq)xߊ@[ Iy+MT%]$YXAz?G^ _4e+@`EGb*835\^+"lCtzy. ?(hXTR)_ݍ=ֽAy|_.yWOXas(T/Ӆ~iyJ}"fHH#X,4BB̏{W$eeI%x )BTVgBK& e'd?q{व<Jߕh%&]}M?Ŭ#+S|応Z:ǞH8֗W1Z2ĻW֡Ԗom%>}GJn[w:\PѴ[kYśt4!jK:tV:|PErcC:^}rN[b Q,Iq#]jmZzCvDu*R`U W_]e V+#VcJI/…v'|Kihp}ِӔn(YvKәPOAB-׌|1+Ħ V Ѐ6~0*uEkJ+AGJM\$ƬP@ $uHch=*de qqGE5ӧ݉m'km`1GfzOO1}w77fNQ"UEPļbߌh:J{ ש5-ƪy;5тQ\^(ӧ7n>HC RB)9v/+MKBZ87 upy/ 44>?1o)y-OLF_L1gtYmf)UsRJw-[ U-JCN~aa ;iq#Q$W :&^ QCAyrhtW)wt`oȄv PdZaq0&:O|A%IJXpѸ|yjk&~#R3}zԊ~|U562%vQ FhbtxAIAF[n5GKI"5P+/~hzzV%)XВ2UJP`q)mfՙ`*Xֿjæ|mMo1^:Xav入Z~DDx\QӖ0w}~W3]US"=h͹%66ZCh]`Px(6 OaXTnzvO(.n 4:RuOh^3Vٹ6~$sP)zQgn>TlΚw˖H$IPlƴ'aA~chբ!Opk_2ue^YD-#@o<9ꚽ{kBM#3@i)"e>6u#fp‹1Ơ*U`c-%5E'{ZNa3*=95H*CߴvgmE2J}0x-iYQ[qF>.A''sQyW&v7p&8]S3HQG+&wLz>Z0QZSepַbZwMK.MJ/Qp۴IVP'eUL!'`O dGCሿP+|M*؍:2)N_(~eJaP$S/ vE'r{ټyCxܢ*4I9A,u-ah?u{HR u5ö SQ,/\\4}tPT+DnM=`uyYjxרQ҆Srs:|zxjVME*"(p[,~rϢYărh@7X}9n\10F9-Fܕ5Zgխyb_GMõf)^Q>1,4.y."I+RB(mt6EISZjNyҼTcz)M5}m. vĿ+]4vH)e(SiZwT"(:dʖh4hK { oPGRyOH/|gn4n WI+nHyκichUx9Hc SΝ?^Dԉ7Hd#jVAMѸ! MVR;N/۪Fq .e܀\kZL eֆI4m#+~jӾr|43 im>fZ*KáYW[8og䶁fͿl.^,V Hb]'{..zrA7;`Y%U5 sO1Ou_.:oĆVVڏS޸L&{R}@>䶯6[&rMy}RW_qp_56j3V Q_a ]A? 6]%{hh W¡&T35]ӯC1GZ 2a7Vk$KGc8Cy+ʹpCX2 {XlX#9`#mZ3g/,BhnXU.bN5[q%IG*Q8$Qzsq,?]$ƍE,+V4v%u$@CMo9;Ȭ 8FYOLrTUTBH*(iq7O&yVv^u-:S.+nk=irl+g:Jwb/4Pw#X;XW!QSOU ~%SᓹUz(z(@s$|}Z6vG_ HFMcox1Wd6yk]4HZ]=K^{V~Ǧ?5"M^_jƧJstTAPh"CiEB:;5O(cD|z |z#֞o_-qkdǐ>+L<_'^ϩXw4Nk ʳKs%Vx>ܖۗ)a|yXXm' &ԷIFM*3r OǢKH!83sxfz^ :C)s^(&nō7Ϡyأ>`dRʼۃvG\U!UZ =yCI2܁%䢭!ed"VE:q̓:tYRo͹8WvÏ?Gfűi52`G >G)jƢ*Z\(?hCwC"iy(>59 Ilc&wj ݛl:3M.~GGX[GBG|վy59GxYvj;' w2-}{1<j vQeefLET*{Sp1`Coŀ?Oaξh4#~p^j{c\h{X7Vߜ~Wķ[QuޮkwɐH,Yg+UzwkNfekeUdsĂ*WΧ9W ޠ LjG=ZLmcEk{!ͼ+>r,[ ]$Z(j&}sy,#NE~܂I/L5>k$f3y ^^MZOf[kֹf89mU(GSr‡zӦ\%- ap#Ww_itird80} } Wo|SQpBGK{GCqt*Wo,sژZ&&&ε@yJ~P)M]Zhy/4M+2U Y}ڽƲw1~-|V;fڠwmb!&vĥ~ v#}JWcBwCz_AYCw8tJe\Iݞ9i'PtׯY~`EKdHT"ԥO]ruiǤ$XV*P#:]ɮ4Kcno$vOLpOu)_)ԝ֝[l9քE^]kg{^(XĮ٪ƭXa6eAXGg}lv%KWF:n9R)<\^.5Do272;RReIc A2X"6YbBN $SHmNgtJO5kM6jUaowGygr2G2`8hc#1%k<UMA޻1WnPEx)幍"EƽlRSM^_LUWhJLK!V 9@ WGE5d_ٓvۦ[A-N-Jo XL-•cLYx$T|kδF?z4i'5iRG9%gElQ񹆈C>M/7%km/GԶjDWz}i+ɯjeЍ0#(K+/m2j/ cOpWdVHVq3 ֬wqq+PuLSo5T{N~B{=kPxIz p<Û?+ks\V MIєot8z}߯4Ogz8:ӦHts2qM@f=k^OH#EPZD ?׉ˆxgѝuAh†64AΚǧ" ON)㯥,G5xdG|ol &k]CWa=FrKɕew'5R &A[smr]XT7iOvK_4bw%>qt3uT ~{vMmV `5GÏNuKı! s1ć1Af/V/ T9Ooݝ\Xvw⠸ Fա"3^`kϊkpL-+&O!ra[lԥ?C6;M>4bk!1R)sNٷ[iT%,T^d>;i8Ɗi,舣Y0YF3%W3 k /|!t-\[Pp£Mהs5[ WN\؎%$T W$!2^c x _9geq4vtGa*?Mֻ2CwQEqXz@1T|Aژ&T8ҽƻ.?1 ңbvҿN#J7}Pt.$kvԱ$Ҁs_=j[HeP>ps-:|[u8Iudo"5M>>4hńGXHʀVWimJ`~4A`Hjt-[Ӽ[{6#5ĒF)CBPHC}tEmfw1 )g 1dV&ShS{S= %ASƁQ9LKq/05# E39ҤUVOuy~6w%3G3H\VN=>:Vc?7,Fvng#( $IsO奕ט$Ķ,#nM-$U8ƀéKt˯2]0SM6OK@FN%ZwRZ*ǐ4S~.+2B~o'e(xOU8ĊG;/(4[jW ׯ/byJwO}~_6GH:6\`!Ia2Α 5SzW <|&R^O}qW^`ҠH3q!*Adڛa^jec50G g;x/с- nag}6YZrhՒ-WMWӀBX/:,DMVƓpރ("fhI,9浉Уn}6i$%H6RPHssmpczeN@mGv>HkxϢ"jetQ|V/TP\kKLPĚ|=jhsc^)^cIMǽqWWC\)6`:_{dgz\,\lyOi't=Z@K+0(#5?%D=/ @*XUoH[>0c52qyT{UC)҄W(]ITe@$-p6_z8&vB>+Jס<&ye%m 7|JޡZUU$}[-jS+$|!u r@H[2Hk)RDx%aFFQ{VwbF8(Eʃ&aJ#(.A +B@w 2sQ'SkGǩ¥6!bxUIO#|ūjHԤVQE qjw譒9ey!6u(BV\3'(e3 #`L(igAY网)bF14CkH=6$vK{`ʵV rBѡWW 3UU]}MO2Yh]MHHeN_~+Ue;|$ cABTDtfRڟF&wO0"RkZAܰ bwjr99_Rh^_&EU܍я&W8άt8%Kki}<~t&-ƅVE!x(Y"k%q4dF ^kGaM )'rN-=CK9"EQzy.j5rk5Ěcy=KSS#avaKKB7&[V Ԗ9Budb{ۛiMM$!%/J?@$@ųwɤ /~g2C+Cܗx^VE>RXj%_Av;(̬(k#@Tt æ#izv}fy'P_0iCΗ2Vᷪ0;fƹ/ida(1~f 2pW6۹US_kR:{'1ZA!P+L!(vNrkkWBH#dYGx~)/46/̒?MJsΒT1=bTZ{ܐ+SZ05^@vَw9lq+%;JC˽(A뉆_[4Rbv+PulȷͿv4~yW3 ~wy=WbYCH-MYNwC Sţ!ht AN7z-(+Ԟ~A Jtm5ƝyL̦ gpmV٤sBAi$^`=3#V;rbCduf=k9aais90I vipȞQH]}UWH9$I V֑R+hgvnnvE8Qm/1_nY@zdO d$E ƟͶyv[-Q)#Ix (V>ӌcm jԦ: >sA`{wR>ԅĬ18D,y {H ;B{g-U}4$Y'uZG,@-H%N6k 4nev;`*OðޝJh+~(E()|*[i.,#gg ^\/8OU:4(pl4K};oo:ޗ9uUi!+Jz{aM;EN.0FR# OqN2Žv!vG?2tƿF`80ܫD@bߔS/-o+/k;;ߩ];ݡ K{gNndc[Y/-ٕA2-)6KP" Qҥ~#^HZȊHC21棹k˴\Ŵ9m"B TRƽn%[6Tj>bMjğ=i;p' jCTPW0cHRhPb+ZkNMAag%$F^Jhx۲ľc#R]J& c=1 8i`GL[Eү+F>R\ڢ<'74Pkۯ'߬$}@xzE'6Fˋm3Fjַ՚3 ZJ&OS"הln$3bs !CU~G˶QAݭ k Eu#*U|zS$1_q5B(Lq@yorGgmGNmr->)`YaMTL FZznC>O\̗љ#_qhɥz[kۛy-A (PNEhzWu}shdvӵ[{e+%'&0tvZV`}.=pP.vֻ}]6 )xnDa"aJoQMK5o]v c*H1Qז,Eab9$Ws$;?+pE;ݕj~ *#+rxҝO'sCGX@??)ӮQ Ժ1+ OOAӭpBҠeQ_ې8WZvwV1LhӦ0ϓtaIuY"DDb X,#1!aE+S `RCBBd y< 赠κmMA;WjJ8rhWͫ0DQ>+ԟx =ǽi_q PB :j1,A؃M9\|Sz0o+%8e( wphƥN܁}̢ب=Ģ(%)p_? >Hӆ=.c$t;Kw<XD&ռ0Ik(Ja:S4/9nwв[8탕9!+e3q hi ^3E@qq *)Aӥӎy@oASC]=]F7XԈ%^!~"μPgukCe,"o$S`ʻ7''>J󏑠hukO[P7*>9|:FH ~z]#h $:{x.#I`HjlAzuA ,jL'9޻%jPXEvĄ(`~"`x8!r}N%ze}X]I Z8 *h* 6YZE}c({(Vb J)Ӊk[K+.m`ZD Ai4?$eg QSk0$*M>[%^[ 5,bio,"d k!Bvba+\kpįĴ⇉Z_ח|曕N!SӍ+)(=MOɿ^HQDv[a)FȊw_~ky\|a $Dr29@(qF6[!-=Qi3Z@Y2ɶkZl_ahvU7LΗH4Ҭlr1 'u[?V3I I cWjL`͇˖weMVVs)qA4oI#r h"gy/*|KZáYp҅oAIJǩgUHGv^_&+dtJW..R V"avU4+EЯD:t< A,qѻypiVp~?)󉵍f],boOJiȠd'Вpg?R7ڛɢZ3/ M!ṃFzfinob+khDઊIy$2}j5WX֍? oLo˽yuXL6^jeXKRD h3~V}[WiZ_AXC24*2LXPƄuXPnէ@zL>9C]sS~⠊߈Iڴ~jնZ0~;hEOL)4)Qf-'zW95R6iV9q$u0 Ata[ǖ5 Dt+Ln%82rV1u*K%Li R.:&@U 1% 4N❆Pu(Mp8R=08bk0[$01%.;y!#y#Z~M=k9Qshxi3ߘ־RCK{4°Y[Zߖtfyn5JsvܤԚx(&zR@<*kw8JPkiAQ? m^h5kA2*hH<~Mq_ \K#a.bhΪ6>p*5[ &meGOq ױ^,NM"g~TNF3욎."sImuU!Z7] <N7ARY5A?z<%iyX!*Aݨw᷷αFuYP7nI߸ Un&2rl:~e MKkޝ7>Ztzm / sDK!Kh|>휇5hG[B&}ut59ui,_ZIVBļ+(d7Y4m>YK4OZP$zm}QMm'D~cyvZ:Քk+őF:/ճi?KyK d7Uڍ9y[\h׶siRR)Ԩ놲~_vY⸉f#`(eoLѹA^p~:08&P9S6";}1)nF( t­W~^`/yơHS$cb;߉sk_zu hT(uJ@4]skGۋ2ϝvS7%RdIZv U$PtUp8ۡ攩;iOmjmbh^"PKUdPd};z [xmG訣<D̋$O#fkI5/[ri7)aҜ sfAݥk[ſDAFX'.FtXiIos^ZԐ eufPX{p"#VO.\YI5>Q6m2+)ޟ*w"$y&RraozP9ݲ8] > :bӡmaxU8ɠOBCWqO a]E5;$Hʋy @N\2QbR}6̨jRJs<^Y'+1ĥe`I8҃:ƭE:^&vn +U04yrOΚƝ}h X}QݟzoKrCYmjutxR\@IJq^qH>-y7V e?qm/ֽۋ–*`r;;6w#VWֻXHpeDK|J3h~r{[qe$h%h/>Е?eQԠTք.hN׏o1P™e7S@8iZ=cX$ZB~eρ6l zWu \B8$t9$WXMf-kAFw c X4-#I[:ID,TAZ g$ֿO&EhNČdKZvl*EQJ{F? ڤSj4TҢPBVAB2 bX[_nMҙnk1qDʕaOs0aYyv%Ֆ kW֚(-GO $1QDġ,7cizNn-&!(}>~k$Sɐ>&#WĚy'+(|w5:n+5>e`|iX^Ԋ##''~B5ƒ&_:[vr4KDR!`CĎ?vz;.WZ NjcS g[]Gg5"`)xT(ʕ_/@uF kmknf(cQO#}+O]7ʚV&YOISxP#mqvqy_Um4׶ۨ_ީCCc2ϥyF{uei [qo /6&efDaP>*bFl/SKЕ;74je%i4'W=Kn\jv~ht-Z׽0mwP%h]I I޻mM$.Za/<ͥ@\_rҕT8ӑjhOSKWRW+!WVuWަ|HvA3fd⍧Czq"*/Qҽ3[i?_drK~Awсe(_Qczm1a> ?t/ːsf BqJm^ـ>+pwޘMvnCu&ѩ~]`q_$k-T3fFPgZq^,oh#";=YYdW`98 };ZKB)2Ry.hpR-J+FY2Ej޷9  |u q<(O{h>WѭYahmbCa('Qܞyq<3 y<_Z AS*jtÛ&"#bj-zu8?Ƨm}#jzF&9͢$ xԍ_9v\IRQ%Zӭco桒 "b7Бپ?ռ="[{/XS " В]ka5_] Y[B#+u)urb*m1~g"W7T*}o*hvf@LҕזI:=*=kb[ң{`}v &#UbStfB5{±@C))8~JOOMg$A/7(RXu/$bKI,fiJS> n@C/2EGuGݾljC郭wMT84S&m8E$0_KZo~1Mr\]Ol[۴eb4 .iU޵-Zb[RQlgpPW&k{]suY#T_lz'}vwc~9*ʋ{H~#5YYsvS{:]3mm= _Kq6Vf; y$j!U)nҴ[i1H8:ڊ{j/Q =3MLvWz&2G))v_Fݎp9ͪC(8{VyP켚pX!HX}UCw|[}4c~'94UZmW>þ('}(Sizt:{n zp^b?i)d?rBcS/ dVRbpA`j({׮uV[=F$#J*y6W`6DO2S(|+ .UjkN߫x c6=sȩP|M>NQ )$WnH3KݨeY`T` 9.&>k6JƣyW4gռ6\tn(/t}Q/&ΏFih)΅gpхyNƨAP >*kj~bI%xH`ȱG=;t%<g/ o)fKvnU=?x VWtHw4ܚA\J#)`Q)§X+HJxݎ8NFm%"oIk5۾Jb98Ռ`SlIcڊU1+iПǶ*(h^E~ *x#ռ39ѥ.=&4F}[f`r%aeiWKVd |T?ZFt$k~\}ΛYw囿.؉ZK{ýcSEuCYipέOLMfPx<]4?/hl[f( ~zP0V9;Oe!;1&xo9-#/)D#U73 *l[Tr Q<[["i!Aƍ]Ǜu1rDHJK4,Ib!Aյ%XOR? `ƕ޸&ǣv.Ke[iK1j-R=;.7:[X kDHϨ$Jcs<VVkگ+r*e4eO O?F.!KMdhVwį.Fm v* MLHKC(~Yji6(Z,m%L7n[,PSW%$[d-X#Pc\cZKrF!/?85r1(>~s;uɦٴTӎ?Y'j_4|EgjZwopS @)_<3˿>n.|qMIt>j,pT׫|4JxXbaʄ-^UQY+@ ~f|mϷ :3,AACM+dfDiT_+7c OcN ΕDn$&x…f`QʛoWZ?leX7ٺ0#&󅶩pCJ"Oo]qf\jTBs{ȷNU%) +  |>/]b'i%E!G8jl.iä܆Y%5tYr]S| X=[!GWjsN>:cխD\O 6*>Usj?\Lx?& e_VvzHPYҀYv={,9rjhku.Ikiȍ#]Q)Bz~42KgIkyzSc|GJb5JBŸF6rڧH~$ʗsXe*IvPXG^H̩ʅ'ol9ҵ)mĐqP)nq[qy[!XRI,; 44-~hKxNR BV[žMAIw=FBn.3\VF,ǰ>yT)gBԒGn:姗t\7'AţJq2*O4]J}gT_i`}V߲g|n˰Pͩ^Bvgci2rc:A=+ 8bn({&??Vq_]n4tY'fo#^Ilԑ0Xe іAw;vp̛Y6x<0V5KHv4wKp`(0#_ Q}\<SBi@O3|bm1j_ GG݌ntRSj};Xk!M2Rmn?d1םѕ] BTMW hbkW'@uXxw ?˩޽rWsP>㚪T;ePwW(91jQA)5"pʶKZTnNE"î>-(O+&Ţռ@Z؀8$x} ~sIuz$6슑Ώl$3SΡ-_vt)$*'hVc:g2>nR5,k1.ޜή\8iB=t {FJqh8 # cE,Ӈ؍kBXSRq#,hKQHxPRӸ8[u&\+.HFx,l%ԤKhXHm'Fj~$Hiu1^pH鲯PF2$V&DHoʿZFSDPX^mro=Km189. 7 ̔W `|B1k<0;zLұyU^':G喯/6}R6h/ Tx„ Q6VҬnNK[NS$P#@pBIӑ?3h:wa} KKė%Wҷ$*'* g&0$3Ξ]@CQ9.Z+ R䍩MW#kwzLX,kǙސvT^ >\zlN-O[ Ğ9Fҧ IkD$}ZlV=zF{X->DuVyD܀~SInS%udèB:6)6{bjz' <ͮ05U._щI:.&iףP7zH`QߪF$vp88m +fVs̟V{O/QIJ2Q!V<=sěFVY#UJYI# n'6o}SH6,$iW[+e;dWPxðHV&~w"B ԕPt߮t$ⴋμdTkRTA¿:uNoe20p DžO.?:~mfѦD4QTPPa.H]1ӗ~~X'_{$P5Qp&6#:սwq) 3<XzCsoanEcۇG*k,t.~dyOMmaPwI)PwQ6:7})-~դǜ4O_Ug94'Gqh\pj5Fy_b(-̍ޫ,ez0*R>9"<`Ee!{3C[=6moUx)5n/&11ڨ! .rMOPRա +bQp*1.ȠA_ 屯%W`7뷆X6>^)CZ'ゖjr+P>F5-H>UӾ9#P|@m'K}Wbu%>8i5;8j_VA!*~}adGOD}>󟕼[7]I6$k]Z2#na&X_aم)}k^Bn,X5t4ux"%$?Eޗ[[_\;$sfQxAQ_a,Gz u-+%FE2զ~`N0+m.̆5 q.MGEZZ{YNʼn';o4kM.Vj`VLӚVY^Wr(6U+#һQl*ҫ[I42oN5 NC9L(GUbgbSοdKR=B|8Gh[I3w/oф1)nP}JvN^X%TLG%Vjɍ(Oќskz&y_DK)ZC0b:ć?,5Ij`]2(@9IFS αw#kN7~d!n%>_ؕnq۳Rqp*~t9~WJ(=x5PT(^#X][yá އt3˿5jWqztėwJ/nof MdPTaJS5[,!V07wi0湒ݶ1O"-+SZ ~Cg-u8<~0([tq _1ZE47 {U;SVZj6,r'8Iۓl7t&)r䅆a@|hkL_Cw8]q?yjw6:uMysYI'YtAeQD¹&+ qF8G(غZO5㴸FtҪI 퓑]Z>eIj<1)d~݀~jޛK;^X([T7]vooq\%5,Z1 9wr1~b_Jg4Pȏ榤e%~">ʊ/rN߿& /յK~ bOڎU.4o7uXAu}\F $匐,9ŹjCХߩ!C]cR335YhW K.~[1,u8Ρq4U"bU5NĽ8]S&d^~ v74Y=H䎫kAO-LTKp ,pjKS)-^Xݙ}DeUtT}OQH,[q+Hfw$m|D|"uXDBDbE*ѹJǓO_(iYEyAlemFTR3꘶`JQl&2d<9@$8T*Wٍi:֝wE@>nEȬhwv{b&4aDnJ I[jZ's Ӌwk ¸E$ǩ([uxdtNe?8{KgMag9( ^>'gڼ`!ykK绿ޤ9դ:/os}SBhdj_뫝-.+Ie[O*S(IV CH\xoUu(u`ks%reG7e@hb{dϿ~d hVҘ#^XXBѨro##' PqI*ഔ p^4@XQ‰d=O khe?CGMr\n^2SC!]Ů$]ˢ܇ulZXH(7A\Te#IgeFec1rzڔqo:sq8#Fq>x 1Jl~ѴT^"h@ݽF=oΛZ}եfܸT ܍>&c]߂IeIX,,CT9nijDApYV2I4/b|ΗV2궶"HQ+voPl*Gڧ] l ߨ^&$; Ma4{q&+GcJ3D~_Q/$ESBJ\~\^u7IcBTI\42zƼuŽN}{SmV"di (oo3UȋȮӮRQ}H.!PdV;2 x͛ uԖ+`dEw(~ohGIUJ2$*r,T\cUe $"!~c!|w"Nү._ǂiSorssnY+qʡFn4*Zp_p%w8kcZH[oZCZɭk'N4m;VxRg$So#dZ=ƁOF^%֔zC'MkIm/SHԤTpeXwm⿟wzŅWAD@kx|ѣe`9)IlagC" B<[ZX HH}BTP|5.[JBHv'-bJvf3B$n~8Ƙ]_X+rTZD;ucĖ*z@uVfrXI>ָzhƵ3Hf XTQXS[붚MI'9_DcӦrJ\4W(h0~jVEKwy(b}Ek6fGɏF 6,B0fn? +ʣuɩA3q u-+H&i)1}xèAOᘣlMX{br$c]R BMlM׋vmW|hsiR`%ODvX꺖rn 1<+W-F? 9ؿ(*u0vGAOo\̍UT Bݳiݵ@Fb pNţb_n Y * ˋi Z q GWJӶ%M]>;h,Z9n!(gt?h9g,Mp[O.C?YN"gY(VX a£y94oHd?s3CJg_2y?TV/ ٙ[fm΅a9 爣S3A"3GiEePGOeJ(e -`~%2k^_ uAKX"KJdy\H|NYfUw$dfdUrG|?u $hޫ= 陝n흶]Ҽ=gkyz.ɭq4]6IKyWQڪmL7\=:^#FSji׷"FU_t=~:u,ni3 o-.'} ĚpPV,YbW9P"Exf./Ynv2ȷp|rj +{ՙ.}`\+)ш&=8z>F_Zj}nVQsrZ~~f?喷Y./uA.Qr!|ߛ?J%ƝDK]44$ah(<|O,^XVntk5;BW+Q6yGZ6\XNy<\QdVN,>NחVҥr\Gmy? M@YLE]n|^~];̉i~.-ⴋT倉$ u(㠯-DSYEЖN5ON=b+#(A@:w8/[iX6@31O ;t`~Ry?QFXfGwsoƠ*` qU3/P=gaai~KςK˭]Zd4`qTһP/qjKUI@$r,+4ח|*eZи,Ui>Xy"I@e$ZW%@%V׋ S5HA'Z:\@N=I>~UøR*F;oEiӳR8ǨPn@sMoT5Ma3OT8̅Q?*wߵpz]e[hdKutc#A?G5|4M[{Xmt߬J]ʻp<\3̱4I1!?ӷyNPWzk;[{ *8GY*aۑUlXbbj*km.ڷ Wd C\jEѯ"IYTL(F,xq~>QHboedcRyn?jՃva)E*K-ZFg#o۰^PPO˜rhQ^]Gm9{h% VF -Լxb qm?wF!pQ`v<#~+y$_"R G}86EGV 6fB+@5BEX@8qxK |F0=)ooB4!]ysTY?_j%T6/ǎz t@ќ_?1R8ۖuyȺuwbssqpqY4VUsf|6oɋO*g `|m\hƏ4w*$S `lB(vol5fhk«YV@q;o-..[ ř!M/90Yđ*&֑M)D/Y>=X'OW`I0' {|1Ȋ$߲GpK;I⧷#TVFgch(U=XX B#BF):.M|lqա*Yh}J@o]T o{$`)"h$&2:ߨ·ɶq+Pm{dRAkll>Ԫۍ oI4?42-"?hҵ06}Ud12!F潽\0d F":d?R˲vӭI+-0k9M $[hCbUL|?y>)_̈}HMK3"'86?>7u$]F-c^fK7NT y SD8umWw飉T$<@`Y|/\Vk'"Rר毕5xėBI R~̼mKt6G-k7__P)ujWBMp Od6լbE;Q,eةNԴ~6*HۚSԓCf₱Vۖ:CmӮ]f?!F2RӈQ|oGs[[=B 0$bEZ0X|58=ޥ5v35BM!8T=E[}eq[RWg#)h@ 1pO1X^[^zRH5[685,;цo"By_U7ou揖uխ<]J1>KTԧRJE65P|J57%Ӥ9ۉ&`=C1x>!,5Sy kvx˴L5F=9%`$ATuHѹP Tx=1,%ROM/ǝ---1Yg^' |3̑fVKk9vTN! 3G~h[Jo+$]HZH"KmH- p&َvwR+ebf@@$U{+8 Ie )U=QҾ?={I򾓥X%Ǚ̿]+u]2rn=8ms-Mi#@̡ܙMjTd>vZVRua7a M*A;T~gpykVךUԡVI%ZSG5N Ա9jjɩ_FnTz0۬&HwjMjuzcs2=r{O+q0¦_]e֧k.4"X%ξpJPNgⴵ;{h% 1(H{qU'##u;۟7n𸠑JoĢA<zȲ|jnT_/\M6b'~dc~;2mj am_UjTL|%,pE"O;ֻ܎0ZG*jZT0D2T`UE9Y)%Nn/7zKΕZ{ *>zUywb$o>MyRfjRM=di>B)߈eWZM)1bضž5SJ4P jq^,r uepƇb"LhNSgJUG'F5,8PNG i7qDRPn]3QӮvqjYIZĶMqDjەZ,s5( FR\ȫRNo?dhMş%iL%<mӑ΁{q%h O1G8C!eRGh3ہ6h̒hI޵7[2C#Iq-dhTԚռ|3U~^+ߙc$^#@xMQZdb5o,בdVO oϗ1Ri|VD~{U?<-A0sjmE "[~#ks_(/ӱ>>6~p21BEU/ɒg6q8oeJVV[˱Pl MǹʾTXQł=NÈLy ^XxMUdAiqpȬ,2NOnB0xz@ǯCAPh=q^@-i!~ mZvʿXP7ϒSXOYb("'ҕ[ֵNSƩlܫ4<\Um:PQ%%4ZJ |k/% 9 3q$a-iᤑnG_JM6Hb VEڳ|[T@=\q}h xTdʯ;H1f j|-ѝ-/EQ\KJV˂EAש'?2h? 1HVR8-px7%ޜ5<M$/teM2g&0^ա%N;S6| ZEmcJ]H5۩˖R}>c0HhH m+zuw&kZLEUXއßjm%ʪ؃ ;So07o_ׁӡ!nmJ7I̾c]JKq Sbw;v=G&er4T WZo -dxg Ty=0u /GPrXoh~yBY:KK4b;+7?qntIw%Z;cd="x_|ynWdckko3-X2<<=iO9+4K_ҞD;fCVLFZTY7kņ0Κ$>efnﴻY'OY eQo-+5{XKqHז"4{L9o 7RSp+ԟ0& \md,wJ^lN;;InX65ɰ&yc@һ-u >f$jê4hSa' rI$`ac= է4GYޣבz dNFndܿ&ՇAH˶@`ƤQ;1> k9ϛ4 Eb4_!m@E3A3)hM߹+N;shWfL#mu^:IRH QYNY"-ޭ: '9IB⿤_?-069"hc"a@$Kr)I_ _KlS9!xv&-EjP"| i x;[9 +?B]L^‰nZdP7T|ߓړ}}O=mPҮaGNX>XH:X7 h$s1dCP7 m-|4b}_i8I`ea9?*N4+>ԃCavAO*{ʺe6PHQFd2)n PA$n]ȧJJT-~*'^[m )c-Z???86*bApŹd2Kh})szLuai{xַAц*x%ektKN{mR 3PKѳo77{Y2RQUfuX'a㞍G强noci ϩE) O P|)]t]ޯjiֈ HĞ1F)_c94~_M#O4Ɏ-6a*=Kv uM^?Nj/i$a__Q) T^jWsGƼf2Y)(J M3y+qZj~fg0DTM[FTK+aiIT+\zB/ZXqP%(i9o?|Ky} {YBweHgy,EzF*hp_g,4㲴F#21%id+ 8m+*bvɏn98?DQ{ `ېT EeJ[0j}'Eq`41XTR(VpE0wؙ}U`P*+S9ΥqyEcIYTԂH;tu"$qے)A1ZT&pQS׭(s*~xb an $=) i9\OȚ>XjV7rsY6R=FDfRnLΓUQ% y=k |:q()WɪѷQQVnoWc@ӎPB>鑏5y2l,𺌂HPEM=]twp!6V!2#*1Zg]4'vlV&3*D¿ sGsM%UN |ݩ]<-$k}7P&JԁʻmWRkPIUGⱩX*$}+hF(0HH<yw}u dnre\C(*![ ,Ci2 VY!Kh9 3!4v[7@~,ޯb;[y\Z.n%΃n!ҼV춡r'9I*QE b8cXE(^a7s5#iWkFސZח'r'Z=EW{hjj|ydO"yb[1~6t\y 78 !!T{{oZ֓hÒYv+[vgron޲\s;=]!1>"2HGIw%ߗk6w tֆ VAĝrqsEsĖS2N9 RHK+x={k+qv, tGznN~k{ʷW~[VRyczC_u،uMϙX|ťpW!4vK"RƆqIm~dcJSҌnMikƺ̓j\\q]-zC4YexXoEpo$l,̼Uci6w蚼޼CVǏ(6E{*y3FKjg"irMҀrU&szտ'|$;+m7I#] ₮cn Af.$aS,y%()HP)466P"Wx9/VEW$՘ Ih棧JN,i숮6ku(T~]kPn&]ִa,j"maAĿ r.}]P yG?&榥9h8㶐ۄBj%oQ޻.9v* v8>MO7U a Nrq4 ;ǭ|0x[g?JZSkx>n v3uO?Z'ћuN31pU90r~UAZGBӧ)Q$:cy?BB%TnĞdNΣN[X[tdaHeLi:·z-o6wq6VW"0XTxd7_H˺~l;%KU#ڞ8etja(WߚO,T6bnSj掾Oˆ<;wr|r}9`ҮVHPH#;}TK[GP6k*Lʊ77 tg1+F  PQ:>IIT<:oЌd]ihc[ɍP leP@%@r,Nmc"qk!>y=ּ}M3ʯ0fBg.G#GzcRl lVOJ3PG';ڟ,uS쏗JbRj{ooL⟞ʞ`89Pl B 6HWnø(tcPRo^nFb}X뱡h y!8|F{Mjkb)m:΃uEͰV \h>a[7%FjaB&FԠ<ƛx\y7XqM͗8.ӝ܋c ,$,#wj,u[/*å4z5 g >$v^{Wѯ:0X3?VFskXxV9 XM#b)U,)@V:Zj$ՏHV"ߨtn~t$c޵s￾!$5aAUxGWƳ^S=}0CP~JH@KwcMj鿦t·;^K)r)K9hnGFZ VڭƆ*{gX~YUKmf^o13IIT2!C&f;JzM~xP$T5'Z||\Gj]X5B~NqF)"c5i5k}>ov)#(dIC]#}ZI3岶O8*S!iFf*XR?e-,kJFZsmE(9[foH فq.`ɒVO2z|GΣ*NK֡z`JFe֊,U@[_[kVh4Lo5Vh7VZ7j푟6iKZ}B"f8[dvitK[h`usksp1MTmIm??44,ԤZwWv5ű;7zV%^_-jwOU( oIU=Ni7ZV5fsfw."CJSJuƱߘzIK9O$0pgGͯ^.]FrF/Uf2+"5)Rei" nʲ P{tMK-*:ooj;,aҭwR%>;X,6}6 TP"wE; m;f+C^1: A;Q.eZJ”9,Gwt4koU"wI+ʑ3H\kӜj̾zI`@f;j{:kgy A= PCv ӨSO``HtǨOޟ9R2TtJj9; +J֝"ISj95լSSVO'V*$8wBæ{-ܹcp=F1"4N'n8qkV]/̗z @µ8eW7ڬ1GUBIE]䇒jG;%~fSs¤(OF֛lv1([{Zmm!Kuz쪦iW-/&$38חW 1'4DvV"A^ZIok|h?:R#a_2e Ga;mUyt=߆>\DුBvn_#tJl:`3X~ mۢے~A7[/#B(&mg}9L"1Oq,6ZӈW!djEkFޛDѴ4EHɡ4zJ4>4 6#]1-cV4].}J$3? qsڮw귚rV*_AȟyE!]ޫ@MkjS4-Cߖ[̷71]7gnr΁ ۿ|J׭|:➘jv_pݟ1uqΟ{ʧ\{us!7|H z aoE֮|^h#oqw[;W7叕|٣N  l҅#0r8A$tã~U~Xyb;+-2[]I܆m[n[al/ @6Z4's<}㚠iRwT۾?RYdQSznA"4tW:my M@Z ooIރ85??RSj4q=:ekS^JӿN:4_>I!h3 z)eybJP{s P*68FiomxJn9]1=5GcsnTvf +M¼ѤP5tMv\ק8Wf 97G`Kn>:ļ0_}:}7?Y1} ퟯOCg(?ok'azw鎗폷NMӿO&={Zgߠss Zr23?k3O:{}>YCӾy8O>yawg_~߷L.Կg_lZ{K쏷?_)Vs'u/%VQ[}5/Osx:=>OO:O~zIgtez_ja_^g8|[k?_?fzcq/uzGtO,?aN?'@?/c~ԼWd}~?fnOי[SOb_o1|>׿F ע={b}u1 wg~ ;I>czӮ/kga7^kLb}>1dnOO~5i=r'iUOL߯SӧCUuݟboz}uߗoq>~z8zu=q|`ItHĿk]~ endstreamendobj15 0 obj<>endobj16 0 obj<>/ProcSet[/PDF/Text]/ExtGState<>>>endobj17 0 obj<>stream /GS1 gs BT /F3 1 Tf 8.9663 0 0 8.9663 48.6425 725.1588 Tm 0 0 0 1 k 0 Tc 0 Tw [(9.)-495.6(Haan)-404.5(J,)-402(Hollander)-406.4(JMR,)-406.4(van)-399.3(Duinen)-405.2(SG,)-402.2(Saxena)-401.2(PR,)-403.6(Wintzen)]TJ 1.2456 -1.2266 TD [(AR:)-472.2(Reversible)-480.5(severe)-476(myopathy)-474(during)-471.6(treatment)-476.3(with)-471(nas-)]TJ 0 -1.2203 TD (teride.)Tj /F4 1 Tf 2.8769 0 TD [(Muscle)-331.7(Nerve)]TJ /F3 1 Tf 5.9562 0 TD (1997;20:502504.)Tj -10.5846 -1.2203 TD [(10.)-501.4(Bisson)-280.1(JF,)-273.6(Hidalgo)-275.9(S,)-279.2(Rozan)-279(P,)-272.9(Messaoudi)-279.4(M:)-275.6(Preventive)-283.5(effects)]TJ 1.7514 -1.2266 TD [(of)-362(ACTICOA)-359.8(powder,)-362.4(a)-356(cocoa)-365.2(polyphenolic)-358.8(extract,)-358.8(on)-359.4(experi-)]TJ 0 -1.2203 TD [(mentally)-465.4(induced)-460.7(prostate)-461.7(hyperplasia)-462.6(in)-458.3(Wistar-Unilever)-460.2(rats.)]TJ /F4 1 Tf T* [(J)-337(Med)-331.9(Food)]TJ /F3 1 Tf 5.3429 0 TD (2007;10:622627.)Tj -7.0943 -1.2267 TD [(11.)-501.4(de)-469.3(Souza)-475.2(PAVR,)-472.4(Palumbo)-466.7(A,)-473.6(Alves)-470.1(LM,)]TJ /F4 1 Tf 19.9551 0 TD [(et)-473.4(al.)]TJ /F3 1 Tf 2.232 0 TD [(:)-471.4(Effects)-473.2(of)-469.5(a)]TJ -20.4356 -1.2203 TD [(nanocomposite)-418.3(containing)]TJ /F4 1 Tf 11.141 0 TD [(Orbignya)-411.7(speciosa)]TJ /F3 1 Tf 8.106 0 TD [(lipophilic)-416(extract)]TJ -19.2469 -1.2203 TD [(on)-492.2(benign)-496.7(prostatic)-490.5(hyperplasia.)]TJ /F4 1 Tf 14.0305 0 TD [(J)-495.1(Ethnopharmacol)]TJ /F3 1 Tf 8.1566 0 TD (2011;135:)Tj -22.1871 -1.2267 TD (135146.)Tj -1.7514 -1.2203 TD [(12.)-501.4(Sun)-471.3(H,)-467.3(Li)-464.4(TJ,)-470.8(Sun)-465(LN,)]TJ /F4 1 Tf 12.355 0 TD [(et)-467(al.)]TJ /F3 1 Tf 2.232 0 TD [(:)-465.1(Inhibitory)-467.6(effect)-468.8(of)-469.5(traditional)]TJ -12.8355 -1.2203 TD [(Chinese)-270.6(medicine)-267.8(Zi-Shen)-263.3(Pill)-267.9(on)-264.6(benign)-262.7(prostatic)-269.2(hyperplasia)-266.6(in)]TJ T* (rats.)Tj /F4 1 Tf 2.0297 0 TD [(J)-337(Ethnopharmacol)]TJ /F3 1 Tf 7.8467 0 TD (2008;115:203208.)Tj -11.6278 -1.2266 TD [(13.)-501.4(Zhang)-524.6(Q,)-517.9(Li)-527.7(L,)-520.7(Liu)-520.8(L,)]TJ /F4 1 Tf 12.4308 0 TD [(et)-523.9(al.)]TJ /F3 1 Tf 2.2826 0 TD [(:)-522(Effects)-523.8(of)-520.1(the)-523.5(polysaccharide)]TJ -12.962 -1.2203 TD [(fraction)-564.3(of)]TJ /F4 1 Tf 5.0773 0 TD [(Urtica)-562.1(ssa)]TJ /F3 1 Tf 5.5009 0 TD [(on)-561.8(castrated)-560.9(rat)-564(prostate)-562.9(hyperplasia)]TJ -10.5782 -1.2203 TD [(induced)-644.1(by)-644(testosterone)-644.4(propionate.)]TJ /F4 1 Tf 16.0792 0 TD (Phytomedicine)Tj /F3 1 Tf 6.6138 0 TD (2008;15:)Tj -22.6929 -1.2266 TD (722727.)Tj -1.7514 -1.2203 TD [(14.)-501.4(Gasco)-430.5(M,)-420.4(Villegas)-428.5(L,)-425.9(Yucra)-425.6(S,)-424.6(Rublo)-423.6(J,)-427.3(Gonzales)-429.2(GF:)-421.8(Dose)]TJ 1.7514 -1.2203 TD [(response)-562.3(effect)-563.6(of)-564.4(Red)-562.1(Maca)-562.4(\()]TJ /F4 1 Tf 13.6006 0 TD [(Lepidium)-564.9(meyenii)]TJ /F3 1 Tf 7.4674 0 TD [(\))-564.8(o)0(n)-555.4(benign)]TJ -21.0679 -1.2266 TD [(prostatic)-408.3(hyperplasia)-405.7(induced)-403.8(by)-403.7(testosterone)-410.5(enanthate.)]TJ /F4 1 Tf 23.5781 0 TD (Phyto-)Tj -23.5781 -1.2203 TD (medicine)Tj /F3 1 Tf 3.9581 0 TD (2007;14:460464.)Tj -5.7096 -1.2203 TD [(15.)-501.4(Zhang)-391.8(W,)-396.4(Wang)-388.1(XB,)-395.7(Liu)-394.4(Y,)]TJ /F4 1 Tf 14.2582 0 TD [(et)-391.2(al.)]TJ /F3 1 Tf 2.1498 0 TD [(:)-389.2(Effects)-397.3(of)-393.6(dietary)-391.4(axseed)]TJ -14.6565 -1.2203 TD [(lignan)-570.3(extract)-577.2(on)-568.1(symptoms)-572.3(of)-570.7(benign)-572.6(prostatic)-572.7(hyperplasia.)]TJ /F4 1 Tf 0 -1.2266 TD [(J)-337(Med)-331.9(Food)]TJ /F3 1 Tf 5.3429 0 TD (2008;11:207214.)Tj -7.0943 -1.2203 TD [(16.)-501.4(Chinese)-555.1(Pharmacopoeia)-558.3(Committee:)]TJ /F4 1 Tf 17.5777 0 TD [(Chinese)-555.1(Pharmacopoeia)]TJ /F3 1 Tf 10.1736 0 TD (.)Tj -25.9998 -1.2203 TD [(China)-337.5(Medical)-335(Science)-337.6(Press,)-335.2(Beijing,)-334.8(2010,)-329.8(p.)-337.5(290.)]TJ -1.7514 -1.2266 TD -.0276 Tc [(1)-27.6(7)-27.6(.)-529(Shu)-273.7(X)1.2(S,)-270.8(Gao)-267.4(Z)-1.6(H,)-277.1(Yang)-273.7(XL:)-271.4(A)1.2(nti-inam)-5.4(m)1(atory)-273.7(a)2.1(nd)-273.7(anti-nociceptive)]TJ 1.7514 -1.2203 TD 0 Tc [(activities)-320.8(of)]TJ /F4 1 Tf 5.0963 0 TD [(Smilax)-320.7(china)]TJ /F3 1 Tf 5.5895 0 TD [(L.)-312.1(aqueous)-318.8(extract.)]TJ /F4 1 Tf 8.0744 0 TD [(J)-318.1(Ethnopharmacol)]TJ /F3 1 Tf -18.7601 -1.2203 TD (2006;103:327332.)Tj -1.7514 -1.2266 TD [(18.)-501.4(Wu)-253.9(LS,)-253.3(Wang)-255.3(XJ,)-259.3(Wang)-255.3(H,)]TJ /F4 1 Tf 13.2528 0 TD [(et)-252.1(al.)]TJ /F3 1 Tf 2.0107 0 TD [(:)-256.4(Cytotoxic)-255.1(polyphenols)-252.9(against)]TJ -13.5121 -1.2203 TD [(breast)-439.7(tumor)-437.7(cell)-440.9(in)]TJ /F4 1 Tf 8.7825 0 TD [(Smilax)-440.8(china)]TJ /F3 1 Tf 5.836 0 TD (L.)Tj /F4 1 Tf 1.3025 0 TD [(J)-438.2(Ethnopharmacol)]TJ /F3 1 Tf 8.0491 0 TD (2010;)Tj -23.9702 -1.2203 TD (130:460464.)Tj -1.7514 -1.2266 TD [(19.)-501.4(State)-837.3(Administration)-842(of)-836.3(Traditional)-839.9(Chinese)-833.3(Medicine)-840.4(of)]TJ 1.7514 -1.2203 TD [(Peoples)-753.4(Republic)-747.1(of)-754.1(China:)]TJ /F4 1 Tf 13.5753 0 TD (Zhong-hua-ben-cao)Tj /F3 1 Tf 7.9479 0 TD [(.)-749(Shanghai)]TJ -21.5232 -1.2203 TD [(Scientic)-454.7(and)-449.9(Technical)-455.7(Publishers,)-448.3(Shanghai,)-455.4(1999,)-449.9(pp.)-450.9(157)]TJ T* (160.)Tj -1.7514 -1.2266 TD [(20.)-501.4(Chen)-327.7(T,)-331(Li)-325.3(JX,)-328.9(Cai)-325.8(Y,)-328.2(Xu)-324.8(Q:)-328.8(A)-331.6(avonol)-324.1(glycoside)-332.1(from)]TJ /F4 1 Tf 25.2727 0 TD (Smilax)Tj -23.5212 -1.2203 TD (glabra)Tj /F3 1 Tf 2.6683 0 TD (.)Tj /F4 1 Tf .5817 0 TD [(Chin)-335.6(Chem)-337.3(Lett)]TJ /F3 1 Tf 6.8414 0 TD (2002;13:537538.)Tj -11.8428 -1.2203 TD [(21.)-501.4(Meng)-298.3(QX,)-299.4(Bai)-294.2(ZC:)-297.9(The)-297.9(investigation)-298(of)-292.5(wild)-300.2(vegetable)-297.8(resource)]TJ 1.7514 -1.2266 TD [(and)-475.2(development)-475(of)]TJ /F4 1 Tf 8.89 0 TD (Smilax)Tj /F3 1 Tf 3.2057 0 TD [(genus)-469.1(in)-477.3(Chongqing)-472.2(mountainous)]TJ -12.0957 -1.2203 TD (area.)Tj /F4 1 Tf 2.2636 0 TD [(Mount)-332.5(Area)-336.6(Dev)]TJ /F3 1 Tf 7.1765 0 TD (2003;8:3536.)Tj -11.1916 -1.2203 TD [(22.)-501.4(Zhou)-257.1(LM,)-261.7(Ruan)-258.1(JL,)-262.2(Guan)-256.7(FL,)-259.6(Cai)-256.3(YL:)-258.6(Screening)-261(of)-260.9(the)-257.9(effective)]TJ 1.7514 -1.2266 TD [(part)-367.5(of)]TJ /F4 1 Tf 3.1298 0 TD [(Smilax)-364.9(china)]TJ /F3 1 Tf 5.6843 0 TD [(L.)-362.6(for)-370.5(the)-365.4(treatment)-368.8(of)-362(non-bacterial)-368.4(pros-)]TJ -8.8141 -1.2203 TD (tatitis.)Tj /F4 1 Tf 2.8263 0 TD [(Herb)-333.7(Med)]TJ /F3 1 Tf 4.4956 0 TD (2008;27:634636.)Tj 21.5991 53.7827 TD [(23.)-495.1(Zhou)-408.8(LM,)-400.8(Ruan)-403.5(JL,)-407.6(Guan)-402.1(FL,)-405(Rao)-404(YQ:)-407.5(Study)-404.8(on)-403.7(anti-inam-)]TJ 1.7451 -1.2266 TD [(matory)-477.5(and)-475.2(antimicrobial)-476.1(of)-475.8(the)-479.2(macroporous)-477.3(resin)-475.7(of)]TJ /F4 1 Tf 23.5212 0 TD (Smilax)Tj -23.5212 -1.2203 TD (china.)Tj /F3 1 Tf 2.8137 0 TD (L.)Tj /F4 1 Tf 1.2014 0 TD [(Chin)-329.3(Pharm)]TJ /F3 1 Tf 5.3302 0 TD (2008;11:402404.)Tj -11.0904 -1.2203 TD [(24.)-495.1(Shu)-401.8(XS,)-402.2(Gao)-402.6(ZH,)-403.4(Yang)-402.1(XL:)-404(Optimization)-399(of)-406.3(purication)-398.4(con-)]TJ 8.9663 0 0 8.9663 334.7715 681.2786 Tm [(ditions)-243.8(for)-244(with)-243.3(macroporous)-243.3(adsorption)-243.3(resin)-241.7(total)-239.7(saponins)-245.2(from)]TJ /F4 1 Tf T* [(Smilax)-339.6(china)]TJ /F3 1 Tf 5.2923 0 TD (.)Tj /F4 1 Tf .5817 0 TD [(Chin)-335.6(J)-337(Chin)-329.3(Mater)-336.1(Med)]TJ /F3 1 Tf 10.2431 0 TD (2005;30:3032.)Tj -17.8622 -1.2203 TD [(25.)-495.1(Baccou)-331.5(JC,)-330.3(Lambert)-333.9(F,)-323.5(Sauvaire)-331(Y:)-328.8(Spectrophotometric)-334.1(method)]TJ 1.7451 -1.2267 TD [(for)-326.2(the)-327.4(determination)-326.6(of)-324.1(total)-321.9(steroidal)-326.1(sapogenin.)]TJ /F4 1 Tf 20.638 0 TD (Analyst)Tj /F3 1 Tf 3.3322 0 TD (1977;)Tj -23.9702 -1.2203 TD (102:458465.)Tj -1.7451 -1.2203 TD [(26.)-495.1(Van)-352(Coppenolle)-347.8(F,)-348.8(Le)-349(Bourhis)-350.6(X,)-353.5(Carpentier)-349.1(F,)]TJ /F4 1 Tf 21.8646 0 TD [(et)-346.9(al.)]TJ /F3 1 Tf 2.1055 0 TD [(:)-351.3(Pharma-)]TJ -22.225 -1.2267 TD [(cological)-381.7(effects)-381(of)-374.7(the)-378(lipidosterolic)-373.7(extract)-381.2(of)]TJ /F4 1 Tf 19.9298 0 TD [(Serenoa)-375.7(repens)]TJ /F3 1 Tf -19.9298 -1.2203 TD (\(Permixon)Tj /F9 1 Tf 6.351 0 0 5.6449 372.6991 607.8613 Tm ()Tj /F3 1 Tf 8.9663 0 0 8.9663 377.7448 604.5731 Tm [(\))-444.7(o)0(n)-454.3(rat)-450.2(prostate)-449(hyperplasia)-450(induced)-454.4(by)-447.9(hyperpro-)]TJ -4.7928 -1.2203 TD [(lactinemia:)-242.9(comparison)-238.9(with)-237(nasteride.)]TJ /F4 1 Tf 16.3068 0 TD (Prostate)Tj /F3 1 Tf 3.6357 0 TD (2000;43:4958.)Tj -21.6876 -1.2203 TD [(27.)-495.1(Guo)-318(QL,)-314.9(Ding)-308.9(QL,)-314.9(Wu)-317.1(ZQ:)-309.2(Effect)-320.8(of)-311.5(baicalein)-314.5(on)-315.2(experimental)]TJ 1.7451 -1.2266 TD [(prostatic)-439.9(hyperplasia)-443.7(in)-433(rats)-438.2(and)-437.2(mice.)]TJ /F4 1 Tf 16.5913 0 TD [(Biol)-435.9(Pharm)-438.2(Bull)]TJ /F3 1 Tf 7.3788 0 TD (2004;)Tj -23.9702 -1.2203 TD (27:333337.)Tj -1.7451 -1.2203 TD [(28.)-495.1(Berry)-275.5(SJ,)-279.9(Coffey)-275(DS,)-275.7(Walsh)-272.7(PC,)-277.1(Ewing)-276.6(LL:)-274.1(The)-279(development)-272.7(of)]TJ 1.7451 -1.2266 TD [(human)-363.9(benign)-363.9(prostatic)-364.1(hyperplasia)-361.5(with)-363.5(age.)]TJ /F4 1 Tf 19.1331 0 TD [(J)-362.3(Urol)]TJ /F3 1 Tf 3.0603 0 TD (1984;132:)Tj -22.1934 -1.2203 TD (474479.)Tj -1.7451 -1.2203 TD [(29.)-495.1(McVary)-659.8(KT:)-650.6(BPH:)-653.6(epidemiology)-653.2(and)-652.2(comorbidities.)]TJ /F4 1 Tf 25.5635 0 TD [(Am)-653.4(J)]TJ -23.8184 -1.2266 TD [(Manag)-334.8(Care)]TJ /F3 1 Tf 5.5009 0 TD [(2006;12\(5)-331(Suppl\):S122S128.)]TJ -7.2461 -1.2203 TD [(30.)-495.1(De)-301.9(Nunzio)-297.7(C,)-304.3(Kramer)-298.5(G,)-296.6(Marberger)-302.2(M,)]TJ /F4 1 Tf 18.2606 0 TD [(et)-302.6(al.)]TJ /F3 1 Tf 2.0613 0 TD [(:)-294.4(The)-304.3(controversial)]TJ -18.5767 -1.2203 TD [(relationship)-461.5(between)-460.1(benign)-452.4(prostatic)-458.9(hyperplasia)-462.6(and)-456.2(prostate)]TJ T* [(cancer:)-341.7(the)-333.8(role)-329.6(of)-336.7(inammation.)]TJ /F4 1 Tf 13.8029 0 TD [(Eur)-334.7(Urol)]TJ /F3 1 Tf 4.053 0 TD (2011;60:106117.)Tj -19.601 -1.2266 TD [(31.)-495.1(Quiles)-460.9(MT,)-457.7(Arbo)]TJ 8.6624 .0443 TD ()Tj .411 -.0443 TD [(s)-462.3(MA,)-454.9(Fraga)-458.8(A,)]TJ /F4 1 Tf 7.3156 0 TD [(et)-460.7(al.)]TJ /F3 1 Tf 2.2193 0 TD [(:)-452.5(Antiproliferative)-464.2(and)]TJ -16.8632 -1.2203 TD [(apoptotic)-360.3(effects)-355.7(of)-355.7(the)-352.7(herbal)-356.3(agent)]TJ /F4 1 Tf 15.2888 0 TD [(Pygeum)-352.8(africanum)]TJ /F3 1 Tf 8.0491 0 TD [(on)-353.1(cul-)]TJ -23.3379 -1.2203 TD [(tured)-392.3(prostate)-392.1(stromal)-393.7(cells)-391(from)-392.5(patients)-393.6(with)-388.8(benign)-389.2(prostatic)]TJ 0 -1.2266 TD [(hyperplasia)-336.2(\(BPH\).)]TJ /F4 1 Tf 8.1439 0 TD (Prostate)Tj /F3 1 Tf 3.7305 0 TD (2010;70:10441053.)Tj -13.6196 -1.2203 TD [(32.)-495.1(Li)-394.9(J,)-389.3(Chen)-390.9(JQ,)-392.1(Ju)-392.2(Y:)-392(Anti-cancer)-400.2(activities)-390.4(of)-393.6(natural)-391.4(steroidal)]TJ 1.7451 -1.2203 TD (saponins.)Tj /F4 1 Tf 4.0846 0 TD [(Nat)-336.1(Prod)-334.2(Res)-330.7(Dev)]TJ /F3 1 Tf 7.8404 0 TD (1997;11:1417.)Tj -13.6701 -1.2266 TD [(33.)-495.1(Shao)-353.1(B,)-354.9(Gu)23(o)-340.9(H)0(Z)16.8(,)-338(Cu)21.6(i)-345(Y)0(J)21.8(,)]TJ /F4 1 Tf 12.747 0 TD [(et)-334.3(a)13.1(l)0(.)]TJ /F3 1 Tf 2.0613 0 TD -.0149 Tc [(:)-353.5(S)-14.9(t)8.8(e)-14.9(r)6.4(o)-14.9(i)7.3(d)-14.9(al)-353.5(s)-14.9(a)1.4(poni)-14.9(ns)-350.7(f)-14.9(r)6.2(o)-14.9(m)]TJ /F4 1 Tf 10.515 0 TD 0 Tc [(Sm)23(il)18.2(a)13.1(x)]TJ -23.5781 -1.2203 TD [(ch)17.5(i)15.4(n)0(a)]TJ /F3 1 Tf 2.4596 0 TD [(an)17.5(d)-277.7(t)15.4(he)17.5(i)15.4(r)-280.3(an)23.9(ti)18.2(-)16.9(i)0(n)22.2()0(a)18.9(m)0(m)19.2(a)0(t)26.2(o)0(r)17.3(y)-271.4(ac)15.1(t)15.4(i)0(v)22.2(i)0(t)18.2(i)15.4(es)16.3(.)]TJ /F4 1 Tf 15.1876 0 TD -.0201 Tc [(P)-6.8(h)-20.1(yt)-4.7(o)-20.1(c)-2.6(h)-7(e)-20.1(mi)-20.1(st)-20.1(ry)]TJ /F3 1 Tf 6.3672 0 TD 0 Tc [(20)19.9(0)13.1(7)0(;)]TJ -24.0144 -1.2203 TD [(68)19.9(:6)22.3(2)13.1(3)0()19.9(6)13.1(30)20(.)]TJ -1.7451 -1.2266 TD [(34.)-495.1(Chen)-397.2(PS,)-391.1(Shih)-386.3(YW,)-392.9(Huang)-395.3(HC,)-389.3(Cheng)-390.4(HW:)-393.5(Diosgenin,)-392.8(a)-394(ste-)]TJ 1.7451 -1.2203 TD [(roidal)-256.7(saponin,)-260(inhibits)-253.6(migration)-262.8(and)-253.9(invasion)-254.3(of)-260.9(human)-256.4(prostate)]TJ T* [(cancer)-546.8(PC-3)-541.4(cells)-542.7(by)-542.8(reducing)-538.7(matrix)-544.8(metalloproteinases)-544.1(ex-)]TJ T* (pression.)Tj /F4 1 Tf 3.9202 0 TD [(Plos)-331.9(One)]TJ /F3 1 Tf 4.1099 0 TD (2011;6:110.)Tj -9.7752 -1.2266 TD [(35.)-495.1(Li)-262.1(F,)-260.2(Fernandez)-265.7(PP,)-264.7(Rajendran)-260.8(P,)-260.3(Hui)-265.1(KM,)-258.9(Sethi)-259.5(G:)-265.6(Diosgenin,)-260.1(a)]TJ 1.7451 -1.2203 TD [(steroidal)-376.7(saponin,)-373.9(inhibits)-373.8(STAT3)-372.1(signaling)-378(pathway)-375.5(leading)-369.9(to)]TJ T* [(suppression)-500.4(of)-494.8(proliferation)-496.6(and)-500.5(chemosensitization)-497.2(of)-494.8(human)]TJ 0 -1.2266 TD [(hepatocellular)-340.1(carcinoma)-337.9(cells.)]TJ /F4 1 Tf 12.9809 0 TD [(Cancer)-336.6(Lett)]TJ /F3 1 Tf 5.1721 0 TD (2010;292:197207.)Tj -19.8982 -1.2203 TD [(36.)-495.1(Jung)-378.6(DH,)-369(Park)-374.7(HJ,)-379.5(Byun)-369.5(HE,)]TJ /F4 1 Tf 14.4984 0 TD [(et)-372.2(al.)]TJ /F3 1 Tf 2.1308 0 TD [(:)-376.6(Diosgenin)-371(inhibits)-373.8(macro-)]TJ -14.8841 -1.2203 TD [(phage-derived)-442.5(inammatory)-439.4(mediators)-439.4(through)-433.2(downregulation)]TJ 0 -1.2266 TD [(of)-241.9(CK2,)-237.1(JNK,)-236.9(NF-)]TJ /F7 1 Tf 7.3599 0 TD (j)Tj /F3 1 Tf .5501 0 TD [(B)-238.2(and)-241.2(AP-1)-236.5(activation.)]TJ /F4 1 Tf 9.3895 0 TD [(Int)-239.1(Immunopharmacol)]TJ /F3 1 Tf -17.2995 -1.2203 TD (2010;10:10471054.)Tj /F13 1 Tf 9.9626 0 0 9.9626 44.1071 748.6864 Tm .0071 Tc [(65)7.1(0)]TJ /F12 1 Tf 23.519 0 TD 0 Tc [(CHEN)-340(ET)-332.8(AL.)]TJ ET endstreamendobj18 0 obj[/Indexed/DeviceRGB 255 19 0 R]endobj19 0 obj<>stream 8;X]O>EqN@%''O_@%e@?J;%+8(9e>X=MR6S?i^YgA3=].HDXF.R$lIL@"pJ+EP(%0 b]6ajmNZn*!='OQZeQ^Y*,=]?C.B+\Ulg9dhD*"iC[;*=3`oP1[!S^)?1)IZ4dup` E1r!/,*0[*9.aFIR2&b-C#soRZ7Dl%MLY\.?d>Mn 6%Q2oYfNRF$$+ON<+]RUJmC0InDZ4OTs0S!saG>GGKUlQ*Q?45:CI&4J'_2j$XKrcYp0n+Xl_nU*O( l[$6Nn+Z_Nq0]s7hs]`XX1nZ8&94a\~> endstreamendobj20 0 obj<>stream h\mLuǯbM.;;%cK斐% }ݲM 6PR}>ݵ]ڻז8ABS: S_y^E_O? RTiƴ_aet&%ZBGEǨ"ȈVqQ>Sx&j,IcxX1(ƾLV,#1-*d>9̚'gL"=~Z1UWNdic[@0 -t6@2S3<Ϥ)M-.S"#mh}܇wŧؕWY;Ȗ lӨ02};O6.SFRq\ԝnxcOcO?^$$g 2prXg"DQ/IsBaNcr1AxK!E<3džQ7LƼt}<31:X+eNp&Dh gs@ @PTve6.7oRH*gdOaBL9qK)VvG|Q|CW^(4ˤPHl746 ~"5Y%03&Qs5Jtњh4C2+Eۋe!s+\VyCyS%ȼloMޖ7I>/4 `TH"ecؠ`j#n9e/)ԒFbb"6ήWzY7ώ,?\ݺ=k;?|mkGsC]D9_^Nd$4*FpZ<ti [^ߢ5M>LER4Fo}(w~gkL{׬K8] endstreamendobj21 0 obj<>stream hw.KSs9q}WpÕL98]qՋ+ ;^e_/*tvv_6m%y Zٚ endstreamendobj22 0 obj<>stream hTPMO +-Ĭ&lêw Jb)/u|fЪ>FoaF3q:(㞭2Ej׍ 9Űt_}u=g*48P`#(iؚƠ\ ڣtvK!$)fESɩ|$iI o ڑ[/׸yszE:]Տ>`Վz endstreamendobj23 0 obj<>endobj24 0 obj<>stream hdU{pSeO$Ũ١At`тT"(R>jJCI@<}|ܼ]` .T| >V|캊f\t]~ٽ)08;ss~s~ss43irrrf=fM.o.\.u 3W8kVosfZNҵadcǝ{6./ MFƺzRdZ]ScڒѴhƭkM6sm}]d6,jRnj-f[~ZL֙*5NijxOhrGsF3W3Gs ͒iY*a VCk>ȩ93mѴM?1#9k+tKuM܇s_y7=on۬M}{(>! dVdBN/͵nʝD1 LΦp%mb޾꿐37w{s9Y"~N^B՛UlsqnʕDax]J&ź(폟IRa6q.XV g!^`O(\Raa'>J`sALӏ!]LVk8CԪo}G{tw +]|/w?+2ChQ BJY⒝r-iS3RW3&uo͏؎+|X"(\ARM.fXڧr]Səz1 \UQBQyυ^f>s^?|h%zu줫@jKF^ǖ@6{mӔzNϤ|V!H?Ol7=Z{\wEK$ĄX/Tɰ^vXWnzvGrǕuԄzPKO뚲%^ 7L;PE1')EF{p{|,upԹϻ'@MLE= T\;ɬ+*UYVR j6؈.l+8y<Ʊ:Q0‡褘? Am4H0ʳ!?c[| @=ɝQwtOYE_~wUNcYCѓdN/^ endstreamendobj25 0 obj<>endobj26 0 obj<>endobj27 0 obj<>stream hLkLSg[fN[}`ͅ13qsq0"2nZXVZ(CK{N)*Ux66:d*K\-L臽5}X!f/N]!IJ1&]*u͛\w5ss}TlѶ|}d4&ZZ fXk֚'h~i]mRJgԔIۨKbRkjS3ehHK@ڢ3-TըmPk:$pMI,HdIº$Y"HRdyRl%h}֣u"uΊ|5m ؖ`|Up0v&p7o]TV2> -*h#c]15遂7⠗yXU\/DIQE][͌Vu\ZrVώq<^E( WSAgzٚ^;gVcu8 Z>ȊΞC3}7c1>6cc@o4b;df2N=Dw7p8*|> iGZzhnymiA_YUDmҵNnp[A o'{<(=+OPO0He"ȝ# lj?l=P*jEx-@P#%e=Ktnv:Zb P Յ-a2O{uw&lupѕ샅8Pu:h \}Q.+ڷ ƕ2>>L,B|WɠvҷA$zpd|Xm%ܷK呉ycm kytdu09 W5]EJlw^9aLz`nS4;^4^½aq4zȱ*|artUqҼ%ˏqNa\]Jy'"ML}x$C/~-"p:^a"'肴uPi;g%3S`OhHz>endobj29 0 obj<>endobj30 0 obj<>endobj31 0 obj<>endobj32 0 obj<>endobj33 0 obj<>endobj34 0 obj<>endobj35 0 obj<>endobj36 0 obj<>stream 8;Z\7;3lhW%.l7QEWG#%.D;>oHgoA-jDPUjGRGg/<(NN+0Ab.dZ5U6&`bWlK.*X]lC*G H/T<9G(G4CXe+a+5.g5QrJO@L76<3Q-rOG?Y"[KW=WURA^$`lRO[d1oEDBN)p7S?\i8;]SWDUJAX&*4'oBL"&/3`n "0ES"'M'U0GHf"(lKZR'3+lNpo.$@U*UVM(FJC6?V4WaLJ#.J/IRC1qL@Un]n(53F >:OF6-bUl3@Hsn%,AfDT?8>lZ$m//ne"7\?iGS]BLTAi~> endstreamendobj37 0 obj<>stream 8;Z\79,<+5%-0,/HN1=qF]8p@IoC(#L%//2,,CFE,Q`H7@V[E(/LW,Ua&7tp(qqp3 pmE_1^9GAAf8S34WP%QU>kcnk8@VUZ#^:H$P?i ,iUku6$>N@6448$SO>;Qmta*]W2%J*F*6NnNf.Nem(DY(l\;E)al(cAX47rp$q%Bl ^P&=[6ork'SXC!2(N=A.W'rR#lTaEgOL=c&-Jgj;J'gc19? qP-/s/Wn(X//&g]5MrS'LEe(B;fqZPZM5*W"MDBBE-t]2OWMF:&j#/T=7*j!"kFbA U(aWU+#b$-FZ/kBeu'(_2ek.-n2D."39rTnRhGop7t$u77C8oq8Gs1A`U6*jAgkGCZ^+@]'md[antlIXlPeN5aV4+ T6O/=#%CGZFOjOd92qCL;Sb1bitZ+hR,aH,?sk&Up9u^.@fWt^`;0~> endstreamendobj38 0 obj<>stream 8;Z\7;6kfs%.l7Qjo/oGlTD;#,S16i@f'brF\kY@?'6K6O.A5(DWaXHGoN,B[SZ_f 4^^F%#+%@2?/%L/F1H,S,&P'N4k)8JZ1inIEU\Mka&(gO4aR(-`mnXp`trL)Xu(Vt =s!Z:O.0_dqDoJdN=YoTNC5n`M>.u1'h/#F/@jG'l1onco0L[G.2HG57PZliYEd$% KtDIB3JQT)#/,7l^20+#m)4k.da^g7C#fPJ-K#6;c&9,^B!IfZ3:Efuf_UD%nKFgC X,!^e5!$3VZoIf``"atP6T*&0=8?rPAu+bMZ`^=:j6Q;4)o)X);(QD>WgSB@qfj,r 1%bY7,>;/7nYKR-ViM_Au3ZG=>2Y;]DL+M.*e>djQ3P)4YgAFMgG&EaW/U0Nt.o&iAT'Z^bJXc-iF0jJ_sA7LTubuM$7B!$cF28OYFV,nBd``4Lh]@9e_S%_^=+NFr$ 3gEAQQHZ_"ISL(>EBY:9o\HtqDNDpS*&gBSXo3AXQ@"5F3/I11NoWjnre.*r @WYH#`&l)bReS]jh?B`8gCKR/T^'9^<;0_odS\4uk-;sE[(cVAC,_*)~> endstreamendobj39 0 obj<>stream 8;Z\7>INQ7$tD$jo7"=op;;?lSWQU75VRJ*E]Y@aS^UY4N0%V5R/P#LnIgtNR(SBM Z@.T5A,cSF%jPjb=d,_QZQr+sT33Gi1H0C6P*3ei'[+H&.)Km+)uS`./e>q%']_Xl +Y")C\XWLH@?k*T$SRg9Qk/u[k!Fg`Tck**^N(`],*j)cco^5[MZ_@_#b:q65=_?njF1BIfo'eRsH7-)I221LF_lm)<500 F-Qn56)C.]$(>,fcNgimj6NF/[)*=I:ilM@6J,FqL'qF::I0qs#cYO&n=!QMh!^0],:@t P/.Su$?IX2V=0>)(o_RNWeBW"XUHd7B<:3b\D1L*<*jT>VWq/82.Vq6`RXM?f7PS! _A2\N*f4Y7d)o>L:JNL(c62`]Le0ls!33YbdNC$bKt[(_7FBNBCJX#_CoPoW=c.nd *-RW`nPTW,#q5qa1+"ds1;E#5Bb6cfB27re1oU)g2;BKdBQY-I0L^mhE+.K1t%DaO]_1Uhr6rSeSt13'7kNh*?WTWYp&2l#]ETKpF",dn[CdN/Xo821s@::HL;#[Z!@Rpd]cOHB[aKOD@WT0b997D7Qip`(;Mi UL7qGMs"uK\Y68l3kPQjkBWnTWQNnQnTCA;`Ah5dK#(=bk3bI]_/S^3%$B-f!eX&*2ZulW+ o/5(uMX(?A0COsgIA62INLB3P1h+na1#!UZCAu!r0#^9ANgT$PIpD5Lb/r+.2kfc] C=(GU`i6[_g`PR:h=&fkh7&o&BpHI')a=m`"osj$?"a~> endstreamendobj40 0 obj<>stream 8;Z\7>E/h0#b8g)+87u-f3)hR?,%"7*CW-V<_X-"PJ^! ^Y:"1E.2PG`ZrDCj3"WRn["(1dORqmpKskp0MRnKEChhZG`-M&=Q"<4"EOj!W[+g& f7QRdP/tB@YPb0^b8%G^0$paXr`(HZ/^XHeaM2hSQo-sM's.)8(83X?H7nqX\9J2i +JiB<$C^GSbiRN:2<50^K3<>qNY]q\Rs`6A%j<^:jGr^N]^P(;,c_D`,[B`:/.8`& @'#sBB;c5RSNu9bfdGh\f>NBoIC,!1lE:l#?.U`b?i+hGKVAol?%F?d`gNHNIS+n2.Za]sd r.6EK@UCWjJ8MC7TVh]bouu&JVKJu),hf(u/aK``fb_4:I%q3T2Jr+1^Om%3-3N#o j)h0rd/LcEkBt/*qOTj0S+(GQ6[8FmLt1@TJLcje7gQ@+"lt8t4Eg)DZ"(h7*W,m1 1B:Z8WH\~> endstreamendobj41 0 obj<>endobj42 0 obj<>endobj43 0 obj<>endobj44 0 obj<>stream 2012-06-22T11:41+05:30 Arbortext Advanced Print Publisher 9.0.114/W 2012-06-22T11:41+05:30 Acrobat Distiller 8.1.0 (Windows) application/pdf untitled uuid:6085777a-2e60-4060-990a-5fb8e9eb1c4c uuid:5c9372e3-eb90-4715-a27d-63a594f34cc1 endstreamendobj45 0 obj<>endobjxref 0 46 0000000000 65535 f 0000038710 00000 n 0000038850 00000 n 0000039017 00000 n 0000054714 00000 n 0000055142 00000 n 0000055354 00000 n 0000055494 00000 n 0000055650 00000 n 0000071594 00000 n 0000072401 00000 n 0000072628 00000 n 0000072771 00000 n 0000072958 00000 n 0000084382 00000 n 0000176826 00000 n 0000176969 00000 n 0000177105 00000 n 0000191129 00000 n 0000191177 00000 n 0000191691 00000 n 0000192879 00000 n 0000193466 00000 n 0000193788 00000 n 0000193902 00000 n 0000196279 00000 n 0000196527 00000 n 0000196714 00000 n 0000197950 00000 n 0000198193 00000 n 0000198424 00000 n 0000198683 00000 n 0000199219 00000 n 0000199376 00000 n 0000199626 00000 n 0000199891 00000 n 0000200188 00000 n 0000200970 00000 n 0000201827 00000 n 0000202686 00000 n 0000203996 00000 n 0000204808 00000 n 0000204844 00000 n 0000204869 00000 n 0000204948 00000 n 0000208481 00000 n trailer <> startxref 116 %%EOF